Targeting the liver via the asialoglycoprotein-receptor : synthesis of directed small molecule libraries for the H1-CRD by Riva, Claudia
Targeting the Liver via the
Asialoglycoprotein-Receptor:
Synthesis of Directed Small Molecule Libraries for the
 H1-CRD.
Inauguraldissertation
zur
Erlangung der Würde eines Doktors der Philosophie
vorgelegt der
Philosophisch-Naturwissenschaftlichen Fakultät
der Universität Basel
von
Claudia Riva
aus Montevideo, Uruguay
Basel 2006
Referent: Prof. Dr. Beat Ernst
Coreferent: Dr. Eric Francotte
1Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von
Referent: Prof. Dr. Beat Ernst
Coreferent: Dr. Eric Francotte
Vorsitz: Prof. Dr. Matthias Hamburger
Basel, den 24. Januar, 2006.
Prof. Dr. Hans-Jakob Wirz
Dekan
2Aknowledgments
First of all I would like to sincerely express my gratitude to my thesis director, Prof.
Dr. Beat Ernst, who gave me the opportunity to discover the fascinating world of
research. He took an active part in helping me to go through the challenges faced by
any PhD student, both professionally and personally.
I would like to thank Dr. Oliver Shwardt for his scientific support along this thesis and
also for his corrections.
Many thanks also to the ASGP-R project team for the fruitful discussions, and
interdisciplinary exchanges: Dr. Daniel Ricklin, Daniela Stokmaier, Karin Johansson,
Oleg Khorev, Dr. Rita Born, and Dr. Said Rabanni. My special thanks go to Dr. Daniel
Ricklin and Daniela Stokmaier for Biacore measurements and IC50 determinations,
respectively. I also would like to thank them for all the time they devoted in giving me
some of their knowledge.
Thanks to Dr. Markus Lill and Michelle Porro for the molecular modelling
contributions.
I want to thank my diploma student Daniela Müller for her contributions to this thesis,
as well as Katrin Schwinburger that collaborated with Daniela Stokmaier for the IC50
determinations.
Very special regards go to Beatrice Wagner, a beautiful person and an excellent
professional, who gave me precious technical advice and support.
Thanks to Dr. M. Spiess (University of Basel) for giving us the clone to start our own
production of H1-CRD, collaboration that made this thesis possible. Thanks also to
Mr. W. Kirsch (University of Basel) for the elemental analysis.
I would like to thank my friends Sebastian and Greg that spent a lot of their free time
performing English corrections to this thesis. In addition, I want to thank Andreas for
all his computer help given as a friend.
3I want to thank all the members of the Institute of Molecular Pharmacy for the
enjoyable time and good memories of all the activities (both official and non-official).
My special thank goes to the “ladies evenings” group: Daniela, Gan-Pan, Karin,
Salome, Tamara, Tina and Zorica (where every other member wanted to participate).
Finally, I would like to thank my family. My parents and sister offered me all their
understanding, motivation and support. Jean-Michel walked with me through this
process and gave me his patience and advice; professionally when he could, but
above all personal. He even thought it was good time to marry me. To them I would
like to dedicate this thesis.
This work was generously supported by the Swiss National Science Foundation.
4Declaration
I declare, that I wrote this thesis (Targeting the Liver via the Asialoglycoprotein-
Receptor: Synthesis of Directed Small Molecule Libraries for the H1-CRD) with the
help indicated and only handed it in to the Faculty of Science of the University of
Basel and to no other faculty and no other university.
Claudia Riva
Basel, January 2006
5Abstract
Asialoglycoprotein-receptors (ASGP-Rs), exclusively located on the cell surfaces of
hepatocytes, bind terminal galactose/N-acetylgalactosamine residues of desialylated
glycoproteins and mediate their endocytosis. Galactosyl-containing molecules can
therefore be employed as hepatotropic vectors of drugs for site-specific drug-delivery
via the ASGP-R. Studies examining the structural requirements of simple
monosaccharide derivatives for high affinity binding to the human hepatic lectin were
performed. The affinity of various synthetic galacto-derivatives was assessed by a
competitive target-based assay and surface plasmon resonance experiments using
the carbohydrate recognition domains (CRDs) of the H1-subunit of the ASGP-R. This
work provides experimental data for simple synthetic ligands for the human H1-CRD.
Based on the crystal structure of the H1-CRD and SAR studies for similar receptors,
four families of D-galactose and D-galactosamine derivatives and mimics thereof,
modified at the 2- (iii and iv) or 6-position (i and ii), were synthesized either in
solution or on solid phase. Similar or improved affinities relative to GalNAc were
obtained. Substituents in the 2-position (iii and iv) tightly interact with the receptor,
while substituents in the 6-position (i and ii) could only modestly improve the affinity.
However, with di-substituted monosaccharide mimics v the additivity of the effects of
substituents in the 2- and 6-position could not be confirmed.
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6Abbreviations
Ac acetyl
AcOH acetic acid
Anal analitycal
Aq aqueous
ASGP-R asialoglycoprotein-receptor
ASGPs asialoglycoproteins
Bn benzyl
BSA bovine serum albumin
Bz benzoyl
calcd calculated
CRD carbohydrate recognition domain
CSA camphor sulfonic acid
d days
DABCO 1,4-diazabicyclo [2.2.2] octane
DBN 1,5-Diazobicyclo [4.3.0] non-5ene
DCE dichloroethane
DCM dichloromethane
DMSO dimethylsulphoxide
DEAD diethyl azodicarboxylate
DIC N,N’-diisopropylcarbodiimide
DIPEA N,N-diisopropylethylamine
DMAP 4-dimethylaminopyridine
DMF N,N’-dimethylformamide
EA ethylacetate
ELS emitted light scattoring
eq equivalent
ESI electrospray ionization
Gal galactose
GalNAc N-acetylgalactosamine
Glc glucose
h hours
H1 major subunit of the human ASGP-R
7H1-CRD carbohydrate recognition domain of the major subunit of the human
ASGP-R
H2 minor subunit of the human ASGP-R
HBTU 2-(1-H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate
HBV hepatitis B virus
HCV hepatitis C virus
HOBt hydrate-1-hydroxybenzotriazole
HPLC high performance/ pressure liquid  chromatography
IC50 concentration of ligand required for 50% of inhibition
(IFN)-α interferon
IgA immunoglobulin A
IR infra red
KD equilibrium dissociation constant
KDa kilo dalton
LC liquid chromatography
MGR macrophage galactose receptor
mHL1 major subunit of the mouse hepatic lectin
mHL2 minor subunit of the mouse hepatic lectin
min minutes
MS mass spectrometry
MW molecular weight
NMM N-methyl morpholine
PE petroleum ether
Py pyridine
P2 sephadex G-15
PPTS pyridinium p-toluenesulfonate
PyBOP benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium
hexafluorophosphate
Quant. quantitative
rHL1 major subunit of the rat hepatic lectin
rHL2/3 two forms of the minor subunit of the rat hepatic lectin
RP reversed phase
r.t. room temperature
8SAR structure activity relationship
SP solid phase
SPR surface plasmon resonance
TBDPS tert-Butyl diphenylsilyl
TBDPSiCl tert-Butyl diphenylchlorosilane
t-BuOH tert-Butanol
Temp temperature
TFA trifuoroacetic acid
THF Tetrahydrofuran
TLC thin layer chromatography
p-TsOH p-toluenesulfonic acid
9TABLE OF CONTENTS
INTRODUCTION ..................................................................................................................12
1 LIVER DISEASES AND THE ASIALOGLYCOPROTEIN RECEPTOR. ........................................12
1.1 LIVER DISEASES AND SEARCH FOR A TARGET. ...............................................................12
1.1.1 The Asialoglycoprotein receptor as liver target...........................................................13
1.1.2 Possible applications of the ASGP-R as a liver target. ...............................................14
1.2 FUNCTION. .................................................................................................................16
1.3 GENERAL BIOLOGICAL FEATURES OF THE ASGP-R........................................................16
2 BINDING TO THE ASGP-R. ..........................................................................................18
2.1 THE CARBOHYDRATE RECOGNITION DOMAIN (CRD) OF H1. ............................................18
2.2 RECEPTOR SPECIFICITY AND BINDING MODE. .................................................................19
2.3 LIGANDS OF THE ASGP-R REPORTED IN THE LITERATURE..............................................23
3 AIM OF THIS WORK......................................................................................................23
3.1 GENERAL STRATEGY. ..................................................................................................23
3.2 CARBOHYDRATES AS LIGANDS. ....................................................................................24
3.3 DIVERSITY THROUGH “CLICK CHEMISTRY”, MICHAEL ADDITIONS AND ...............................25
NUCLEOPHILIC SUBSTITUTIONS.....................................................................................25
3.4 SOLID PHASE SYNTHESIS. ............................................................................................26
3.5 COMPETITIVE TARGET-BASED ASSAY. ...........................................................................27
3.6 SURFACE PLASMON RESONANCE..................................................................................28
RESULTS AND DISCUSSION .............................................................................................30
4 LINKER STRATEGY. .....................................................................................................30
4.1 SYNTHESIS OF THE LINKER. .........................................................................................31
4.2 COUPLING OF LINKER AND SCAFFOLDS. ........................................................................32
5 INFLUENCE ON THE BINDING AFFINITY OF MODIFICATIONS TO THE 6-POSITION OF
GALACTOSE DERIVATIVES............................................................................................33
5.1 MICHAEL ADDITIONS WITH OH AS NUCLEOPHILE. ...........................................................33
5.1.1 Synthesis of the scaffold............................................................................................34
5.1.2 Trials for Michael additions........................................................................................35
5.2 MICHAEL ADDITIONS OR NUCLEOPHILIC SUBSTITUTIONS WITH SH AS NUCLEOPHILE. .........36
5.2.1 Synthesis of the thio-scaffold.....................................................................................37
10
5.2.2 Michael additions and nucleophilic substitutions optimization. ....................................38
5.2.3 Solution library modified by conjugated additions or nucleophilic substitutions............42
5.3 CLICK CHEMISTRY AT THE 6-POSITION OF GALACTOSE MIMICS ........................................43
5.3.1 Solution phase ..........................................................................................................44
5.3.2 Trial on solid phase ...................................................................................................47
5.4 COMPETITIVE TARGET-BASED AND BIACORE ASSAYS (IN COLLABORATION WITH D.
STOKMAIER AND DR. D. RICKLIN FROM THE INSTITUTE OF MOLECULAR PHARMACY,
UNIVERSITY OF BASEL)................................................................................................48
5.4.1 Reference compounds ..............................................................................................48
5.4.2 Biacore preliminary ranking. ......................................................................................50
5.4.3 Competitive target-based assay ................................................................................52
5.4.4 Biacore ranking vs. IC50 determination and further investigations. ..............................55
6 INFLUENCE ON THE BINDING AFFINITY OF MODIFICATIONS TO THE 2-POSITION  OF
GALACTOSE. ..............................................................................................................57
6.1 LIBRARY IN SOLUTION..................................................................................................57
6.1.1 Synthesis of the scaffold............................................................................................58
6.1.2 Synthesis of the library. .............................................................................................60
6.2 COMPETITIVE TARGET-BASED AND BIACORE ASSAYS (IN COLLABORATION WITH D.
STOKMAIER AND DR D. RICKLIN FROM THE INSTITUTE OF MOLECULAR PHARMACY,
UNIVERSITY OF BASEL)................................................................................................64
6.2.1 Biacore preliminary ranking. ......................................................................................64
6.2.2 Competitive target-based assay. ...............................................................................66
6.2.3 Biacore ranking vs. IC50 determination and further investigations. ..............................68
6.3 COMPOUNDS MODIFIED AT THE 2-POSITION ON SOLID PHASE. .........................................69
6.3.1 Synthesis of the scaffold for solid phase strategy.......................................................69
6.3.2 Solid phase tests required for modifications at the 2-position. ....................................78
6.3.3 Amino acid coupling on solid phase...........................................................................80
6.3.4 Compounds modified at the 2-position on solid phase................................................82
6.4 COMPETITIVE TARGET-BASED AND BIACORE ASSAYS (IN COLLABORATION WITH D.
STOKMAIER AND DR. D. RICKLIN FROM THE INSTITUTE OF MOLECULAR PHARMACY,
UNIVERSITY OF BASEL)................................................................................................83
6.4.1 Competitive target-based assay. ...............................................................................84
6.4.2 Biacore assays..........................................................................................................85
6.4.3 Biacore ranking vs. IC50 determination. ......................................................................87
7 INFLUENCE ON THE BINDING AFFINITY OF THE COMBINED ACTIONS OF THE 2- AND 6-
POSITIONS OF GALACTOSE MIMICS. ..............................................................................91
7.1 SOLID PHASE PRELIMINARY EXPERIMENTS.....................................................................91
11
7.1.1 Loading capacity. ......................................................................................................92
7.1.2 Linker stability assays. ..............................................................................................93
7.1.3 Loading and cleaving procedures. .............................................................................93
7.2 SYNTHESIS OF THE LIBRARY ON SOLID PHASE................................................................94
7.2.1 Click chemistry optimization. .....................................................................................95
7.2.2 Synthesis of the library. .............................................................................................98
7.2.3 Purification. .............................................................................................................100
7.3 COMPETITIVE TARGET-BASED ASSAY (IN COLLABORATION WITH D. STOKMAIER AND DR D.
RICKLIN FROM THE INSTITUTE OF MOLECULAR PHARMACY, UNIVERSITY OF BASEL). ......101
CONCLUSION AND OUTLOOK.........................................................................................105
8 SUMMARY OF THE THESIS..........................................................................................105
8.1 GALACTOSE MIMICS MODIFIED AT THEIR 6-POSITION. ...................................................105
8.2 GALACTOSE DERIVATIVES AND MIMICS THEREOF MODIFIED ONLY AT THEIR 2-POSITION. ..107
8.3 MONOSACCHARIDES MIMICS MODIFIED SIMULTANEOUSLY AT THEIR 2- AND 6-POSITIONS.
...............................................................................................................................108
9 OUTLOOK.................................................................................................................111
EXPERIMENTAL ...............................................................................................................112
ANNEX 1: DATA EXTRACTED FROM THE LITERATURE................................................177
ANNEX 2: COMPETITIVE TARGET-BASED ASSAY.........................................................193
ANNEX 3: BIACORE EXPERIMENTS................................................................................207
REFERENCES...................................................................................................................211
CURRICULUM VITAE ........................................................................................................216
12
Introduction
Liver diseases and the asialoglycoprotein receptor.
1.1 Liver diseases and search for a target.
The liver is probably the biochemically most complex organ within the body. It
possesses the enzymes and cofactors for an unparalleled number of metabolic
reactions.[1] In addition, it is involved in detoxification, storage of various substances
(e.g. glucose, vitamin B12 and iron) and plasma protein synthesis. The liver performs
several roles in carbohydrate metabolism including gluconeogenesis, glycogenesis
and glycogenolysis. It breaks down insulin and other hormones as well as
hemoglobin, toxic substances and most drugs. It also performs several roles in lipid
metabolism as the synthesis of cholesterol and triglycerides. Among the proteins
produced by the liver are coagulation factors I (fibrinogen), II (prothrombin), V, VII, IX,
and XI, as well as protein C, S and anti thrombin.[2]
The diseases the liver is prone to can be guessed from its biosynthetic and metabolic
activities. Not only are there a multitude of diseases directly related to its functions,
but also a great number of infections that can alter its capacities to different levels,
e.g. different types of hepatitis, viral infections. The hepatitis C virus (HCV) infection
is a major health problem affecting an estimated 170 million people worldwide.
Persistent infections occur in more than 70% of the people infected, which may be
complicated by cirrhosis and/or hepatocellular carcinoma. A highly effective
treatment is not yet available.[3] Hepatitis B virus (HBV) infection causes a wide
spectrum of acute and chronic liver diseases ranging from latent infection to
hepatocellular carcinoma. In the Asia Pacific area more than 10% of the population
have chronic hepatitis B. The overall benefit from the most commonly used therapies
is limited for most patients.[4,5]
Because of the numerous liver diseases, targeting of drugs to hepatocytes has a
great potential. First of all, hepatic targeting will allow a higher and more efficient
concentration of drugs in liver. It will also enable therapies with reduced extrahepatic
side effects as well as administration of more powerful drugs whose use without
being directed to the site of action may be prevented by extrahepatic side effects.
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Gene transfer to hepatocytes should be also of great therapeutic interest, since
hepatocytes are responsible for the synthesis of a wide variety of proteins. In vivo
gene transfer would avoid invasive surgery, and problems arising from viral vectors.
In addition, it would be important to address the liver for diagnostic purposes.
The Asialoglycoprotein receptor as liver target.
The asialoglycoprotein-receptor (ASGP-R), also called hepatic lectin or galactose
receptor, was originally discovered during studies on the metabolism of serum
glycoproteins by Morell et al.,[6,7] and since then has called the attention of many
research groups. It belongs to the superfamily of Ca2+-dependent (C-type) lectins, i.e.
mediates specific interaction with carbohydrates in a calcium-dependent manner.[8-10]
In fact, it clears desialylated glycoproteins with terminal galactose or N -
acetylgalactosamine residues from circulation.[6,11]
The hepatic lectin, as is indicated by its name, is highly expressed on the basolateral
(blood facing) surface of parenchymal hepatocytes, which contain 100.000-500.000
binding sites per cell. The receptor does occur extrahepatically in the thyroid, in the
small and large intestine, the testis and in the proximal tubular epithelial cells of the
kidneys. However, in adult rats it was demonstrated that the extrahepatic binding
capacity ranges between 1 and 5% of that found in the liver, reflecting a low level of
expression.[12,13]
The ASGP-R receptor belongs to the recycling receptors group. The receptor-ligand
complexes are endocytosed by clathrin-coated vesicles and once in the acidic
environment of the endosomal compartment (pH 5-6) there is a conformational
change, causing dissociation of the ligand-receptor system. The receptor is sorted
into recycling vesicles that bring it back to the plasma membrane for re-use, while the
released ligands take the degradative route (figure 1). Like other recycling receptors,
the ASGP-R is endocytosed and recycled constitutively, i.e. in the presence or
absence of ligands.[14,15]
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Figure 1: Model for the receptor-mediated endocytosis. Following internalization, the ASGP-R is
recycled to the plasma membrane.
Due to the high concentration of the receptor on the liver cells, its specificity, the
mechanism of internalization of the complex receptor-ligand, and the high
internalization rate, the ASGP-R is a highly interesting target for addressing the liver
and a promise for clinical application.
Possible applications of the ASGP-R as a liver target.
Galactosyl-terminated macromolecules can be used as selective hepatotropic
vectors of drugs for site-specific drug-delivery. Specific therapeutic agents were
successfully targeted to the parenchymal cells of the liver: Biologically active
molecules have been covalently linked to galactose-terminated saccharides or
incorporated in liposomes,[16,17] as  a mean of guiding them effectively to the desired
tissues.[7,18]
Conjugated viral nucleoside analogues coupled to galactosyl-terminated
macromolecules were used for the treatment of chronic viral hepatitis. The
conjugates selectively entered the hepatocytes after interaction with the ASGP-R.
The bond between carrier and drug was cleaved in the lysosomes, allowing the latter
to be concentrated in the liver. The validity of this chemotherapeutic strategy has
Coated pit
Coated
vesicle
recycling
vesicle
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been endorsed by clinical studies.[18] The presence of ASGP-R on the cell plasma
membrane in the majority of differentiated hepatocellular carcinoma cells (HCC) and
its maintenance on proliferating cells encouraged studies aimed at restricting the
action of the inhibitors of DNA synthesis to HCC by their conjugation with galactosyl-
terminated carriers and reducing in this way their extrahepatic toxicity.[18]
Interferon (IFN-α) is the most commonly used antiviral reagent in the treatment of
hepatitis, but its overall benefit is limited for most patients as there may be insufficient
uptake of the cytokine by hepatocytes. Its receptor is present on most cell types in
rather low abundance. Directing IFN-α to the ASGP-R by desialylation (asialo- IFN-α)
facilitated it’s uptake by the liver, and is therefore useful in overcoming the limited
antiviral effect of conventional IFN-α.[5]
Attempts of gene transfer and modulation of gene expression to improve or down
regulate the biosynthesis of clinically relevant proteins are also under study by
addressing the specificity of the ASGP-R. Encapsulation of oligodeoxynucleotides or
DNA in liposomes (vehicle able to protect them) labeled with natural ligands of the
ASGP-R, resulted in successful internalization.[19,20] In one reported case,
transfection was achieved.[20]
It is believed that the hepatic lectin is already the target for hepatitis virions to enter
human hepatocytes.[3,21,22] Furthermore, it has been shown to represent a common
target for humoral and cellular autoimmune responses in chronic hepatitis, probably
contributing to disease perpetuation.[23]
In general, the ASGP-R has been implicated as a site mediating the uptake of
viruses as hepatitis A/B and C, leading to diseases that do not have yet an
appropriate therapy and can even degenerate to chronic states in some cases. The
study of this receptor for the clinic is therefore of interest. Moreover, it allows
directing chemotherapeutic agents and foreign genes more efficiently to hepatocytes
leading to a localized therapy, which will therefore improve the efficacy and minimize
secondary effects.
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1.2  Function.
As was mentioned before, the role of the ASGP-R is to eliminate glycoproteins with
terminal galactose or N-acetylgalactosamine from circulation. However, its true
physiological function is still unknown. The existence of a pool of circulating
asialoglycoproteins (ASGPs) with potential diagnostic value in patients with liver
diseases is not a direct evidence for a regulatory function of serum glycoprotein
homeostasis.[6,14] Other proposed functions include the clearance of apoptotic cells
and IgA/IgA-antigen complexes, the participation in lipoprotein-(a) in vivo
catabolism[24], and cell-cell interactions.[8,12]
Despite its at least partially unknown role, its study has provided many insights into
the biology and pathology of the liver cells.
1.3  General biological features of the ASGP-R.
The hepatic lectin has been isolated from a number of sources including rabbit,[13]
rat,[25] mouse,[26] and human.[27-29] It is a non-covalent hetero oligomer formed by two
homologous subunits (H1 and H2 in the human system), which are both required to
form high affinity binding sites. However, H1 contains all the necessary signal motifs
for endocytosis and recycling with kinetics similar to those of the complete H1-H2
complex.[15] In different species, differences in the number and complexity of the
polypeptide subunits that constitute the receptor were found (table 1 and table 2).
Table 1: The two homologous subunits of the ASGP-R.
Major subunit-1 Minor subunit-2
Rabbit 48 KDa 40 KDa
Rat a) rHL1: 41.5 KDa rHL2/3: 49/54 KDa
Human H1: 46KDa H2: 50 KDa
a) rHL2 and rHL3 are encoded by a single gene and differ from each other in the glycosylation
pattern but not in the amino acid sequence.
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Table 2: Homologies between subunits of the ASGP-R.
Compared sequences
% homology (protein
sequence)
H1-H2 58
rHL1-rHL2 51
mHL1-mHL2 49
H1- rHL1 80
H1- mHL1 79
rHL1- mHL1 89
In the case of the human galactose receptor, there is 58% of homology at the amino
acid level between the major (H1) and the minor subunit (H2). The interspecies
homology is larger for the same type of subunit, being 80% between the major
subunits of human and rat, and 89% between mouse and rat. In the case of the
minor subunits, the homology is smaller, being 63% between rat and human.[26,29,30]
Each subunit is a type II membrane protein, i.e. it spans the membrane with its amino
terminus facing the cytoplasm. They can be subdivided into 4 functional domains; the
cytosolic N-terminus domain of ∼40 amino acid residues, the transmembrane domain
and the exoplasmic C-terminus of ∼230 amino acid residues. This last portion is
composed of a stalk segment of ∼80 residues and a C-terminal carbohydrate
recognition domain (CRD) of ∼150 amino acids (figure 2). Oligomerization occurs via
the stalk segment, which forms a coiled-coil structure (figure 2). In the oligomeric
receptor, high affinity and specificity of ligand binding are the result of multiple
interactions of the CRDs with galactoses in the ligand.[10]
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Binding to the ASGP-R.
1.4 The carbohydrate recognition domain (CRD) of H1.
The carbohydrate-binding affinity of C-type lectins is a prerequisite for the receptors
to execute their function.
The CRD of subunit H1 of the ASGP-R (amino acid residues 147 to 290) was
expressed and co-crystallized with 20 nM lactose in the presence of calcium. The
diffraction data were collected by M. Meier et al. It is a globular protein with six long
and two short β strands and two α-helices. Three disulphide bridges are formed
between Cys 153 and 164, Cys 181 and 276 and Cys 254 and 268.[10] (figure 3).
Figure 3. From M. Meier et al.[10] Ribbon
diagram of H1-CRD. α-Helices are shown in
magenta, β-strands in blue, calcium ions in
green and the three disulphide bridges in
yellow. The sugar binds to calcium ion 2 in
front of a glycine-rich loop in the upper part
of the protein.
Type II receptor
COOHH2N
Transmembrane domain
CRD
NN N
Figure 2: Cartoon representation of the ASGP-R domains and oligomerization via 
the stalk segment.
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The protein contains three calcium-binding sites. Calcium is essential for ligand
binding.  It is the calcium ion at binding site 2 that is essential for sugar binding. In all
three calcium-binding sites of the H1-CRD, the calcium ions are coordinated by eight
oxygen atoms. Five of them are arranged into a pentagonal ring, two are located
above this plane and one below. At binding site 2, the two ligands above the
pentagonal ring are two water molecules that are replaced by the oxygen atoms of
the 3- and 4-hydroxyl groups[10,31] of the galactose molecule upon binding. This is
reflected by the requirement of these two hydroxyl groups to be free and also their
spatial arrangement (equatorial and axial respectively) for the binding to occur. The
pentagonal ring in this particular binding site, is formed by oxygens of Gln 239, Asp
241, Glu 252, Asp 265 and Asn 264. Below the plane this Ca2+-ion coordinates with
the oxygen of Asp 265 (figure 4).[10]
Figure 4. From M. Meier et al.[10] Stereo picture of Ca2+ binding site 2 of H1-CRD, which is
the sugar-binding site. The axial water molecules 11 and 13, are replaced by the 3-hydroxyl
and 4-hydroxyl groups of the carbohydrate upon sugar binding.
1.5 Receptor specificity and binding mode.
The mammalian hepatic lectin binds asialoglycoproteins specifically with terminal D-
galactose (Gal) or D-N-acetylgalactosamine (GalNAc) moieties. In competitive
assays performed with the rHL1, GalNAc competes approximately 60-fold more
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effectively than galactose for binding to the CRD. Interestingly, this preferential
binding of GalNAc to the rat hepatic lectin is not a property of the ASGP-R of rat
peritoneal macrophages, even though the CRDs share 85% sequence identity.[32,33]
For rabbit ASGP-R the preferential binding is also observed for GalNAc, being the
inhibitory power between 10 to 30-fold better than the one for Gal.[34,35] (table 3)
Table 3: Inhibition of 125I-asialo-orosomucoid binding to isolated hepatic lectin and to rabbit
hepatocytes by Gal/GalNAc. Data extracted from Connolly et al.[34]
Inhibitors Isolated lectin (IC50 µM) Hepatocytes (IC50 µM)
Asialo-orosomucoid a) 0.005 0.003
Gal 1700 1900
Methyl β-D-Gal 1000 1000
Methyl α-D-Gal 1600 1900
GalNAc 90 70
a) Asialo-orosomucoid is a natural ligand of the ASGP-R.
Beyond the specificity for terminal Gal/GalNAc, clustering of glycosides enhanced the
affinity of certain ligands towards the hepatic lectin. Mono-, bi-, tri- and tetra-
antennary oligosaccharides with terminal galactoses bind with increasing affinities to
the rabbit hepatic lectin, with dissociation constants of 10-3, 10-6, 5x10-9 and 10-9 M
respectively.[34,36] An important difference between the isolated rabbit protein and the
hepatic lectin on the cell surface was that the former displays only slightly greater
affinity for the cluster glycosides relative to the mono derivatives. This difference may
reflect a structural or organizational difference between the isolated and the intact
receptor in the membrane.[34]
For the rabbit ASGP-R, it was shown that the anomeric configuration of the glycoside
or the substitution of sulfur for oxygen at the anomeric center did not affect binding
affinity significantly.[34] However, a bulky aglycon α-anomerically linked to galactose
might interfere with the binding.[37]
Similar results from NMR in the case of rHL1-CRD and the crystallographic model of
a mutant of the mannose binding protein with the same binding specificity as the
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ASGP-R showed that the 6-hydroxyl is directed away from the binding site.[32] This is
in agreement with data presented by R.T. Lee et al.[37,38] indicating that the binding
site for the C-6 region of Gal is rather spacious and capable of accommodating a
bulky substituent. Moreover, the environment in this region of the lectin is rather
hydrophobic.[38]
There may be a hydrophobic region of rHL1-CRD that can accommodate small alkyl
chains of the 2-substituent of galactosamine. Binding of a series of N-acyl derivatives
of galactosamine to rHL1 suggested that the 2-substituent interacts with the surface
of the hepatic receptor with higher affinity when the length of the chain increased
from formyl to propionyl. However, more bulky substituents lower the affinity
substantially.[32,39]
Molecular modeling performed in our institute[40] confirmed that, as also indicated in
the crystal structure of H1-CRD, the 3-OH of the sugar moiety must be equatorial and
the 4-OH must be axial for binding to occur. It showed as well the possibility to
modify the 2- and probably the 6-positions of the sugar ring. The substituent at the 2-
position of Gal is directed towards the core of the protein, and in this region either H-
bonds or hydrophobic interactions can be established (Tyr 272, His 256, Asn 264,
Asp 266). The 6-position of Gal is pointing towards the surrounding water, but may
be extended to reach Trp 243, suggesting a hydrophobic interaction (figure 5). These
findings are in accordance with the literature as summarized above.
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Figure 5: Model of the H1-CRD with GalNAc bound. Calcium ions are in green, 3- and 4-OHs are
coordinated to the Ca2+. The N-acetyl group at the 2-position of the sugar is directed towads the core
of the receptor and the 6-OH is pointing to the surrounding water. Picture courtesy of Markus Lill,
Institute of Molecular Pharmacy, University of Basel.
To summarize the information about the binding mode of a galactose residue to the
H1-CRD:
• The 3- and 4-OHs of the galactose moiety should remain unsubstituted for
binding to occur.
• The substituent at position 2 of Gal may help to gain affinity by either
hydrophobic interactions or hydrogen bonds. However, only a short extension
is tolerated.
• The substituent at position 6 of Gal may help to increase the affinity by
hydrophobic interactions. Bulky groups are accepted by the receptor.
6-position
2-position
Ca2+
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1.6 Ligands of the ASGP-R reported in the literature.
Synthetic glycosides have become important tools for the elucidation of the binding
requirements of the ASGP-R (mentioned in section 2.2). Numerous research groups
investigated the binding properties of the ASGP-R. A literature status is summarized
in annex 1.
Aim of this work.
1.7 General strategy.
The aim of this work - in the context of an interdisciplinary project on the ASGP-R at
the Institute of Molecular Pharmacy, University of Basel (Prof. B. Ernst) - is to
improve the understanding of the structural requirements for simple mono- galacto-
derivatives for improved binding to the H1-CRD. Moreover, it is to provide
experimental data of synthetic simple galactose derivatives and mimics thereof for
the human H1-CRD. These data can be then used, together with the crystal structure
of the H1-CRD, for more accurate in silico studies. This approach will lead to novel
and improved ligands for this receptor. The work is based on the integration of results
from various synthetic efforts and disciplines:
• Synthesis in solution and on solid phase of galactose derivatives and mimics
thereof, modified at position 2 of the sugar ring.
• Synthesis of directed libraries of small molecules based on lyxo-hexitol
derivatives as mimics of galactose, to identify the optimal modification at the 6-
position of Gal.
• Solid phase synthesis of a library of mimics of galactosamine derivatives
combining modifications at positions 2 and 6 of the galacto moiety.
• Determination of the IC50 values of members of all three libraries by a
competitive target-based assay.
• Ligand ranking and determination of dissociation constants by surface
plasmon resonance analysis.
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Results of this study are expected to give guidance for the rational design of new and
improved ligands for the human hepatic lectin.
The goal of this project is mainly focused in the synthesis of simplified galactose
derivatives and mimics thereof as ligands for the H1-CRD. The knowledge base are
experimental data available for analogous receptors present in other species, as well
as in house molecular modeling data[40] (section 2.2). For fulfilling our objectives,
approaches in solution and on solid phase were established. Five varied small
libraries of galacto-derivatives were synthesized and analyzed through competitive
assays and surface plasmon resonance experiments providing the IC50 and kinetic
values for synthetic small ligands of the H1-CRD.
1.8 Carbohydrates as ligands.
Oligosaccharides play many important roles in biological processes like cell-cell
recognition, viral/bacterial-host cell interaction, cellular trafficking, cellular
differentiation, etc.[41]  It is not surprising therefore, that saccharides are important
constituents of drugs (antibiotics, cardiac glycosides, gangliosides).[42] However,
most natural carbohydrate ligands bind with low affinity to their receptors (KD
normally in the range of µM to mM), one of various drawbacks for carbohydrates as
drugs.[43,44] That is also the case for non-clustered Gal/GalNAc binding the ASGP-R
(table 3, section 2.2). Nature often employs oligovalency to overcome this problem.
With multiple carbohydrate-protein interactions the weak monovalent interaction can
be amplified. Succesful examples (improvement of affinity by up to a factor of one
million) are reported.[45]
A key feature of the binding of an oligosaccharide to the binding site of a receptor is
that only a portion of the oligosaccharide is usually in an intimate contact with the
protein. Often, as it is the case for the hepatic lectin, only one sugar residue, the so-
called “key sugar”, is in contact into the protein. Therefore, molecules containing the
key monosaccharide core with modifications unrelated to the sugar, have been
synthesized. This strategy is aiming to yield additional interactions with the
receptor.[43,44] Such small monosaccharide based inhibitors are attractive lead
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compounds since they are of low molecular weigh, hydrolytically more stable and
more hydrophobic than natural oligosaccharides.
1.9  Diversity through “click chemistry”, Michael additions and
nucleophilic substitutions.
A set of powerful, highly reliable and selective reactions for the rapid synthesis of
single compounds or combinatorial libraries through a heteroatom link (C-X-C), is
called “click chemistry”.[46] To be considered as “click”, the reaction must be modular,
wide in scope and provide high yields. Moreover, the by-products generated by these
reactions should be removable by non-chromatographic methods. It should be
stereospecific, require only simple reaction conditions. Some examples of this type of
reactions include cycloadditions, nucleophilic substitutions and Michael additions
(scheme 1).
a) 1,3 dipolar cycloaddition of azides and alkynes
or triazole version of Huisgen's [2+3] cycloaddition
family.
R N3 + R1
N
N
NR
R1
b) Michael additions R R1
O
+
R2 NuH
Nu: nucleophile
e.g. SH
R R1
ONu
R2
c) Nucleophilic substitutions
R
R1
O
X
X = Br, Cl
R2 NuH
R
R1
O
Nu
R2
+
1,4 regioselective
 [1,2,3]-triazoles
Cu (I)
Scheme 1: Introduction of diversity via 1,3-dipolar cycoadditions of azides and alkynes, Michael
additions and nucleophilic substitutions.
Huisgen 1,3-dipolar cycloaddition between alkynes and azides are the example “par
excellence” for click chemistry. It is a fusion process that combines two unsaturated
reactants and provides fast access to an enormous variety of five member
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heterocycles. Recently, efforts to control the 1,4- (anti) regioselectivity vs. 1,5-
disubstituted triazoles (syn) were successful. Copper-(I) catalyzed reactions,
preferentially with the catalyst formed in situ yield exclusively 1,4-disubstituted-
[1,2,3]-triazoles.[47] (scheme 1)
In combinatorial synthesis Michael additions and nucleophilic substitutions on α-halo
ketones have often been applied (scheme 1). Moreover, a large number of Michael
acceptors and α-halo ketones are commercially available ensuring rapid access to
diverse libraries.[43,44,48]
1.10  Solid phase synthesis.
The design of small molecules efficiently inhibiting polyvalent carbohydrate-protein
interactions is a challenging task for what solid phase chemistry has proven to be a
successful strategy.[44] Solid phase synthesis offers the possibility to use an excess
of reagents to drive reactions to completion and therefore obtain high chemical
yields, and at the same time, eliminating tedious work up and purification steps.  In
the 1990s, companies applied combinatorial chemistry techniques with the goal to
generate large libraries. The actual trend, however, is the tailor-made approach
leading to small libraries with high diversity.[49]
One common aspect between solid phase and solution phase synthesis of
carbohydrate libraries is the complexity of the monosaccharide building blocks
involving multiple similar reactive sites for which the application of a set of
orthogonally stable protecting groups is required. However, this small drawback can
be minimized on solid phase by using a linker that will act as protective group for
some of the reactive positions. The linker has to be stable throughout all other
protecting group manipulations and reactions.
In this thesis, SynPhaseTM lanterns were used as solid phase support.  The core
technology is the grafting of a mobile surface polymer onto a rigid unreactive base
polymer (figure 6). One of the main advantages of the modular nature of lanterns in
comparison to resin as a solid support is the ease of handling, avoiding tedious
weighing and sometimes inaccurate distribution of the resin into the reaction wells, as
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well as minimizing the working volumes. However, the modular nature also implies
that for any test to be run on solid phase at least one whole lantern must be loaded,
requiring bigger amounts of starting material than the use of resins. The amount of
product obtained from a single lantern will provide enough material for biology tests.
Figure 6.  SynPhaseTMLanterns as solid phase support.
1.11  Competitive target-based assay.
To analyze the inhibitory potentials of the compounds from all libraries synthesized, a
competitive target-based assay was employed. As target, immobilized H1-CRD
expressed in E.coli and purified as a single batch, was used.[50-52]
Microtitre plates coated with H1-CRD were incubated with the ligand to be tested in
the presence of Ca2+ and a competitor complex formed from biotinylated β-GalNAc-
polyacrylamide-polymer and streptavidin peroxidase (figure 7). After washing the
plates, color development was obtained from the enzymatic reaction between the
peroxidase and its substrate (ABTS color development solution consisting of
hydrogen peroxide and 2,2’-azino-di-[3-ethylbenzthiazoline-6-sulfonic acid]). A plate
reader at 415 nm then determined the optical density.
Linker
Chemical
Scaffold
Base polymer Grafted
surface
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Figure 7. Competitive target-based assay. 1) Plate coated with H1-CRD. 2) The ligand is added to the
coated plate. 3) The plate was incubated with the competitive ligand (biotinylated β-GalNAc-
polyacrylamide-polymer-streptavidin peroxidase complex). 4) Addition of peroxidase substrate
(ABTS), enzymatic color development. B = biotin, S = Streptavidin, PO = Peroxidase.
The concentrations of ligand required for 50% inhibition (IC50) are determined from
inhibition curves using the program Prism4. This method developed by D.
Stokmaier[50] proved to be reliable and stable.
1.12  Surface plasmon resonance.
The use of surface plasmon resonance (SPR) technology allows monitoring
interactions of macromolecules in real time and label free. Therefore not only
specificity can be determined, but also affinity and binding kinetics.
H1-CRD from the same batch used in section 3.5 was immobilized on a sensor chip
surface. When ligands are injected in solution, the interaction with the immobilized
protein causes a change of mass and refractive index at the gold surface of the
sensor chip. These changes can be detected by SPR and plotted as a sensogram.
When the solution of ligand is passed over the sensor surface, the sensogram shows
an increasing response as molecules interact with the immobilized H1-CRD
(association phase). The response remains constant if the interaction reaches
equilibrium (steady state). After injection ends, the response decreases as
dissociation of protein and ligand occurs (dissociation phase) (figure 8).
1
H1-CRD
2 3
.
B
S
POPO 4
.
B
S
POPO
Coating Addition of ligand Competition
Addition of ABTS
Substrate: color 
development
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Figure 8. Processes occurring during the different sections of a sensogram from a surface plasmon
resonance analysis.
Components of the synthesized libraries were ranked according to their affinities
towards H1-CRD. Kinetic values of some of the members were also determined by
Dr. D. Ricklin.[53]
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Results and Discussion
Linker strategy.
Various small libraries of galactose derivatives and mimics thereof, were synthesized
to explore the binding site of H1-CRD and the possibilities of improving the affinity
towards the receptor. The ligands were synthesized in solution and on solid phase.
Modifications involving only one position of the building block of choice were selected
for solution chemistry. In contrast, scaffolds to be simultaneously modified at two
different positions were selected for the application of solid phase protocols.
The use of solid phase chemistry introduces two new steps into a library synthesis,
loading and cleavage of the products. The linker must allow these two steps to occur
in essentially quantitative yields. In addition, it has to be stable throughout all
protecting group manipulations and reaction steps.[54] Moreover, it can be seen as a
specialized protecting group that can tie up functional groups to reappear at the end
of the synthesis. This is very useful in the case of potential ligands for the ASGP-R,
in which the 3,4-OHs of the galactose moiety should remain unmodified. As a
consequence, the galacto-scaffolds, used on solid phase, were covalently attached
to the polymer in the form of a 3,4-benzylidene acetal[55-57] (figure 9). Acetals are
easily hydrolyzed by acids, but they posses virtually unlimited stability to basic
conditions. In this way, polymer-bound diol scaffolds can be more easily used in
multistep functional transformations.[56,57]
O
O
O
R'
R
OCH3
Solid phase support
vi
Figure 9: Galacto-scaffold attached to solid phase with its 3,4-OHs protected by a benzylidene acetal.
To assure the stability of the linker, it was first tested in solution phase chemistry.
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1.13 Synthesis of the linker.
The linker has to be a bi-functional molecule, allowing the attachment to the polymer
support and the immobilization of the building block. The attachment to the
aminomethylated solid support was established through a stable amide bond
formation with a carboxyl containing linker. The immobilization of the scaffold was
achieved by the formation of a p-benzylidene acetal as discussed above.
The carboxylic acid function required temporally protection until the loading of the
material to the lanterns was performed. The carboxylic acid of 4-dimethoxymethyl-
benzoic acid was allyl protected before coupling the linker with the 3,4-OHs of the
galacto-scaffolds (scheme 2). Allyl esters and ethers are often employed as
temporary protecting groups. The ease of its formation, its general stability and the
many mild methods for its cleavage in the presence of numerous other protecting
groups renders the allyl group very attractive.[58,59] Esterification of the carboxylic acid
was based on the use of CsF-celite as solid base in acetonitrile.[60] Probably, traces
of water present in the base, lead to the unfortunate hydrolysis of the
dimethoxyacetal present in the starting material. The re-formation of the acetal was
done using trimethylorthoformate in the presence of catalytic amounts of p-
toluenesulfonic acid monohydrate (p-TsOH⋅H2O).
Either 1 or 2 can be successfully used as linkers. However, compound 2 proved in
different attempts to give better yields in the coupling step with different scaffolds in
comparison to aldehyde 1.
OMeMeO
OHO
O
OO
OMeMeO
OO
a) b)
1 2
Scheme 2: a) CsF-celite, allyl bromide, CH3CN, 95°C, 20 h (93%);
[60] b) (CH3O)3CH, p-TsOH⋅H2O,
MeOH, r.t., 30 min (97%).[55,57]
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1.14 Coupling of linker and scaffolds.
The building blocks were connected by condensation of 1 or 2 with the 3,4-OHs of
the galacto-moiety by reflux in CH3CN in the presence of catalytic amounts of p-
TsOH⋅H2O. The reactions were carried out in a Soxhlet apparatus with azeotropic
removal of water and absorption on 3 Å molecular sieves.[56,57] A diasteromeric
mixture of benzylidene acetals was obtained in different yields depending on the
scaffold and linker used (scheme 3). After allyl deprotection of iii, linkage to the solid
support was achieved by an amide bond formation.
O
HO
HO
R1
a)
O
O
O
R1
O
O
R2
R R
R2
1 or  2
vii viii
O
O
O
R1
R2
b), c)
ix
RO
NH
Scheme 3: a) p-TsOH⋅H2O, molecular sieves 3 Å, CH3CN, 100°C, 48 h;
[56,57] b) Different methods for
allyl deprotection employed; c) HOBt, DIC, DMF, r.t., 15 h.
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Influence on the binding affinity of modifications to the 6-position of galactose
derivatives.
Possible contributions of substituents in the 6-position are not reported. According to
molecular modeling, the 6-OH of Gal is directed towards the surrounding water.
However, Trp 243 may be reached with an appropiate extension and the affinity
improved by hydrophobic interactions.[40]
Modifications at the 6-position of galacto-derivative based on the 1,5-anhydro-2-
deoxy-D-lyxo-hexitol structure (figure 10), which binds to the H1-CRD with an affinity
comparable to Gal, were introduced. Despite intensive work reported in the
literature,[104] little was done with this particular core structure to the best of our
knowledge. The lack of the anomeric center renders scaffold 3 highly attractive for a
number of reasons. Firstly, the derivatives synthesized will be less prone to metabolic
modifications.[45] Secondly, the reduced number of H-bond donors on the new
derivatives improves their drug-like character compared to monosaccharide
derivatives. Finally, the use of 3 reduces the number of tedious protecting and
deprotecting steps.
O
HO
HO
OH
3
Figure 10: 1,5-Anhydro-2-deoxy-D-lyxo-hexitol
For the introduction of diversity, two families of compounds using Michael additions
or nucleophilic substitutions and 1,3-dipolar cycloadditions of azides and alkynes
were synthesized.
1.15  Michael additions with OH as nucleophile.
Michael additions, also known as conjugated additions, are powerful transformations
that allow the introduction of great diversity due to the numerous commercially
available Michael acceptors.[43,44]
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 Synthesis of the scaffold
The 1,5-anhydro-2-deoxy-D-lyxo-hexitol core was synthesized as scaffold for
performing Michael additions on its 6-hydroxyl (scheme 4). The 3,4-OHs were
protected as a benzylidene acetal by the linker 1 or 2. This strategy also allowed
studying the robustness of such a linkage under different synthetic conditions.
3,4,6-Tri-O-acetyl-D-galactal was reduced to its 1,5-anhydro-D-lyxo-hexitol form. After
de-acetylation under Zemplén conditions, tert-butyldiphenylsilyl (TBDPS) was
selectively introduced at the 6-position. This protecting group was selected for its
stability especially to acid hydrolysis[61] (100-250-fold compared to te r t-
butyldimethylsilyl),[59,62] making it ideal for resisting the long acid catalysis at high
temperature required for the benzylidene acetal formation[61] between the linker 1 or
2 and compound 5. The coupling reaction yielding 6 was performed in a Soxhlet
apparatus with continuous azeotropic extraction of water. The allyl group was then
removed by transition-metal catalyzed isomerization leading to 7 in 88% yield.
Tetrakis triphenylphosphine palladium (0) (Pd(PPh3)4) provided neutral conditions
[63]
(compatible with the acid labile acetal) for the allyl removal and acetylacetone acted
as allyl scavenger.[64] Finally, the free 6-OH required as nucleophile for the
conjugated additions, was obtained by selective removal of the silyl ether with
tetrabutylammonium fluoride (Bu4NF). Fluoride ion in an aprotic medium is a powerful
agent for the removal of silyl ethers in general, a key discovery done by Corey and
Venkateswarlu.[65]
The scaffold 8 was obtained in 6 synthetic steps with 62% of overall yield.
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3,4,6-Tri-O-acetyl-D-galactal
a) b)
OAc
O
HO
HO
OH
c)
4 3
O
HO
HO
OTBDPS
5
d)
O
O
O
OTBDPS
O
O
6
R
O
O
e)
7
f)
8
O
O
O
OTBDPSO
Et3HNO
O
O
O
OHO
Et3HNO
1:R = CHO, 2:R = CH(OMe)2
Scheme 4: a) H2, Pd/C, MeOH, r.t., 15 h (99%);
[66] b) NaOMe, MeOH, r.t., 4h (quant.);[66] c) TBDPSiCl,
Et3N, DMAP, DCM, r.t., 24 h (76%);
[67] d) pTsOH⋅H2O, CH3CN, 100°C, 48 h (94%) when 2 was used,
(67%) when 1  was used;[56,57] e) Pd(PPh3)4, PPh3, acetylacetone, THF, r.t., 21 h, column
chromatography with Et3N (88%);
[64] f) Bu4NHF, THF, r.t., 22 h (quant.).
[65]
Trials for Michael additions
Different conditions for conjugated additions were tried on 8. Unfortunately, the
expected reaction was not observed even after extended reaction times and the
employment of several bases (table 4).
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Table 4: Conditions tested for Michael additions of 6-OH as nucleophile to 2-cyclohexene-1-on as
Michael acceptor.
8
O
O
O
OHO
Et3HNO
+
O
Entry 2-cyclohexene-
1-on
Base Solvent Temp. Time
1 a) 2.0 eq 33 eq Et3N
[43] DCM r.t.-40°C 28 h
2 b) 2.0 eq 28 eq Et3N DMF 50-90°C 24 h
3 c) 2.0 eq 28 eq Bu4NF
[68] DCM/THF (4:1) r.t.-50°C 36 h
4 2.0 eq 3.2 eq NaOMe[69] DCM/MeOH (4:1) r.t. 72 h
5        2.0 eq 10 eq DBN DCM r.t. 120 h
a) r.t. for the initial 9 h, then warmed to 40°C; b) 50°C for the first 8 h, then warmed to 90°C; c)
DCM/THF (4:1), warmed only the last 8 h.
In none of the cases the anticipated product was obtained and 8 could be recovered.
The amount of alkoxide present depends on the pKa of the base. However,
increasing the pKa of the base (Et3N pKa ≅ 11, DBN pKa ≅ 13, MeO
- pKa ≅ 16) did not
result in the expected addition.
1.16 Michael additions or nucleophilic substitutions with SH as nucleophile.
In contrast to the poor nucleophilicity of alcohols, thioles are among the best
nucleophiles. To exploit the possibilities of high diversity offered by Michael additions
and nucleophilic substitutions on α-haloketones, the 6-hydroxyl was replaced by a
thiol group.
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Synthesis of the thio-scaffold
Starting from 5 (scheme 4), the 6-S-acetyl-1,5-anhydro-2-deoxy-6-thio-D-lyxo-hexitol
derivative 11 (scheme 5) was synthesized and used after in situ S-deacetylation as
nucleophile in conjugated additions and nucleophilic substitutions to Michael
acceptors and α-haloketones. The thio-acetate 11, was obtained after 6 synthetic
steps from D-galactal with 47% of overall yield.
O
HO
HO
OTBDPS
5
O
O
O
OTBDPS
9
O
O
O
OH
10
O
O
O
SAc
11
a) b)
c)
O
OAc
AcO
OAc
3,4,6-Tri-O-acetyl-D-galactal
Scheme 4
Scheme 5: a) 2,2-dimethoxypropane, CSA, CH3CN, r.t., 62 h (92%); b) Bu4NF, THF, r.t., 1 h (97%);
[65]
c) PPh3, DEAD, HSAc, THF, -10°C to r.t., 39 h (70%).
[70]
The acetonide group was introduced to protect the 3,4-hydroxyls of 5 (92%). This
transformation produced an interesting change in the coupling constants of the
directly affected protons indicating a conformational change (as an example H-4:
3→10, J3,4 = 1.4 Hz→J3,4 = 5.6 Hz). The order in which the acetonide and the silyl
ether were introduced was relevant. Whereas the protection of the 3,4-OHs by the
acetonide in the fully deprotected methyl β-D-galactopyranoside is regioselective, that
was not the case for 3 (scheme 6). Neither solvent nor temperature changes
improved the selectivity (table 5), and in all cases a mixture of the 3,4- and 4,6-
protected derivatives was obtained. This may reflect an increased reactivity of the 6-
hydroxyl in the hexitol derivative 3  relative to the 6-OH of methyl β -D-
galactopyranoside. Therefore, the TBDPS protection was introduced first in the fully
deprotected compound 3 (76%). The selectivity for primary alcohols in presence of
secondary ones is well known.[61,67] The combination of the acetonide and the
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TBDPS groups leads to an orthogonal protection. After selective deprotection of the
6-position by means of Bu4NF (97%), the thioacetate group was introduced using
Mitsunobu conditions (70%).[71]
Methyl β-D-galactoside
a)
12
O
HO OH
3
O
HO OH
OMe
OH
O
O
O
OH
OMe
OH
b) O
O
O
OH
10
+ O
O O
2:1
13
HO
HO HO
Scheme 6: a) 2,2-dimethoxypropane, p-TsOH ⋅H2O, DMF, 80°C, 4 h (quant.); b) 2,2-
dimethoxypropane, p-TsOH⋅H2O, DMF, 60°C, 18 h (quant., 2:1).
[72]
Table 5: Lack of selectivity for the 3,4-O-sopropylidene introduction on the hexitol derivative 3.
Entry 2,2-dimethoxy-
propane
Solvent Temp Time Yield 10:13
1 1.4 eq DMF 60°C 18 h quant. 2:1
2 1.5 eq CH3CN 90°C 21 h quant. 2:1
3 a) 1.5 eq CH3CN r.t. 35 h 80% 2:1
a) The reaction was not complete, starting material was also recovered.
Michael additions and nucleophilic substitutions optimization.
The use of the thio-derivative 11 in Michael additions or nucleophilic substitutions
involves a selective removal of the acetyl group to obtain the corresponding free thiol.
One-pot S-deacetylation and conjugated additions or nucleophilic substitutions
procedure according to Bennet et al.[69] and modifications thereof[43] were employed.
Diethylamine and piperidine (pKa ≅  11) were tested for the in situ deprotection
followed by conjugated additions or nucleophilic substitution reactions. However, the
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yields obtained were too low (< 39%) for employing the procedure for the generation
of a compound library. Lack of good deprotecting capacity of the bases employed
was the suspected problem. Two different experiments were run to verify this
assumption. On one hand, in a control reaction, the addition of 2-mercaptoethanol to
2-cyclohexene-1-on in the presence of Et2NH clearly showed that the Michael
addition conditions used were adequate to provide the conjugated product in good
yields (scheme 7). On the other hand, tests were run with 11 in the presence of two
different bases (Et2NH vs. H2NNH2⋅AcOH), but without any Michael acceptor to
evaluate the degree of deprotection obtained with each of them (table 6).
HO
SH
O
O
S
HO
2-Mercaptoethanol 14a)
Scheme 7: a) 2-cyclohexene-1-on, Et2NH, DCM, r.t., 6 h (72%).
[43]
Table 6: Comparative study of thioacetate deprotection procedures in 11.
Entry Base Solvent Temp. Time Deprotection
1 a) Et2NH DCM r.t. 96 h 4%
2 H2NNH2⋅AcOH 6 eq DMF r.t. 45 h quant.
a) 75% of the starting material was recovered
The Et2NH showed not to be strong enough for deprotecting the thioacetate at the 6-
position of the hexitol derivative 11. Similar problems are reported in the literature.[48]
S-deacetylation at the anomeric center of Gal derivatives proceeds with excellent
yields in the presence of diethylamine.[43] These conditions are however, not
sufficient for the same reaction at the 6-position. Due to the proximity of the oxygen
atom of the pyranose, a carbonyl group of an anomeric thioacetate is more
electropositive and hence increasingly ready to leave.
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After deprotection of the thioacetate 11 with the more nucleophilic base hydrazine
acetate (H2NNH2⋅AcOH), the Michael additions were still accompanied by a
competitive formation of the dimer hexitol-S-S-hexitol-derivative 15 (scheme 8). The
disulphide formation was suppressed or significantly reduced by working in complete
absence of O2. Solvent, reagents and starting material were degassed and reactions
were performed in completely closed and inert systems. The TLCs performed during
the experiment, showed that after 4 to 5 h oxidation of 11 was minimal and the
freshly added acceptor reacted with the thiol pushing the equilibrium and shortening
the time required for quantitative deprotection.
O
O
O
SAc
O
O
O
SH
O
O
O
S
O
O
O
S
H2NNH2•H2O O2 presence
11 15
Scheme 8: Oxidation product isolated from reactions without degassing procedures.
To summarize, the conditions for a one-pot S-deacetylation at the 6-position of 11
followed by conjugated additions or nucleophilic substitutions (scheme 9), were
improved to obtain satisfactory yields. A total of twelve Michael acceptors and α-
haloketones were used to sythesize a compound library in solution. Compounds 16-
17 and 19-27 were then deprotected according to scheme 9. However, due to the
delicate manipulations required for avoiding high degree of oxidation even in the
presence of small amounts of oxygen, scaffold 11 was not considered ideal for its
employment in solid phase chemistry.
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O
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b)
X = Br, Cl
Scheme 9: a) H2NNH2⋅AcOH, Et3N, DMF, r.t., (51-94%);
[48] b) aqueous 80% AcOH, 80°C, 3-6 h (60-
95%).
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Solution library modified by conjugated additions or nucleophilic
substitutions.
Table 7: Library synthesized by conjugated additions or nucleophilic substitutions. Numeration of 3,4-
O-isopropylidene-protected derivatives followed by the corresponding deprotected one is shown.
Compound R Yielda) Compound R Yielda)
16/28
O
51% 22/33
O
Cl
94%
17 b)
O
14% 23/34
O
OCH3
H3CO
75%
18/29
O
78% 24/35
O
60%
19/30
O
76% 25/36
O
65%
20/31
O
77% 26/37
O
OCH3
28%
21/32
O
F
67% 27/38
O
66%
a) Yield of Michael addition or nucleophilic substitution step; b) Because of continuous decomposition,
17 was not deprotected as to form part of the final library.
As expected, no stereoselectivity in the reaction of 11 was observed for the cases of
16 to 19 and 25 to 27. The diastereomeric mixtures obtained have to be considered
as a mixture of substances like any other. As a consequence, results of binding
affinity studies obtained with these compounds are to be considered as initial
screening experiments. If highly active inhibitors are detected, the problem of the
stereoisomers should then be addressed.
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The isolated product of oxidation 15 was also deprotected under identical conditions
of scheme 9 to afford compound 39 (scheme 10) in 70% yield, that was also
submitted for competitive assays.
O
HO
HO
S
O
OH
OH
S
39
O
O
O
S
O
O
O
S
15
a)
Scheme 10: a) aqueous 80% AcOH, 80°C, 3-6 h, 70%
1.17 Click chemistry at the 6-position of galactose mimics
Copper-(I)-catalyzed [1,2,3]-triazole formation from azides and alkynes, a modified
Huisgen 1,3-dipolar cycloaddition, gained high attention in the recent time.[47] On top
of the chemical advantages of this reaction,[46] triazoles are very interesting potential
pharmacophores.[73]
1,4-disubstituted-[1,2,3]-triazoles were successfully introduced in the 6-position of a
hexitol moiety (figure 11) by 1,3-dipolar cycloadditions of the 6-azido group of the
hexitol and various alkynes. This strategy was also useful for evaluating the potential
of this powerful modification for its use in solid phase chemistry.
O
HO
HO
N
x
NN
R
Figure 11: 1,4-disubstituted-[1,2,3]-triazoles
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Solution phase
To afford 1,4-disubstituted-[1,2,3]-triazoles at the 6-position of a hexitol moiety, an
azido functionality had to be introduced. 1,5-Anhydro-6-azo-2-deoxy-D-lyxo-hexitol
(41) was synthesized as scaffold from D-galactal by transforming 10  in the
corresponding mesylate (96%), followed by azide substitution (80%) (scheme 11).
The 13C NMR spectrum showed a characteristic shift in the signal of C-6 (C-6: 3→41:
63.84 ppm→52.04 ppm) indicating the presence of the N-linked carbon. Moreover,
the finger print region of the IR spectrum of 41 showed the expected very strong
signal at 2099 cm-1 of the antisymmetric stretching of the azide bonds. The azido-
derivative 41 was obtained in 7 steps from galactal with an overall yield of 52%.
1,4-disubstituted-[1,2,3]-triazoles were regioselectively obtained following the
procedure developed by Sharpless and co-workers.[46] The copper-(I) catalyst was
prepared in situ by reduction of a less costly copper (II) salt (CuSO4⋅5H2O) using
sodium ascorbate as reducing agent. This practice avoided undesired secondary
products. In contrast to the standard procedure,[47] several additions of the reagents
for in situ generation of the catalyst, had to be performed to drive the reactions to
completion.
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O
O
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3,4,6-Tri-O-acetyl-D-galactal
Scheme 5
e)
R
Scheme 11: a) MsCl, Py, 0°C to r.t., 1 h (96%);[74] b) NaN3,15-C-5, DMF, 100°C, 3.5 days (80%);
[74] c)
Alkyne, sodium ascorbate, CuSO4⋅5H2O, H2O/t-BuOH (1:1), r.t., 2-4 days (67-91%);
[47] d) 80% aq
AcOH, 85°C, 3 h (95%-quant.); e) 80% aq AcOH, 85°C, 3 h (96%); f) 2, p-TsOH⋅H2O, mol. sieves 3 Å,
CH3CN, 105°C, 36 h (44% 1:1);
[56,57] g) 3-ethynyl-thiophene, sodium ascorbate, CuSO4⋅5H2O, H2O/t-
BuOH (1:1), r.t., 40 h (79%).[47]
Compounds 42 and 43 were synthesized from 41 as well as compound 48 from the
benzylidene acetal-protected compound 47 in good yields in solution (scheme 11,
table 8). The derivatives obtained were subsequently deprotected by acid hydrolysis.
After removal of the 3,4-O-isopropylidene protection in 41 (96%), an isomeric mixture
of 3,4-benzylidene acetals (47) was obtained by protection with the linker of choice
(2) (scheme 11). This allowed not only adjusting conditions for future click chemistry
on solid phase but also assessing the robustness of the linker under the tested
conditions.
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Table 8: Results of click chemistry step on the hexitol derivatives 41 and 47.
Protected
Compound R
Cycloaddition
yield
Deprotected
compound
42 91% 44
43 CF3 67% 45
48
S
79% 50
(see scheme 12)
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Trial on solid phase
A test experiment to establish the methodology was carried out (scheme 12).
O
O
O
N3
47
O
O
O
O
O
N3
O
Et3HNO
49
NH2
O
O
O
N3
O
N
H
S
c)
O
O
O
N
NN
S
O
HO
HO
N
NN
S
50
b)
d)
a)
Scheme 12: a) LiOH, H2O/dioxane (1:1), r.t., 17 h, column chromatography with Et3N (77%); b) HOBt,
DIC, DMF, r.t., 15 h;[75] c) 3-ethynyl-thiophene (3eq x day), sodium ascorbate (0.3 eq x 3/day),
CuSO4⋅5H2O (0.03 eq x 3/day), H2O/t-BuOH (1:1), r.t., 3 days
[47]; d) 80% aq AcOH, 2% TFA, r.t., 2 x
15 h, (58%).[55]
Previous to loading 47 to the activated solid phase, the allyl ester-protection was
cleaved under basic conditions with LiOH to afford 4 9 in 77% yield. The
triethylammonium salt of the carboxylate was obtained by performing the purification
of 49 in the presence of 0.5-1% of triethylamine. This avoided the acetal cleavage
due to acidic silica gel.  In addition, the solid support needed to be conditioned. The
lantern was first treated with DMF to allow the polymer to swell and then activated
with triethylamine, since the aminomethylated lanterns were available in their
trifluoroacetate form. Finally, 49 was coupled with the aminomethylated lanterns by
using a standard amino acid coupling procedure generating an amide linkage. The
click modification was then performed on the immobilized scaffold using a modified
procedure (section 5.3.1). To shift the reaction to completion, excess of reagents and
repeated reactions were applied. The product was finally detached from the solid
support by acid hydrolysis of the acetal linkage.
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50 was obtained in more than 98% purity and 58% of the theoretically loaded
material was recovered. The click modification, therefore, proved to be highly
valuable for solid phase application.
1.18 Competitive target-based and Biacore assays (In collaboration with D.
Stokmaier and Dr. D. Ricklin from the Institute of Molecular Pharmacy,
University of Basel).
The competitive target-based assay developed in our institute by D. Stokmaier[50]
(section 3.5) was employed to determine the IC50 values of the Gal mimics based on
the 1,5-anhydro-2-deoxy-D-lyxo-hexitol core.
Surface plasmon resonance technology (SPR/Biacore; carried out by Dr. D.
Ricklin[53]) was employed for preliminary monitoring of the interactions between test
compounds and the receptor H1-CRD in its monomeric form (section 3.6).
Results obtained from both methods (competitive assay and Biacore), were carefully
analyzed considering the differences and limitations of the asssays. The
complementary use of the two assays was extremely helpful for accurate
conclusions.
All curves for IC50 determination of references and tested samples as well as the
protocol employed can be found in Annex 2 and were kindly provided by D.
Stokmaier. SPR fits and methods can be found in Annex 3 and were kindly provided
by Dr. D. Ricklin.
Reference compounds
Galactose, methyl α-D-galactopyranoside, methyl β-D-galactopyranoside, N-acetyl-D-
galactosamine and synthesized compound 3 served as reference compounds (table
9). IC50 values were compared with the equilibrium dissociation constants (KD)
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determined by the Biacore assay and both sets of results were validated with data
reported in the literature.
All measurements were performed in HEPES buffer containing Ca2+ and DMSO. As
the IC50 values in the absence of DMSO were significantly lower (50%-60%), DMSO
was employed independently of the samples solubility.
Table 9: IC50 (µM) values determined by competitive target-based assay and equilibrium dissociation
constants KD (µM) determined by SPR for monosaccharides and mimic 3 to be used as reference
compounds.
Compound IC50 (µM) KD (µM) 
b) Literature
Gal 1754 ± 57 2080 1700 c)
Methyl α-D-Gal 1280 ± 49 2840 1600 c)
Methyl β-D-Gal 545 ± 39 1780 1000 c)
GalNAc 78 ± 5 112 90 c)
3 1399 ± 368 a) 1480 n.d.
IC50 values are the media ± standard deviation of two independent determinations except for a) in
which three independent determinations were done. b) Obtained from randomized triplicate injections
of 8 concentrations between 6.0 mM and 2.7 µM. c) Data extracted from Connolly et al.[34] IC50 values
for isolated hepatic rabbit lectin determined by competitive assay with 125I-asialoorosmucoid. n.d.
means “not determined”.
All values obtained for monosaccharide moieties in SPR experiments and with the
competitive target-based assay were in the same range. Differences in the absolute
values (usually within a factor of 2-3) are the result of the intrinsic difference between
the assay types. The IC50 values from our competitive target-based assay and the
literature ones were in a close range while direct binding values from Biacore were
always slightly higher.
In competitive assays, galactose showed the lowest affinity towards H1-CRD
followed by methyl α- and β-D-galactopyranoside. However, in the case of SPR,
methyl α-D- galactopyranoside showed the lowest affinity. As expected, GalNAc was
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the best binder in both assays with approximately a 20-fold enhancement of the
binding affinity relative to galactose.
Literature data for α/β-galacto isomers,[34] did not clearly document the preference of
the receptor. However, in our competitive assay and the SPR experiment methyl β-D-
galactopyranoside was superior by a factor of 1.6 to 2. The Biacore curves obtained
with both galactosides clearly show a parallel shift between them. In this case, a
direct comparison can be done due to identical molecular weights (figure 12).
Figure 12: Superimposed Biacore curves of methyl β-D-galactopyranoside (left curve) and methyl α-D-
galactopyranoside (right curve). Shows that from both monosaccharides compared, methyl β-D-
galactopyranoside is the best binder.
Biacore preliminary ranking.
Hexitol derivatives modified by conjugated additions or nucleophilic substitutions,
were submitted for SPR preliminary ranking. It is important to stress the preliminary
character of the results obtained by this experiment. Only a single injection at a
constant concentration (1 mM) was performed for each compound. Therefore, values
from SPR cannot be directly compared. This can be exemplified by the comparison
of the results obtained for Gal and GalNAc in the ranking (figure 13) where the 20-
fold higher affinity of GalNAc is not reflected by the SPR signal. The raking
experiment serves to detect unexpected or unusual behaviors, such as non-specific
binding, and to identify binders with extremely high or low affinities.
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Figure 13: Biacore ranking of the binding affinities towards H1-CRD of the hexitol derivatives modified
by nucleophilic substitutions at the 6-position and reference compounds. The data was obtained for
immobilized H1-CRD (aprox 8000 RU density equivalent to aprox 8 ng/flow cell) by performing a
single injection at a concentration of 1 mM per sample and was then normalized with the
corresponding analytes MW.
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Figure 14: Biacore ranking of the binding affinities towards H1-CRD of the hexitol derivatives modified
by nucleophilic substitutions at the 6-position and references compounds. Same original data from
figure 13 was normalized with the reciprocal of the MW (1/MW) of the corresponding analytes.
When the MW-normalized data set is considered, only three samples resulted to be
worse binders than galactose while the rest showed higher affinity. In contrast, if the
reciprocal MW-normalized data set (figure 14) is taken into account, all library
members tested seem to have improved affinities for H1-CRD compared to
galactose. The best binder was compound 39, the only analyte with a different
general pattern. In addition, compound 38 generated a positive signal opposing to
the general behavior of the other members and the references used (Gal and
GalNAc) that gave negative signals. Further investigations were therefore performed
on 38 and 39 and are discussed in section 5.4.4.
Competitive target-based assay
IC50 values of hexitols based on nucleophile 11 or [1,2,3]-triazoles derivatives are
presented in table 10 and 11, respectively. Unless specified, the galactose mimics
were tested in replicates with good reproducibility.
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In general, the binding affinities towards H1-CRD were approximately 3 times better
than those of Gal or compound 3.
Table 10: IC50 (µM) values determined for Gal mimics modified at the 6-position by conjugated
additions or nucleophilic substitutions.
O
HO
HO
SR
28 to 39
Hexitol R IC50 (µM) Hexitol R IC50 (µM)
28
O
868 a) 34
O
OCH3
H3CO
983 a)
29
O
575 ± 15 35
O
n.s.
30
O
450 ± 3 36
O
346 ± 37
31
O
519 ± 147 37
O
OCH3
n.s.
32
O
F
472 ± 216 38
O
n.s.
33
O
Cl
524 ± 134 39
O
HO
OH
S
94 ± 18
a) One determination done. n.s. means “non soluble” compounds in HEPES buffer (even with
5% DMSO). For all other compounds two independent determinations were performed and
are informed as the media ± standard deviation.
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Table 11: IC50 (µM) values determined for Gal mimics modified at the 6-position by 1,3-dipolar
cycloadditions.
O
HO
HO
N
NN
R
Compound R IC50 (µM)
46 a)
O
HO
HO
N3 _ 248 ± 41
(KD = 855) 
b)
44 Precipitationc)
45 CF3 481 ± 127
50
S
421
a) Compound measured was 1,5-Anhydro-6-azido-2-deoxy-D-lyxo-hexitol, precursor of the other
derivatives tested. b) KD value also determined with Biacore c) Precipitated during assay. Values are
the media ± standard deviation of two independent determinations, except for compound 50, for which
only one measurement was performed.
To summarize, the three kinds of chemical modifications that were carried on the
hexitol moiety generated a group of inhibitors that had approximately 3 times
enhanced affinity for H1-CRD relative to Gal. However, the binding is still weak and
in the order of methyl β-D-galactopyranoside with the exception of the azido
derivative 46. Nevertheless, these findings encouraged future studies with additional
modifications in the 2-position of galactose.
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Biacore ranking vs. IC50 determination and further investigations.
The preliminary Biacore ranking of the hexitol derivatives tested in this chapter
predicted a general improvement in the H1-CRD binding affinity relative to galactose.
Such behavior was confirmed by the competitive assay.
An interesting finding in both experiments (Biacore and competitive assay) was that
compound 39 resulted to be the best binder. In further SPR-experiments, randomized
triplicate injections of 8 concentrations (three-fold serial dilutions) between 6.0 mM
and 2.7 µM were performed. Negative signals that could be mirrored were obtained
showing fast binding kinetics. As expected, the equilibrium responses could be fitted
to a simple 1:1 binding model.  Nevertheless, a slight signal increase could be
observed during steady state (figure 15). This is indicative either of a low degree of
non-specific binding or a more complex binding mode. However, these deviations
were rather small and are not expected to largely influence the binding data. Due to
the special characteristics of 39, which possess two pairs of 3,4-OHs free, it might
improve the local concentration. The KD of 1.13 mM for 39, was not in the range of
GalNAc as determined in the competitive assay.
Figure 15: SPR curve obtained for 39.
In the Biacore ranking, compound 38 appeared to be a good binder but contrary to all
other compounds tested the signal generated was positive. As no additional
information could be obtained from the competitive assay due to poor compound
solubility (precipitated in the buffer during the assay), further investigations were
39
mirrored
O
HO
HO
S
O
OH
OH
S
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performed with Biacore. A positive signal with fast kinetics was recorded but no
saturation was achieved. Based on a linear relationship between response and
concentration, the compound was eliminated from the data set under evaluation. The
non-specific type of binding detected can be explained by two possible theories. On
one hand, the high hydrophobicity of 38 can generate non-specific hydrophobic
interactions. On the other hand, this effect can be also observed if precipitation
occurs, as it was the case during the competitive assay.
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Influence on the binding affinity of modifications to the 2-position  of
galactose.
Substituents linked to the 2-position of Gal derivatives have a privileged situation
upon binding to the H1-CRD. They are directed towards the core of the protein and
can establish either hydrophobic interactions or hydrogen bonds with the various
amino acids in this area of the protein (Tyr 272, His 256, Asn 264, Asp
266)[10,32,35,39,40]. Furthermore, GalNAc competes approximately 10 to 60-fold
(depending on the animal species) more effectively than galactose for binding to the
H1-CRD.[32,34]
The aim of this particular work was to study the influence on the binding affinity to
H1-CRD, of a collection of substituents at the 2-position of Gal with varied
characteristics and sizes. Due to possible steric clashes, the length of the chain or
size of the substituent may be a limitation.[32,40]
Modifications at the 2-position of methyl α-D-galactosides and derivartives thereof
were performed. The compound library was synthesized in solution and on solid
phase by two main approaches. On one hand, 1,3-dipolar cycloadditions were
performed using alkynes and an azido groups. The later was introduced with a two-
carbon spacer attached to the 2-position of Gal. On the other hand, solid phase
amino acid coupling was performed with a galactosamine derivative.
1.19 Library in solution
A library of methyl α-D-galactosides in which diversity was introduced by copper-(I)-
catalyzed 1,3-dipolar cycloadditions of an azide and alkynes was synthesized in
solution. Once again the broad spectrum of advantages offered by click chemistry[46]
(reactions discussed in section 5.3) were put into practice.
When this work was initiated, experimental data were only available for non-human
receptors. IC50 values for methyl β- and methyl α-D-galactopyranoside from Connolly
et al.[34] for isolated rabbit hepatocytes are 1.0 mM and 1.6 mM, respectively. Since it
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was reported that the anomeric configuration of glycosides or even the substitution of
sulphur for oxygen at the anomeric center did not affect binding significantly,[34] the
above difference was considered to be an experimental error. Furthermore, there are
a number of examples in the literature (see annex 1) where the α derivative shows a
higher affinity than its β counterpart.[34,35,39] Based on that and due to the ready
availability of the starting material, a library of methyl α-D-galactosides was our option
of choice. However, in the meantime are found in competitive and in Biacore
experiments that methyl β-D-galactopyranoside shows an affinity for H1-CRD two
times better than its α counterpart (table 9).
Synthesis of the scaffold
Methyl 2-O-(2-azidoethyl)-α-D-galactopyranoside (58) was synthesized as scaffold of
the triazole library. According to in silico data,[40] short aliphatic chains at the 2-
position of galactose derivatives may generate hydrophobic interactions with the
protein. As a consequence, the azido group was connected to the 2-position by a two
carbon chain (scheme 13).
The desired scaffold 58 was synthesized from the commercially available methyl α-D-
galactopyranoside applying orthogonal protection. The synthetic pathway was based
on the knowledge of the different order of reactivity of the hydroxyl groups in
galactose. The primary hydroxyl is much more reactive than the secondary
hydroxyls, the 3-OH is more reactive than the 2-OH, while the 4-OH is the least
reactive one. Therefore, the TBDPS group was quantitatively introduced at the
primary alcohol.[61] Secondly, the 3,4-diol was protected by 3,4-O-isopropylidenation
(89%).[58] Thirdly, a two-carbon chain was introduced by alkylation of the 2-hydroxy
group of 52 with 53 (50%). During the selective cleavage of THP[58] in the presence
of the acetonide[79,80] group only a very low concentration of PPTS was applied.
Finally, 55 was transformed in the corresponding mesylate in pyridine (92%) followed
by azide substitution (quant.) to obtain the protected azido-scaffold 57. The selective
removal of the TBDPS group with tetrabutylammonium fluoride[65] (quant.) followed
by  acetonide deprotection by acid catalyzed hydrolysis (quant.) yielded the target
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derivative 60. It was obtained from methyl α-D-galactopyranoside in 7 synthetic steps
with an overall yield of 34% (scheme 13).
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Scheme 13: a) TBDPSiCl, Et3N, DMAP, DCM, r.t., 64 h (quant);
[67] b) 2,2-dimethoxypropane, p-
TsOH⋅H2O, CH3CN, r.t., 29 h (89%);
[72] c) 5 3, NaH, anh DMF, 0°C-40°C, 29 h (50%);[81] d) PPTS,
MeOH, 55°C, 5 h (83%);[79] e) MsCl, Py, 0°C-r.t., 3 h (92%); f) NaN3, DMF, r.t.-50°C, 18 h (quant.); g)
i) Bu4NF, THF, r.t., 2 h, (quant),
[65] ii) 80% aq AcOH, 50°C, 12 h (quant) h) DHP, PPTS, DCM, r.t., 2 h,
(quant).[79,82]
In the synthetic pathway to 58 there were two critical steps. The first one was the
careful selection required for the protecting group for 2-bromoethanol. Originally, the
basic labile benzoate group was chosen. On one hand, Br/Cl exchange occurred
between 2-bromoethanol and benzoylchloride generating a mixture of the expected
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3-bromoethylbenzoate (59) and the less reactive chloro counterpart 60. This could be
mostly solved by a reduced reaction time (scheme 14). On the other hand, a
transesterification occurred when trying to introduce the two-carbon spacer to the
galacto-derivative. The 2-O-benzoyl derivative 61 was instead obtained (figure 16).
The protecting group of second choice was the also basic labile but more stable
pivaloate group to possibly avoid transesterification. Unfortunately the introduction of
this group could not be achieved at different temperatures and in the absence or
presence of DMAP as catalyst. Finally, THP was employed successfully.
 The second critical step was the low yield obtained for the introduction of the
properly protected 2-(2-bromoethoxy)-tetrahydro-2H-pyran to the 2-position of 52.
The cause was the partial deprotection of the TBDPS group.[58]
Br
OH
Br
OBz
+ Cl
OBzBzCl
a)
59 60
8 : 1
Scheme 14: BzCl, Py, 0°C-r.t., 4 h (51%).
O
O
O
OTBDPS
BzO
OCH3
61
Figure 16: transesterification product.
 Synthesis of the library.
A collection of nine methyl α-D-galactosides and two related secondary products,
modified at the 2-position, was obtained by click chemistry performed in H2O/t-BuOH
(1:1). Derivatives were obtained from scaffold 57 (scheme 15, table 12). Because the
triazol formation from acetylenes and azides is possible in presence of free OH- and
NH2- groups, the reaction is carried out as well with the deprotected precursor 58
(scheme 16, table 13). In both cases, the standard procedure of Sharpless and co-
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workers[47] had to be slightly modified. As in section 5.3.1, several additions of
CuSO4⋅5H2O and sodium ascorbate had to be performed to drive the reactions to
completion.
O
O
O
OTBDPS
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OCH3
N3
57
O
O
O
OTBDPS
O
OCH3
NN
N
R
O
HO
HO
OH
O
OCH3
NN
N
R1
a) b)
62 to 65 66 to 71
Scheme 15: a) Alkyne, sodium ascorbate, CuSO4⋅5H2O, H2O/t-BuOH (1:1), r.t., 1-3 days, (81%-
98%);[47] b) i) Bu4NF, THF, r.t.; ii) 80% aqueous AcOH, 80°C (12%-60%).
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OCH3
N3
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O
HO
HO
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OCH3
NN
N
R
a)
66, 72 to 75
Scheme 16: a) Alkyne, sodium ascorbate, CuSO4⋅5H2O, H2O/t-BuOH (1:1), r.t., 1-4 days, (51%-
87%).[47]
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Table 12: Methyl α-D-galactosides modified at the 2-position by click chemistry, synthesized from the
protected scaffold 57. Products and yields of cycloaddition step and after deprotection are presented.
Alkyne  Yield a) R R1
OH
81%
OH
62
OH
 66 (12%)
+
    67 b) (39%)
S 97% S
63
S   68 (47%)
+
 S ,  6-Ac 69c)
(53%)
NH2
98%
NH2
64
NH2
70d) (24%)
N
83%
N
65
N
71 (60%)
R and R1 as in scheme 15. a) Yield of cycloaddition step from scaffold 57. b) Elimination of the tertiary
alcohol occurred under acidic conditions used for acetonide deprotection originating two final products
66 and 67. c) Since acetylation of the 6-position occured, two final products were obtained (68 and
69). d) Decomposition lowered the yield.
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Table 13: Methyl α-D-galactosides modified at the 2-position by click chemistry from the fully
deprotected scaffold 58.
Alkyne Yield R Compound
HN
51%
HN
72
OH
57%
OH
66
57% 73
Cl
74%
Cl
74
N
N
N
87% N
N
N
75
R as in scheme 16.
The yields of the cycloaddition step using scaffold 57, were good to excellent.
However, the new entities had yet to be submitted to acidic conditions for the
hydrolytic cleavage of the acetonide group, leading to the formation of side products.
Elimination of the tertiary alcohol in 62 , acetylation of the 6-OH in 68  and
decomposition of 70 were obtained.
The eleven methyl α-D-galactosides afforded either from scaffold 57 or 58, were
submitted to the competitive target-based assay for exploring the binding behavior
towards H1-CRD.
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1.20 Competitive target-based and Biacore assays (In collaboration with D.
Stokmaier and Dr D. Ricklin from the Institute of Molecular Pharmacy,
University of Basel).
Preliminary monitoring of the interactions between the methyl α-D-galactosides (66 to
75) and H1-CRD was performed by surface plasmon resonance (section 3.6). The
compounds were ranked according to their binding behavior and compared with the
positive controls Gal and GalNAc and the negative control Glc (KD > 20 mM). The
ranking experiments were performed in parallel with the members of the hexitol-
derivatives library. Further information to the data set normalization is reported in
section 5.4.2, SPR fits and details about the employed methodologies in Annex 3
(provided by Dr D. Ricklin).
IC50 values and equilibrium dissociation constants (KD) for reference compounds can
be found in section 5.4.1 in table 9. Experiments were run under the same general
conditions as for the hexitol-derivatives library.
IC50 values were determined with the competitive target-based assay (section 3.5).
All curves for IC50 determination of references and tested samples can be found in
Annex 2 (provided by D. Stokmaier).
Biacore preliminary ranking.
A preliminary ranking of the binding affinities of the methyl α-D-galactosides modified
at the 2-position (66 to 75) towards H1-CRD was obtained by SPR. A single injection
at a constant concentration (1 mM) was performed for each analyte giving
preliminary binding information. Due to the negative SPR responses explained in
section 5.4.2, the binding affinities were normalized by the reciprocal of the MW
(1/MW) (figure 17).
Six out of ten compounds analyzed bind either with lower or slightly better affinities
than Gal. The exception is compound 69. Some compounds (67, 72, 73), need to be
further analyzed as they generated positive signals in contrast to all other members
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and references where negative responses were observed. In comparison with the
hexitol-derivatives library (figure 18), all methyl α-D-galactosides studied, except 69,
were ranked worse than them. The exception to the rule, compound 69, is the only
member that is also substituted at the 6-position and therefore has a different general
substitution pattern than all other compounds ranked.
Figure 17: Biacore ranking of the binding affinities towards H1-CRD of the methyl α-D-galacto-
derivatives modified at the 2-position. Comparison with reference compounds Gal, GalNAc and Glc
was performed. The data was obtained for immobilized H1-CRD (aprox 8000 RU density equivalent to
aprox 8 ng/flow cell) by performing a single injection at a constant concentration (1mM) per sample
and was then normalized with the inverse of the corresponding analytes MW.
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Figure 18: Biacore ranking of the binding affinities towards H1-CRD of methyl α-D-galacto-derivatives
(yellow) and lyxo-hexitol (blue) libraries and reference compounds (red). The data was obtained for
immobilized H1-CRD (aprox 8000 RU density equivalent to aprox 8 ng/flow cell) by performing a
single injection at a constant concentration (1 mM) per sample and was then normalized with the
reciprocal of the corresponding analytes MW. Positive signals were excluded from the compared
rankings as they need to be further analyzed.
Competitive target-based assay.
IC50 values for the methyl α -D-galactosides were determined (table 14) by a
competitive target-based assay. Due to the low affinities observed, no replicates
were done unless unexpected values were obtained. As a consequence, the reported
IC50 values should only be considered as preliminary.
Most compounds tested showed preliminary IC50 values that were of the same order
of magnitude as methyl α-D-galactopyranoside. One possible explanation for the lack
of improved affinity could be the steric factor leading to a clash with the receptor.
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Table 14: IC50 (µM) values determined by competition target-based assay for methyl α-D-galactoside-
derivatives modified at the 2-position.
O
HO
HO
OH
O
OCH3
NN
N
R
Compound R IC50 (µM) Compound R IC50 (µM)
66
OH
914 71
N
805
67 581 72 a)
HN
110 ± 13
68
S
952 73 399
69 b) S,
6-Ac
592 74
Cl
1209
70
NH2
561 75 N
N
N
971
a) Value is the media ± standard deviation of two independent measurements b) same modification in
position 2 as for compound 68 but acetylated in the 6-OH.
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Biacore ranking vs. IC50 determination and further investigations.
Results from the ranking by Biacore and from the competitive target-based assay, for
the methyl α-D-galactoside-derivatives 68 to 77, were compared.
In general, the preliminary Biacore ranking of the binding affinities of the methyl α-D-
galactoside-derivatives tested, predicted a lack of general improvement in the binding
affinity towards H1-CRD relative to galactose. Such behavior was further sustained
by preliminary IC50 values determined for the same derivatives. The chemical
modifications performed did not translate into an improvement of the affinity for H1-
CRD. However, they also do not interfere with the binding. An exception to this rule
was compound 72 with a binding affinity of the same order of magnitude as GalNAc.
Of interest is the difference found between 68  and 69  in both assays. Both
derivatives have the same substituent in position 2 but 69 has its 6-OH acetylated.
The introduction of the acetyl group enhanced the affinity of 69. A similar effect to this
preliminary result was reported in the literature[35] for allyl α-D-GalNAc and its 6-O-
methyl derivative. The introduction of this methyl group reduced the IC50 value
approximately to its half as in the present case.
Compounds showing positive signals and 72 are further discussed.
Compound 72 was further analyzed by Biacore. Randomized triplicate injections of 8
concentrations between 6.0 mM and 2.7 µM were performed. A positive response
with slow binding kinetics was obtained. However, the binding mode could not be
fitted to a 1:1 model. The binding was nevertheless Ca2+ dependent, when Ca2+ was
removed with EDTA no binding could be detected. Even if the binding is apparently
specific, this molecule seems to bind in a completely different manner to H1-CRD. If
the molecule binds near the binding site of the receptor, it might also avoid in the
competition assay the binding of the competitor polymer, resulting in a low IC50 value.
Compound 67 was as well further analyzed by Biacore. Unfortunately, no good SPR
fits were achieved possibly due to the presence of impurities. This compound was
eliminated from the data set.
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1.21 Compounds modified at the 2-position on solid phase.
Encouraged by the privileged situation of the substituents at the 2-position of Gal
derivatives upon contact with H1-CRD, a new strategy for modification of the
monosaccharides moieties was planned. Furthermore, to determine if a combined
effect of the substituents does have an added impact on the overall affinity, a method
which later on could  also be used on solid phase to introduce diversity at the 2- and
6-positions of Gal derivatives in a combined way was developed. In addition, the
robustness of the linker under the required reaction conditions was assessed.
The galacto-scaffold for solid phase was chosen as for allowing amino acid couplings
at its 2-position. The scaffold was in addition developed as a 6-azidosugar for
introducing later the 2,6-disubstituted combined strategy.
On one hand, these are high yielding reactions very much employed on solid phase.
On the other hand, a 2-N-acyl galacto moiety is expected to maintain some of the
characteristics that GalNAc has for an increased selectivity to our protein[32,34] and to
interact with His 256 which is responsible for the preferential binding of GalNAc
relative to Gal,[32,33]. Moreover, by varying the length of the chain coupled to the 2-
amino group, it is possible to study the optimal situation for the interaction with the
receptor.
Synthesis of the scaffold for solid phase strategy.
The scaffold of choice had to fulfill a number of requirements for achieving the
objectives of this strategy. First, a 2-deoxy-2-amino-galactosamine derivative was
needed and therefore a protection for the nucleophilic amino group was developed.
Second, the new galacto moiety was planned as a 6-azidosugar for modifications
that were later introduced. Third, a selective synthesis for obtaining only the β
derivative (in general, enhanced affinity towards H1-CRD than its α counterpart) was
designed.
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The synthesis was started from glucosamine hydrochloride available in large
amounts at our facilities. It offered an elegant approach for the synthesis of the
galactosamine derivative for which an epimerization was required to obtain the axial
orientation of the 4-OH.
1.21.1.1 Synthesis of the galactose epimer
The β selective oriented synthesis and the epimerization process can be seen in
scheme 17. The 2-amino group of glucosamine was N-blocked with the basic labile
phthaloyl group. For this purpose glucosamine hydrochloride was smoothly
converted by phthalic anhydride in aqueous dioxane into its O-carboxybenzoyl
derivative (76) and hence by acetic anhydride with sodium acetate as basic catalyst
in 1,3,4,6-tetra-O-acetyl-2-deoxy-2-phtalimido-D-glucose (77).[45,83] Having the α face
of the sugar partially blocked, the formation of the anomeric bromide by use of 33%
HBr in AcOH, gave mainly the β-anomer (α:β = 1:4) as indicated by 1H NMR. Clearly
the two anomeric centers with the characteristics coupling constants, J1,2 = 3.7 Hz for
the α-anomer and J1,2 = 9.6 Hz for the β-anomer, could be assigned. Due to the
instability of brominated compounds, the product, quantitatively afforded, was
submitted immediately to the next step without further purification. Methyl β-D-
glucopyranoside was obtained by the Koenigs-Knorr reaction with employment of
silver carbonate on the poly-O -acetylglucosyl bromide.[84] In this opportunity β
selectivity was achieved in very good yield (87%). 1H NMR showed a single anomeric
center with coupling constant J1,2 = 8.4 Hz characteristic for the β isomer.
In order to epimerize C-4 the method of Cipolla et al. was employed.[85] The
epimerization was achieved taking advantage of acyl migration in basic media
preferring an axial configuration to an equatorial one. After deacetylation under
Zemplén conditions, the pivaloy ester was introduced at positions 3 and 6 selectively.
The selective character of the pivaloylation can clearly be deduced from the
analytical data. Protons H-3 and H-6 suffered a dramatic shift to lower fields in the 1H
NMR of 80 compared to 81 (80 → 81: H-3 δ 4.27 ppm → 5.59 ppm, H-6 δ 3.88 ppm
→ 4.45 ppm). The resulting compound 81 was converted into the corresponding
triflate derivative by triflic anhydride.[86] Immediate displacement with water gave the
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expected epimer 82 in 59% yield. Comparison of the H-4 signals in the 1H NMR
spectrum of the initial gluco form and the epimer 82 shows a clear shift to lower fields
of the mentioned protons (H-4: 81 →  82: δ 3.59 ppm → 5.34 ppm) indicating the
presence of the pivaloyl protecting group at the 4-position consequence of its
migration.[87] However, due to lack of good resolution in the 1H NMR spectrum
recorded for compound 82 the characteristic doublet of the galacto H-4 could not be
well observed. The signal appeared instead as a broader peak assigned as a
multiplet. Nevertheless, the difference with the gluco moiety was clear. The H-4 of
the gluco form 81 showed in its 1H NMR spectrum a triplet with a big coupling
constant J3,4 = 8.9 Hz. In contrast, derivatives obtained from 82 had small coupling
constants between protons H-3 and H-4 (2.8 Hz - 3.2 Hz) characteristic for the
galacto epimer. For derivatives where the doublet could not be seen, the coupling
constant was obtained from the H-3 signal.
 The newly obtained galactose derivative 82 was then deprotected to obtain methyl
2-deoxy-2-phtalimido-β-D-galactopyranoside (83). The basic conditions required for
the removal of the pivaloyl groups produced the opening of the phthalimido ring that
had to be closed once again as in step b) (scheme 17). This procedure caused the
acetylation of the hydroxyl groups that could be deprotected under only slightly basic
conditions, resisted by the phthalimido protecting group.
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Scheme 17: a) Phthalic anhydride, NaHCO3, H2O/dioxane (4:3), r.t., 4 days;
[83] b) NaOAc, Ac2O,
140°C, 20 min, (57% a) and b));[83] c) HBr/AcOH, DCM, r.t., 5h (quant.);[83] d) Ag2CO3, CaSO4, MeOH,
r.t., 23 h (87%); e) NaOMe, MeOH, r.t., 12 h (quant.); f) PivCl, DMAP, Py, -38°C, 19 h (67%); g) i)
Tf2O, DMAP, DCE/Py (2:1), 0°C, 17 h, ii) H2O, 80°C, 5 h (59%);
[85] h) i) NaOMe (0.5 M), MeOH, r.t., 12
h, ii) NaOAc, Ac2O, 140°C, 15 min,  iii) NaOMe, MeOH, r.t., 12 h (quant.).
1.21.1.2 Functionalization of the scaffold.
Methyl 2-deoxy-2-phtalimido-β-D-galactopyranoside (83) had to be properly
functionalized to obtain a scaffold suitable for the modifications planned on solid
phase. In addition, the amount of scaffold obtained in this strategy is not trivial. For
quantitative loading of each lantern a large excess of material is required (3.3 eq.).
The modular nature of the lanterns employed as polymer support, suppose a
disadvantage for the minimal amount of material required for loading one unit. As a
consequence, it was developed a synthetic pathway with preferred overall higher
yield in spite of the number of steps required for it.
To transform 83 into a 6-azidosugar, a very good leaving group such as tosyl could
be ideally selectively introduced, to then be displaced by the azido function. Two
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different methods employing pyridine or dibutyltin oxide catalysis[88]  were tested for
this purpose (table 15). Either due to lack of selectivity or selective but insufficient
yield of the 6-tosylated product, the overall yield obtained was still not satisfactory for
the purpose of this work. Other alternatives were studied to improve the overall yield
in spite of the additional steps required.
Table 15: Results of tosylation procedures on compound 83.
O
HO
HO
OH
PhthN
OCH3
83
O
HO
HO
OTs
PhthN
OCH3
84
TsCl Solvent Other cond. Temperature Time Yield
1.5 eq Py _ r.t. 20 h 16%a)
1.0 eq DCM Bu2SnO,
Et3N
[88]
r.t. 4 h 60%b)
a) Many polytosylated products were obtained. b) 60% of 6-monotosylated product 84 obtained
considering the starting material that was recovered. Other bi-tosylated products obtained as well.
A second alternative, including tosylation but on a protected derivative was
considered. The aim was to simultaneously protect the 3,4-OHs with the acetonide
group followed by tosylation at the 6-position with subsequent cleavage of the
acetonide group. The selective protection of the 3- and 4-positions of the fully
deprotected methyl β-D-galactopyranoside with the acetonide group is well known[72]
and was also corroborated by myself (compound 12). However, a mixture of the 3,4-
and 4,6-protected derivatives (scheme 18) was in every case obtained (table 16) with
predominance of the non-desired later product. The bulky phthalimido group might be
the cause resulting in steric hindrance around the 3-OH. This second alternative
could therefore not be employed.
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+
85 86
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Scheme 18: Lost of selectivity for the acetonide introduction at the 3,4-OHs on the 2-deoxy-2-
phtalimido derivative 83.
Table 16: Lost of selectivity for the acetonide introduction at the 3,4-OHs on the 2-deoxy-2-phtalimido
derivative 83.
2,2-dimethoxypropane Solvent catalyst Temp. Time 85:86
1.5 DMF p-TsOH⋅H2O 80°C 7 days 1:6
1.5 DMF p-TsOH⋅H2O 80°C 2.5 h 1:3
1.5 CH3CN CSA r.t. 55 h 100% 86
The third attempt to achieve a better overall yield of the entire synthesis was the one
finally applied (scheme 19). Three subsequent protecting and deprotecting steps
resulting in 78% of overall yield were applied to obtain the mesylated derivative 89
(95%), transformed into the desired azido compound 90 with 96% yield. After final
acetonide deprotection (quantitative), 91 could be coupled with the allyl-protected
linker 2. Allyl removal exposed the free carboxylic acid required for coupling with the
aminomethylated lanterns.
The overall yield could be improved by 14% and short reaction times and easy
purifications were possible.
75
O
HO
HO
OH
PhthN
OCH3
O
HO
HO
OTBDPS
PhthN
OCH3
O
O
O
OTBDPS
PhthN
OCH3
O
O
O
OH
PhthN
OCH3
O
O
O
OMs
PhthN
OCH3
O
O
O
N3
PhthN
OCH3
O
HO
HO
N3
PhthN
OCH3
O
O
OMe
OMe
O
O
O
N3
O
O
OCH3
PhthN
83 87 88
85 89 90
91 92
2
a) b) c)
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O
O
O
N3
O
Et3HNO
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PhthN
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f)
h)
Scheme 19: a) TBDPSiCl, Et3N, DMAP, DCM, r.t., 12 h (96%); b) 2,2-dimethoxypropane, p-
TsOH⋅H2O, CH3CN, r.t., 16 h (96%); c) Bu4NF, THF, r.t., 3 h (85%); d) MsCl, Py, 0°C to r.t., 2.5 h
(95%); e) NaN3, 15-C-5, DMF, 100°C, 5 days (96%); f) 80% aqueous AcOH, 80°C, 2 h, (quant); g) 2,
p-TsOH⋅H2O, CH3CN, 105°C, 66 h, (64%); h) Pd(0)(PPh3)4, pyrrolidine, N-methyl morpholine, THF,
0°C, 30 min[89], column with Et3N, (86%).
Monosaccharide mimic 93 adequately functionalized for performing amino acid
couplings at the 2-position and 1,3-dipolar cycloadditions at the 6-position on solid
phase, was obtained from glucosamine hydrochloride in 18 synthetic steps with an
overall yield of 8%. A more elegant alternative synthetic pathway via the 6-
monotosylated compound 84 was also developed and represents an alternative
method for the production of the final compound with a relatively lower yield.
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1.21.1.3 Cleavage of the allyl group.
The various functionalities present on the carbohydrate mimic 92 made it difficult to
find a selective method for the removal of the allyl-protecting group. Several methods
were tried for its cleavage (table 17). Experiments were performed using different
starting materials or a combination of them as to simulate the situation on compound
92.
First, basic conditions employing LiOH were examined. Allyl removal was previously
performed under these conditions and can be found in scheme 12, section 5.3.2.
Compound 88 was submitted to the mentioned cleaving conditions, but the
phthalimido group was as a result cleaved. Moreover, if less equivalents of LiOH
were employed as to avoid the loss of the phthalimido group, no cleavage of the ally
ester from compound 2 could be afforded.
Second, potassium t-butoxide in dimethyl sulphoxide (DMSO)[59,90-92] and THF was
employed for isomerization of the ally to its labile 1-propenyl form. No cleavage of the
allyl group was achieved.
Third, the Wilkinson catalyst was used for the isomerization of the allyl ester. A
combination of an allyl ester containing moiety (6) and an azido sugar (58) were
employed for  reproducing the s i tuat ion of  compound 9 2 .
Tris(triphenylphosphine)rhodium(I)-chloride with temperature and at room
temperature but in presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) were
tested.[58,63,93] The removal of the protecting group was still not satisfactory in the best
of the cases. Nevertheless, this experiment showed that the phosphine, probably
because it was coordinated to the transition metal, did not affect the azido
functionality of 58.
Finally, the cleaving method of choice involved the use of
tetrakis(triphenylphosphine)palladium(0) ((PPh3)4Pd(0)) with participation of a
nucleophilic base as scavenger. The selected method, shows in entries 7 and 8 of
table 17 to cleave the allyl ester and allowed the quantitative recovery of the azido-
containing compound 50 used for the test.[63]
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Table 17: Conditions tested for the removal of the allylic ester of compound 92. Experiments were
performed using different starting materials or a combination of them as to simulate the situation on
compound 92 with respect to other functionalities. The precious material 94 was not consumed.
Entry
Starting
material General conditions Temp time Result
1 88
LiOH 10 eq
Dioxane/H2O (1:1) r.t. 22 h
Phth
opening
2 2
LiOH 1.5 eq
Dioxane/H2O (1:1) r.t. 24 h n.c.
3 6
i) KtBuOH, DMSO
ii) HgO/HgOAc,
 Acetone: H2O (10:1)
i)100°C
ii) r.t.
i) 15 min
ii) 2 h
n.c.
4 6
i) KtBuOH, THF
ii) HgO/HgOAc,
Acetone: H2O (10:1)
i) 60°C
ii) r.t.
i) 24 h
ii) 5 days
n.c.
5 6 + 58
(PPh3)3RhCl (0.1 eq)
EtOH:H2O (9:1)
i) 70 °C
ii) r.t. 40 h 35%
6 6 + 58
(PPh3)3RhCl, DABCO
EtOH:H2O (9:1) r.t. 14 h n.c.
7 6
(PPh3)4Pd(0), NMM,
pyrrolidine,THF 0°C 30 min
quant.
8 50
(PPh3)4Pd(0), NMM,
pyrrolidine, THF 0°C 30 min
quant.
recover
n.c. means “no cleavage”
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Solid phase tests required for modifications at the 2-position.
To assure the lasting life of  scaffold 93 on the solid support and the correct evolution
of the experiments, few analyses were carried out in solution.
a) Stability experiments
Two stability tests under different handling conditions of intermediate steps were
performed to study the stability of the connection between linker and scaffold. The
main interest was to study the stability towards amino acid coupling conditions as
well as Fmoc-deprotection conditions. To avoid consuming 93, which is a very
expensive material in terms of effort and time, a new intermediate was synthesized in
only 4 steps from methyl β-D-galactopyranoside (scheme 20).
Derivative 96 was easily synthesized and the two isomers could be separated and
tested independently. After selective 3,4-O-isopropylidenation (quantitative), the 2-
and 6-hydroxyls were benzylated with NaH and benzylbromide (63%). Subsequent
removal of the acetonide provided the 3,4-OHs free to be coupled with the linker 1 to
form the benzylidene acetal linkage for stability studies.
O
HO
HO
OH
OH
OCH3
O
O
O
OH
OH
OCH3
O
O
O
OBn
OBn
OCH3
O
HO
HO
OBn
OBn
OCH3
O
O
O1 O
O
O
OBn
O
O
OCH3
OBn
12 94
95 96
a) b) c)
d)
Scheme 20: a) 2,2-dimethoxypropane, p-TsOH⋅H2O, DMF, 80°C, 4 h (quant.);
[72] b) NaH, BnBr, DMF,
0°C-r.t., 4 h, (63%); c) 80% aqueous AcOH, 80°C, 3 h, (94%); d) 1, p-TsOH⋅H2O, r.t., 24 h, (63%).
First, stability studies for the benzylidene acetal linkage under the Fmoc-deprotection
conditions were carried out. The amount of material that would be possible to load on
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one lantern for each isomer was separately dissolved in 20% piperidine solution in
DMF. The solutions were followed at different intervals of time by HPLC. At intervals
of 10 min during the first 30 min, and then 2 h after the beginning of the test, aliquots
of the solutions were taken and diluted with DMF. 10 µL from the resulting 1-2 mg/mL
solutions were injected in the HPLC. No changes were detected in the
chromatograms or in the UV spectrums of the peak detected. The benzylidene acetal
linkage resisted at all tested times the conditions required for Fmoc-deprotection.
Second, the stability of the benzylidene acetal linkage was investigated in a similar
way for standard amide bond formation. Both isomers of 96 were separately
dissolved in DMF and diisopropylcarbodiimide (DIC) and hydrate-1-
hydroxybenzotriazole (HOBt) were added as coupling reagents. The test was
executed in solution with the amounts required as for one lantern. In parallel, a
solution containing only DIC and HOBt in DMF was also closely followed. As
references the corresponding isomers of 96 were used as well as HOBt and DIC.
Aliquots of the test solutions were taken at different time intervals, diluted with DMF,
analyzed by HPLC and compared with the corresponding references. 96 showed to
be stable during the testing period (72 h) for the condition tested.
In addition, similar developed experiments to show the versatility of the selected
linker were performed. The linkage under study proved to be stable under basic
conditions like large excess of diethylamine, or tetrabutylammonium fluoride. This
fact can provide flexibility in modifications to be planned for solid phase with this
linker. It would be possible to work with acid labile protecting groups in the presence
of the similarly acid labile benzylidene acetal.
b) Loading experiment.
This specific experiment had to be carried out with 93, the scaffold to be modified on
solid phase. The aim was to test the quantitative character of the loading and
cleavage procedures, a prerequisite for working with the solid support.
Due to the aminomethylated nature of the lanterns, a standard coupling procedure
using DIC as activating agent in the presence of HOBt for OBt-ester formation,
resulted in a satisfactory loading protocol.[75] More than 92% of the material loaded in
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the lantern could be recovered after hydrolytic acid cleavage of the acetal linkage,
and the excess of 93 used could also be successfully retrieved. (scheme 21)
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Scheme 21: a) i) DMF, r.t., 30 min; ii) 20% Et3N, DMF, r.t. 3 x 10 min, iii) HOBt, DIC, DMF, r.t., 15
h;[75] b) 80% aqueous AcOH, 2% TFA, r.t., 2 x 15-20 h.[55]
 Amino acid coupling on solid phase.
Since the pioneering work of the Nobel laureate Merrifield in 1963, every step in the
peptide synthesis process has been scrutinized and optimized to produce high
yielding reactions. Many improvements in conditions and reagents transformed the
peptide synthesis into a reliable procedure.
The conditions used for coupling amino acids to the immobilized 2-deoxy-2-amino
sugar mimic are based in the same chemical principle as the solid phase peptide
synthesis. After phthalimido deprotection of the amino group on the immobilized 93,
an amide bond is formed by condensation of the afforded free amine with the
carboxylic acid of an Fmoc-protected amino acid. Due to the low reactivity of the
reaction partners and the establishment of a equilibrium, the carboxylic acid needs to
be activated for achieving satisfactory yields. Many different activating reagents are
available and for each case the best options should be found as to obtain the best
outcome.
Three different coupling procedures were tested in parallel on solid phase trials as to
select the best option for the present case.
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First, one of the most popular in situ activating reagents DIC was used in
combination with HOBt.[94]
Second, HBTU (2-(1-H -benzotr iazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate) assisted coupling in the presence of HOBt, for the generation
of the OBt ester was performed.[95]
The third method employed was a PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino-
phosphonium-hexafluorophosphate) mediated condensation.[96] PyBOP is a standard
in situ coupling reagent employed also in combination with HOBt.
The last two methods also require the use of a tertiary base as for example
diisopropylethylamine (DIPEA)[97]. DMF was in every case the solvent of choice.
In a first attempt, after deprotecting the phthalimido group with hydrazine in MeOH,
the lantern was left to react overnight with alanine. Analysis of the cleaved material
by MS and 1H NMR showed a mixture of two products (data not given). To elucidate
the composition of the mixture, the crude material was acetylated and only then the
products obtained separated by silica gel chromatography. It was then clear that the
amino acid-coupled and non-coupled materials were present in the original mixture in
a ratio 0.6:1. Even though the phthalimido deprotection was complete, one cylce of
amino acid coupling gave only 38% of the expected product. Several cycles of
coupling procedures had to be employed to achieve completion, a standard
procedure in solid phase synthesis. After different attempts it was found that five
coupling cycles were necessary to drive reactions to completion. Alanine was used
as Fmoc-protected amino acid for all the trials.
After five coupling cycles, all three methods provided only the expected product.
Recovery of the loaded material was satisfactory in every case (81% to 95%). In the
presence of HBTU, fewer impurities were detected by 1H NMR spectroscopy and
was the reason for selecting it as the method of choice (scheme 22).
After activation of the solid phase (provided as trifluoroacetate salt) with
triethylamine, 93 was loaded using a 3-fold excess of it (scheme 21) and standard
coupling conditions mediated by DIC/HOBt . First, the phthalimido group was cleaved
with hydrazine monohydrate in methanol using repeated cycles. Second, an Fmoc-
protected amino acid was coupled to the 2-amino sugar by HBTU assisted process.
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In every step, excess of reagents were employed for driving the reactions to
completion. Third, the Fmoc group was easily cleaved under mild conditions with an
amine base. Finally, the target product was cleaved from the solid phase by acid
hydrolysis of the benzylidene acetal linkage (scheme 22). The acetate form of the
product was obtained. Reversed phase purification with a gradient of 5% MeOH in
H2O gave the expected final products.
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Scheme 22: a) H2NNH2⋅H2O, MeOH, 80°C, 4 x 3 h, 1 x 12 h
[98]; b) Ala-Fmoc, HBTU, HOBt, DIPEA,
DMF, r.t., 3 x 4 h, 2 x 12 h; c) 20% Piperidine, DMF, r.t., 3 x 10 min; d) 80% aqueous AcOH, 2% TFA,
r.t., 2 x 15-20 h.
Compounds modified at the 2-position on solid phase.
Few compounds were synthesized following the procedure of scheme 22, to
determine the impact of the modifications of choice on the binding affinity for H1-CRD
(table 18). Glycine, Alanine and Valine were the amino acids selected.
83
Table 18: Compounds synthesized on solid phase modified by amino acid coupling at the 2-position of
a methyl β-D-galactosamine mimic.
Amino acid Compound Structure Recovery
Gly 98 O
HO
HO
N3
OCH3
NH
O
NH2
a)
Ala 99 O
HO
HO
N3
OCH3
NH
O
NH2
81% b)
Val 100
O
HO
HO
N3
OCH3
NH
O
NH2
100% b)
a) Decomposition occurred when concentrating at 40°C under reduced pressure. Colorless to
yellowish color change was observed. The residue after evaporation represented 100% of the
material loaded, however, after purification only 20% of the material could be obtained. b)
Purity equal or higher to 98% according to 1H NMR.
1.22 Competitive target-based and Biacore assays (In collaboration with D.
Stokmaier and Dr. D. Ricklin from the Institute of Molecular Pharmacy,
University of Basel).
Competitive target-based assays (section 3.5) as well as SPR experiments (section
3.6) were carried out with the compounds modified by amino acid coupling (98 to
100 ). These experiments allowed evaluating the impact of these specific
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modifications on the affinity for H1-CRD. The use of the two complementary analyses
offered highly reliable data.
Competitive target-based assay.
IC50 values for compounds 98 to 100 (table 18) were determined with the competitive
target-based assay (table 19). Unless specified, duplicates were performed with good
reproducibility.
All three compounds modified at the 2-position by amino acid coupling showed
increased affinities towards H1-CRD compared to methyl β-D-galactopyranoside. The
best inhibitor found was the alanine derivative 99, which competed approximately 20-
fold more effectively than Gal, and 12-fold with respect to methyl β-D-
galactopyranoside for binding to the H1-CRD. The IC50 value of 99 was nearly half
(1.7 times better) of that of GalNAc.
Table 19: IC50 (µM) of methyl 6-azido-β-D-galactosamine derivatives modified at their 2-position.
Compound Amino acid IC50 (µM)
98 Gly 401 a)
99 Ala 46 ± 9
100 Val 385 ± 61
Gal - 1754 ± 57
Me β-D-Gal - 545 ± 39
GalNAc - 78 ± 5
Me 6-azido-α-D-Gal - 1200 b)
46 248 ± 41
Values are the media ±  standard deviation of two independent measurements. a) Only one
determination performed. b) Data from Lee et al.,[38] IC50 value determined for isolated rabbit lectin for
methyl 6-azido-α-D-galactopyranoside.
Lee et al.[38] determined in competitive assays IC50 values for the isolated rabbit
lectin. It was showed in the present work, the close relationship between the IC50
values obtained for both receptors; H1-CRD and the rabbit lectin (table 9). Methyl 6-
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azido-α-D-galactopyranoside showed in the experiments of Lee and co-workers[38] no
improvement in the binding affinity as a consequence  of the introduction of the azido
group at the 6-position. In our collected data, the azido derivative 46 (1,5-anhydro-6-
azido-2-deoxy-D-lyxo-hexitol) showed an important increase in the binding affinity
compared to the IC50 value of 1,5-anhydro-2-deoxy-D-lyxo-hexitol (3). Further studies
to evaluate the real influence of the 6-azido group will still be performed.
 Biacore assays.
Biacore determinations of equilibrium dissociation constants (KD) of compounds 46
and 98 to 100 were carried out (table 20). Gal, methyl β-D-Gal and GalNAc were
used as reference compounds.
Table 20: Equilibrium dissociation constants KD (µM) of methyl 6-azido-β-D-galactosamine derivatives
modified at their 2-position by amino acid coupling.
Compound Amino acid KD (µM)
98 Gly 1120
99 Ala 134
100 Val 1268
Gal - 2080
Me β-D-Gal - 1780
GalNAc - 112
46 - 855
Randomized triplicate injections of 8 concentrations (three fold serial dilutions) between 6.0 mM and
2.7 µM were performed.
All compounds tested in Biacore showed an increased affinity for the receptor with
respect to Gal and methyl β-D-galactopyranoside. The binding affinity of compound
99 was of the same order of magnitude as GalNAc while for the other two N-acyl
derivatives measured only a two-fold improvement in the binding affinity was
detected relative to Gal. In the case of the galacto-mimic 46 (1,5-anhydro-6-azido-2-
deoxy-D-lyxo-hexitol), the binding affinity for H1-CRD was two times better than for
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methyl β-D-galactopyranoside. The differences recorded between compounds can be
appreciated in figure 19 where the response obtained for each analyte was plotted
against the concentration. In the first set of graphs, the responses were normalized
with the reciprocal of the MW (due to negative SPR responses) of the corresponding
compounds (section 5.4.2). In the second set of curves (figure 19) the normalization
was done considering also the maximum response achieved. Only by doing so did it
become clear for all the analyzed compounds that there is a parallel shift towards
lower concentrations of the inflection point of the curves. The high similarity in
binding behaviour between GalNAc and 99 can also be observed.
Figure 19: Curves of SPR response vs. concentration. Normalization by the reciprocal of the MW was
done in the first set of curves and also to the maximal response, where the saturation is achieved, in
the second set. Measurements were performed in 10 mM HEPES buffer with 50 mM CaCl2, pH 7.4
with 3% DMSO. Randomized triplicate injections (three fold serial dilutions) between 6.0 mM and
2.7µM were done.
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 Biacore ranking vs. IC50 determination.
IC50 values determined using the competitive target-based assay were compared to
the equilibrium dissociation constants (KD) determined by Biacore experiments (table
21, figure 20).
Table 21: IC50 (µM) values determined by competitive target-based assay and equilibrium dissociation
constants KD (µM) determined by SPR for the methyl 6-azido-β-D-galactosamine derivatives modified
at their 2-position by amino acid coupling.
Compound Amino acid IC50 (µM) KD (µM) 
b)
98 Gly 401 a) 1120
99 Ala 46 ± 9 134
100 Val 385 ± 61 1268
Gal - 1754 ± 57 2080
Me β-D-Gal - 545 ± 39 1780
GalNAc - 78 ± 5 112
46 - 248 ± 41 855
IC50 values are the media ± standard deviation of two independent determinations except for a) in
which only one measurement was performed. b) Obtained from randomized triplicate injections of 8
concentrations (three fold serial dilutions) between 6.0 mM and 2.7 µM.
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Figure 20: Graphic comparison of IC50 (µM) values and equilibrium dissociation constants KD (µM) for
methyl 6-azido-β-D-galactosamine derivatives modified at their 2-position with amino acids. Relevant
reference compounds are included. Same batch of H1-CRD was employed in both experiments.
Standard deviations are not graphically represented.
All KD values obtained by SPR were higher than the corresponding IC50 values
determined with the competitive target-based assay. Values generated by Biacore
were always 2-3 times higher than by competitive assay. However, the general
monosaccharide ranking, when the standard deviations were considered, was
consistent in both experiments.
The competitive target-based assay proved to be more sensible to the changes than
Biacore for molecules with improved affinities relative to Gal but still in the high or
medium µM range (IC50 of 300-500 µM). However, when a real improvement in the
binding affinity occurs, like in the case of 99, both experiments measured it similarly.
Compound 99 reached binding affinity values in the low µM range, very similar to
GalNAc.
Using instead methyl β-D-galactopyranoside as reference compound, differences
between the binding affinities determined for a given analyte in both experiments
(Biacore and competitive-assay) were conserved. Methyl β-D-galactopyranoside is
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still a weak antagonist (mM range) but 2-3 times better than Gal allowing better
comparisons between values.
Compounds 98 (glycine coupled) and 100 (valine coupled) resulted only between 1.3
to 1.5 times better binding monosaccharide mimics than methyl β-D-
galactopyranoside. Valine may cause steric hindrance problems and glycine
possesses a much more flexible chain than alanine. These two factors may prevent
an improved fit into the binding pocket of H1-CRD. Similar relationships between
binding affinities and the types of N-2 linked chain were reported in the literature by
Iobst and Drickamer[32]. Binding of a series of N-acyl derivatives of galactosamine
suggested a better interaction with the rat hepatic lectin than with Gal or even
GalNAc. The highest binding affinity was observed for the N-propionyl derivative,
similarly to the tendencies observed in our case (table 22). Among our compounds
the alanine derivative 99, which possesses a 3 C N-acyl chain coupled at the 2-
position, also resulted in the best binder. Furthermore, the relative potency to GalNAc
found for 99  is very similar to that one found in the literature for the N -iso-
butanoylgalactosamine, which conserves a higher structural similarity with our
alanine coupled derivative.
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Table 22: Relative potencies to GalNAc of a panel of N-acyl derivatives. First, derivatives reported in
the literature[32] tested towards the rat hepatic lectin are presented. Second, the monosaccharide
mimics modified in the present work with amino acids at the N-2 position and tested towards H1-CRD
are shown.
N-acyl
derivatives[32] O
HO
HO
OH
NH
O
OH
O
HO
HO
OH
NH
O
OH
O
HO
HO
OH
NH
O
OH
O
HO
HO
OH
NH
O
OH
  
€ 
IC50
IC50GalNAc
(rHL-1)a)
13 ± 1 0.13 ± 0.04 0.82 ± 0.06 0.29 ± 0.06
O
HO
HO
N3
OCH3
NH
O
NH2
98
O
HO
HO
N3
OCH3
NH
O
NH2
99
O
HO
HO
N3
OCH3
NH
O
NH2
100
  
€ 
IC50
IC50GalNAc
(H1-CRD)
5 0.6 5
a) Iobst and Drickamer[32] informed the values as Ki. However, a competitive binding assay was
performed and they defined Ki values as the concentration of monosaccharide giving 50% of inhibition.
As a consequence, their values were employed as IC50 values for this comparative table.
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Influence on the binding affinity of the combined actions of the 2- and 6-
positions of galactose mimics.
The aim of the present chapter is the study of the combined influence and the impact
on the binding affinity of substitutions at the 2- and 6-positions of the galacto moiety.
It is of high interest to determine if an added effect could be observed and thus, the
affinity for H1-CRD further optimized. Comparisons of the 2,6-disubstituted
compounds with their parent mono substituted models will permit to evaluate the real
contribution of each partner to the overall binding affinity.
The new combined strategy will take advantage of some of the benefits of solid
phase chemistry. Reactions that were employed with satisfactory to very good yields
can be now driven to completion by using excess of reagents and repeated reaction
cycles.[45,54,99] The general approach in this thesis was the synthesis of various small
libraries that will provide more diverse information than a single big library.[49]
A set of ten new compounds was synthesized by modifying the 2- and 6-positions of
building block 91 (methyl 6-azido-2-deoxy-2-phthalimido-β-D-galactopyranose),
immobilized on solid phase as 93. This scaffold was developed in section 6.3.1 for
amino acid couplings on solid phase. Firstly, amino acid couplings were performed
as described in section 6.3.3 . Secondly, copper-(I)-catalyzed 1,3-dipolar
cycloadditions between the 6-azido group and acetylenes were performed.
1.23 Solid phase preliminary experiments.
Solid phase reactions are not always as easily monitored as solution chemistry. For
this reason a series of experiments were performed to reduce the number of possible
problems along the synthetic pathway. Single problems were solved in advance and
therefore avoided on the more complex system.
Experiments to optimize the solid phase procedure were run along the whole project.
As a consequence, many of those tests were already presented. In this chapter, only
a compilation of the performed studies can be found.
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Loading capacity.
The aminomethylated polystyrene lanterns (Mimotopes SynPhaseTM, D series) used
as polymer support possess a declared average loading capacity of 35 µmol per unit.
This capacity was verified by our own methods to adjust the amount of starting
material required and to exclude problems during loading and cleavage optimization.
The method employed was based on the quantitative determination of an UV active
specie loaded and subsequently cleaved from the support material.
The polymer support, provided in its trifluoro acetate form, was first let to swell in
DMF followed by activation with triethylamine. After standard washing protocols, the
polymer support was coupled with Fmoc-protected succinimidyl carbonate. Three
hours later, the ninhydrin test[94] for detection of primary amines was negative (yellow
color), indicating that the coupling was complete. The Fmoc group was then cleaved
in a volumetric flask (scheme 23). The resulting solution, after adequate dilutions,
was used for determining the Fmoc concentration, calculated from the UV absorption
at 300nm and directly related with the amount of reacting sites in the lantern.
The average loading capacity determined was 37 µmol and was obtained from two
measurements.
NH3TFA NH2 NHFmoc
a) b)
Fmoc
c)
Scheme 23: a) i) DMF, r.t., 30 min, ii) 20% Et3N in DMF, r.t., 3 x 10 min; b) 9-fuorenylmethyl N-
succinimidyl carbonate, DIPEA, THF, r.t., 3 h;[100] c) 20% Piperidine in DMF, r.t., 30 min.
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Linker stability assays.
The stability and compatibility with the chemistry of choice of the acetal linkage
between compounds 1 or 2 and the various scaffolds employed, is summarized here.
The linker proved to be stable under different conditions for amide bond formation as
well as Fmoc deprotection (sections 6.3.2 and 6.3.3). Moreover, it also showed good
stability under the click chemistry conditions (section 5.3.2). In addition, it remained
stable in presence of large excess of diethylamine, tetrabutylammonium fluoride,
sodium methoxide and 1,5-diazobicyclo [4.3.0] non-5ene (DBN) (section 5.1.2).
The versatility of the linker and linkage of choice was demonstrated and provides
open access to many possible chemistry methods.
 Loading and cleaving procedures.
Coupling the activated aminomethylated solid support with two different initial
materials immediately followed by their cleavage from the solid phase helped to
optimize both processes.
Compounds 7 and 93 (see also section 6.3.2) were coupled with the solid phase
using DIC and HOBt as activating reagents.[75]
Acid hydrolysis of the acetal connection between linker and scaffold was employed
for cleaving the immobilized material. Treatment of the lantern with 80% aqueous
AcOH containing 2% of trifluoroacetic acid (TFA)[55] was compared with milder
methods such as 4% TFA in MeOH or dioxane.[57] These two last methodologies did
not provide the expected cleaved material. Nevertheless, the first method provided
the expected compounds in satisfactory yields. In the case of compound 7, a mixture
of products was obtained after cleavage caused by the deprotection of the acid labile
TBDPS group. The fully deprotected hexitol 3 and its 6-acetylated derivative (101)
were obtained. The recovery represented 75 % of the theoretical loading capacity
(scheme 24).
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Scheme 24: a) i) 20% Et3N, DMF, r.t. 3 x 10 min, ii) HOBt, DIC, DMF, r.t., 15 h;
[75] b) 80% aqueous
AcOH, 2% TFA, r.t., 2 x 15-20 h.[55]
1.24 Synthesis of the library on solid phase.
A collection of 10 derivatives (102 to 111) of methyl β-D-galactosamine, modified at
the 2- and 6-positions on solid support, was synthesized.
Scaffold 91 (scheme 19) was coupled with 2 and immobilized on the polystyrene
lanterns. First, following the removal of the phthalimido protection at the 2-position,
amino acid couplings were performed. The same procedure used in section 6 was
employed. Five consecutive HBTU mediated standard coupling cycles in the
presence of HOBt and DIPEA were applied to drive the reactions to completion at the
hindered 2-amino group. Glycine, alanine and valine were the selected amino acids.
Second, the azido group introduced at the 6-position of the sugar moiety was
employed for performing copper-(I)-catalyzed 1,3-dipolar cycloadditions between it
and a number of acetylenes. The successful trial for click chemistry on solid phase by
immobilization of 49 (section 5.3.2), indicated a good transposition from solution to
solid phase of this type of chemistry.
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Click chemistry optimization.
Performing 1,3-dipolar cycloadditions on the new immobilized scaffold 91 (or 93)
involved many optimization efforts to obtain quantitative single products. In spite of
the lower reactivity of the methyl 2-N-acyl-2-deoxy-6-azido-β-D-galactoside mimic for
1,3-dipolar cycloadditions than its hexitol counterpart it was possible to optimize
conditions in order to obtain quantitative conversions. In all the cases tested, excess
of acetylenes was employed and reactions were run during four consecutive days,
starting each day a new synthetic cycle. Each cycle was started by treatment of the
lantern with a freshly prepared solution of the corresponding alkyne. Four to five
additions of sodium ascorbate and copper sulfate as to produce in situ the catalyst,
were performed every 3 hours during the course of one cycle.
In all the attempts during optimization, the recoveries of loaded material were
satisfactory (table 23), indicating good performance of every other step involved in
the methodology. For the calculations of the recovered material, the MWs of the
corresponding acetates were used considering that after cleavage the acetate form
of the derivatives modified by amino acid coupling was obtained.
The protocol used for modifying the hexitol derivative on solid phase by click
chemistry (section 5.3.2), was initially applied on the polymer bound 93. This method
involved three consecutive cycles of reaction (one day per cycle) and three
equivalents of acetylene each time. However, the expected product could not be
obtained under these conditions for the new scaffold 93 (entry 1, table 23). As a
consequence, different experiments were run to determine the optimal conditions
(table 23).
First, the amount of alkynes employed was increased to 9 and 10 equivalents.
However, even if a slight improvement could be observed, results were still not
satisfactory as to obtain a robust methodology. Employing 9 equivalents of 3-ethynyl
thiophene (entry 2, table 23) generated a mixture of two products in the cleaved
material. Only 43% was the expected product and the rest was the 2-N-acyl modified
compound synthesized in the previous step (amino acid coupling). However, for other
alkynes either no reaction was observed or in the case of 3-ethynyl-α ,α,α-
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trifluorotoluene (entry 5, table 23) only traces of the product were detected. The
product cleaved from solid phase resulted to be compound 99.
As a consequence of the problems found during optimization on solid phase, studies
in solution were performed to investigate about the intrinsic reactivity of the scaffold
without the influence of the solid phase that renders the reactive sites less
accessible.
Compound 99, was then reacted in solution for obtaining the [1,2,3]-triazole. After
two days of reaction and having added in total 15 equivalents of the corresponding
alkyne (3-ethynyl-α,α,α-trifluorotoluene), only a very small amount of the expected
product was obtained (entry 6, table 23). Two products could clearly be detected in
the crude mixture obtained after the reaction. The presence of the triazole in one of
them was clear due to the strong shift to lower fields experienced for the H-6 protons
in the 1H NMR spectrum (H-6: 99 → 109 δ 3.24 and 3.68 ppm → 4.77 ppm). After
purification of the material by reversed phase chromatography, with a gradient of 5%
MeOH in H2O, only 27% of the material recovered was the expected 1,4-
disubstituted-[1,2,3]-triazole 109, while the rest was compound 99. This trial put into
evidence two points: first it was shown that the azido group was intact and reactive;
second, it emphasized the intrinsic lower reactivity of the 6-azido in the galactose
mimic 91 compared with the hexitol derivative 46. The observation justified an
important increase of the equivalents of alkyne employed in solid phase considering
on one hand the already high quantities required in solution and on the other hand,
the excess usually demanded by solid phase reactions.
Finally, by increasing the amount of alkyne equivalents to 30, the expected triazoles
could be afforded in quantitative yields independent of the acetylenes employed and
with more than 98% purity according to 1H NMR results. (scheme 25)
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Table 23: Trials for solid phase optimization of 1,3-cycloaddition reactions on the immobilized scaffold
93. Previous modifications by amino acid couplings at the 2-position were performed.
Entry Alkyne
Equivalents
per cycle
Type of
chemistrya) Outcome Recovery
1
S
3 SP Not obtained 79%
2
S
9 SP 43% 90%
3
OH
10 SP Not obtained 91%
4 10 SP Not obtained 86%
5
CF3
10 SP Not obtained 89%
6b)
CF3
15 Solution 27% -
7 N
N
N
30 SP quantitative 60%
8
Cl
30 SP quantitative 80%
a) SP means “solid phase” reactions. b) Reaction performed in solution using as starting material
compound 99 obtained from the cleaved material from entry 5.
The difficulties found in the triazole formation at the 6-position of 93 compared to the
use of 49 as scaffold could be explained by the more electro deficient azido group of
93 consequence of the effect of the close anomeric center.
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Scheme 25: a) i) DMF, r.t., 30 min, ii) 20% Et3N, DMF, r.t., 3 x 10 min; b) DIC, HOBt, DMF, r.t., 15
h;[75] c) H2NNH2⋅H2O, MeOH, 80°C, 4 x 3 h, 1 x 12 h;
[98] d) Ala-Fmoc, HBTU, HOBt, DIPEA, DMF, r.t.,
3 x 4 h, 2 x 12 h; e) Alkyne (30 eq), sodium ascorbate, CuSO4⋅5H2O, H2O/t-BuOH (1:1),
[47]r.t., 4 x 24
h; f) i) 20% Piperidine, DMF, r.t., 3 x 10 min, ii) 80% aqueous AcOH, 2% TFA, r.t., 2 x 15-20 h.[55]
Synthesis of the library.
A collection of 10 methyl β-D-galactoside mimics (102 to 111), modified at the 2- and
6-positions on solid phase, was successfully synthesized (table 24).
During the library production all compounds that could not be previously obtained
during the optimization process with fewer equivalents of alkynes were obtained in
quantitative amounts with the new methodology developed. That is the case of
compounds 104, 108 and 109 (table 23).
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Table 24: Compounds synthesized on solid phase modified at the 2- and 6-positions of building block
93.
Compound R1 R2 a) Recovery b)
102 Gly 100%
103 Gly 96%
104 Ala 82%
105 Ala 93%
106 Cl Ala 80%
107 N
N
N
Ala 60%
108
S
Ala 100%
109 CF3 Ala 93%
110 Ala 100%
111 Val 100%
R1 and R2 as in scheme 23. a) N-acyl derivative from Gly, Ala or Val. After cleavage, the acetate form
was obtained. After reversed phase chromatography the free amino group was afforded. b)
Percentage of loaded material recovered after cleavage considering 35 µmol as the theoretical
capacity of one lantern.
1H NMR spectroscopy was performed with the materials obtained after cleavage and
evaporation until dryness with a geenevac. For all new entities except 103 and 104,
only one product could be detected with purities equal or above 98%. In the case of
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102 and 104, the crude 1H NMR was very affected by rests of copper, not allowing
the direct identification of the products. However the signal corresponding to the H-6
protons was clearly identified. The strong shift suffered by the H-6 signal to lower
fields indicated the formation of the triazole ring. In addition, only the mass of the
expected product could be found in mass spectrometry after sample filtration. As a
consequence, it is possible to affirm that the desired products were obtained in these
two cases as well but it was impossible to determine their purity directly after
cleavage. The free amino group of the compounds was only obtained after
purification by reversed phase chromatography.
Purification.
All compounds obtained from solid phase synthesis were purified before submitting
them to the competitive target-based assay. Different methods for purification by LC-
MS were tried.
First, an analytical run for compound 107 using a SunFireTM C18 column with
CH3CN/H2O with additional 0.2% formic acid as mobile phase was performed. The
linear gradient run from 5% to 95% acetonitrile in 7 min followed by 2 min at 95%,
before returning to the initial conditions in another 2 min. The product came with the
injection peak and no separation at all was achieved. Second, the system was run
free of formic acid to avoid the protonation of the amino acid and the triazole rings
present. However, no modification of the elution pattern was observed.
Third, a change in the elution gradient from the standard one was tried. In absence of
formic acid, 100% water was used as mobile phase and only after the first 8 min a
1:1 mixture of CH3CN/H2O was applied for 2 min to return then to the initial solvent.
Once again the peak corresponding to the expected mass was found with the
injection one.
Finally, a new type of silica gel based column that allows better interactions with
basic substances was employed. A Reprosil-Pur basic analytical column from Dr.
Maisch GmbH (5 µm, 4.6 x 250 mm) was employed with a flow of 1 mL/min and was
submitted to a linear gradient of CH3CN/H2O as in the standard procedure with
absence of formic acid. In this case, a good separation was achieved. The retention
time of the peak of interest was 8.31 min. The method could therefore be employed
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for purifying the library in an automated way. However, a preparative column of these
characteristics was not available in our facilities. As a consequence, each compound
was manually purified by reversed phase chromatography with a 5% MeOH gradient
in H2O.
1.25 Competitive target-based assay (In collaboration with D. Stokmaier and Dr D.
Ricklin from the Institute of Molecular Pharmacy, University of Basel).
Methyl β-D-galactoside mimics 102 to 111 were submitted to the competitive target-
based assay for determination of their IC50 values (table 25).
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Table 25: IC50 (µM) values determined by competitive target-based assay for compounds 103-112.
Compound R1 R2 a) IC50 (µM)
102 Gly 228 ± 176
103 Gly 403 b)
104 Ala 98 ± 2
105 Ala 34 ± 4
106 Cl Ala 126 ± 29
107 N
N
N
Ala 64 ± 46
108
S
Ala 63 ± 38
109 CF3 Ala 48 ± 15
110 Ala 62 ± 0.4
111 Val 287 b)
R1 and R2 as in scheme 23. a) N-acyl derivative from Gly, Ala or Val. Values are the media ± standard
deviation of two independent measurements except for b) where only one measurement was done.
Good reproducibility between independent determinations was in general obtained.
Firstly, all compounds had improved binding affinities towards H1-CRD relative to
methyl β-D-galactopyranoside. All derivatives coupled with alanine had lower IC50
values than their glycine or valine counterparts. The same general behavior observed
for the compounds modified only at the N-2-position with N-acyl chains (98 to 100)
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was observed. That is to say, 2,6-disubstituted compounds with alanine coupled at
the N-2 were all in the binding affinity range of GalNAc and in most of the cases even
slightly lower. For all compounds coupled with one specific amino acid no preference
between the various substituent types of the triazoles could be observed. Moreover,
no changes in the binding affinity were experienced as a consequence of the
different modifications introduced at the 6-position. (table 26)
Only the triazole ring might be able to establish contact with the Trp 243 of the
receptor. Nevertheless, the 4-substituents at the triazole do not interfere with the
binding and bulky substituents could be accommodated. The 6-position of the studied
derivatives does not further improve the binding affinity of the 2-substituted
compound but it also does not interfere with it.
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Table 26: Comparison of IC50 (µM) values for 2,6-substituted galactose mimics and their mono
substituted parents.
R a) Gly b) Ala b) Val b) Hexitol mimics c)
N3 401 46 ± 9 385 ± 61 248 ± 41
N
N
N
228 ± 176 98 ± 2 - -
N
N
N
403 b) 34 ± 4 - Precipitated
during assay
N
N
N
Cl - 126 ± 29 - -
N
N
N
CF3 - 48 ± 15 - 481 ± 127
N
N
N
- 62 ± 0.4 287 b) -
N
N
N
S
- 63 ± 38 - 421 d)
N
N
N
N
N
N
- 64 ± 46 - -
a) R is the 6 substituent. b) N-acyl derivative from Gly, Ala or Val. c) Hexitol mimics 47-49. Values are
the media ± standard deviation of two independent measurements except for d) where only one
measurement was performed.
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Conclusion and outlook
Summary of the thesis.
The ASGP-R, exclusively located on the cell surfaces of hepatocytes, is well known
for removing desialylated glycoproteins with terminal galactose or N -
acetylgalactosamine residues from circulation. However, small high affinity ligands
with more drug-like properties than the natural glycoproteins, that can be used for
specific targeting of the liver, were not yet investigated for the human H1-CRD.
Various small-directed libraries of galactose derivatives and mimics thereof were
synthesized in this work. The design of the ligands was based on the crystal structure
of the H1-CRD[10], and on data from in silico studies[40] as well as from previous SAR
studies for similar receptors. The influence of different types of modifications at the
galacto moiety on the binding affinity, were analyzed by a competitive target-based
assay and Biacore experiments, both performed with immobilized H1-CRD.
Monosaccharide mimics with slightly improved binding affinities for the H1-CRD
relative to GalNAc were found. This work provides experimental data for simple
synthetic ligands of the H1-CRD and therefore gives guidelines for the rational design
of a novel generation of improved ligands.
1.26 Galactose mimics modified at their 6-position.
Galactose mimics based on the 1,5-anhydro-2-deoxy-D-lyxo-hexitol core were
modified at their 6-position by conjugated additions, nucleophilic substitutions and
1,3-dipolar cycloadditions. Compound 3 was used as scaffold (figure 14). By
substituting its 6-position it was attempted to establish hydrophobic interactions with
the Trp 243. Due to the reduced number of sites with similar reactivity, short synthetic
pathways provided fast access to these ligands.
All the derivatives competed approximately two to three-fold better for H1-CRD than
Gal (figure 21). Binding affinities comparable to the one of methyl β -D -
galactopyranoside were obtained. Since for derivatives modified with 1,4-
disubstituted-[1,2,3]-triazoles (45, 50), the behavior was independent of the 4-
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substituent at the triazole, the interaction with Trp 243 is possibly restricted to the
triazole ring. The 6-position is directed towards the surrounding water and bulky
substituents could be accommodated without interfering with the binding.
O
HO
HO
OH
IC50 (µM) 1399    368
KD = 1480
O
HO
HO
SR
IC50 (µM) 690 to 310
O
HO
HO
N
NN
R
IC50 (µM) 610 to 420
3 28-38 45, 50
O
HO
HO
OH
OH
OMe
IC50 (µM) 545    39
KD = 1780
Methyl β-D-Gal
Figure 21: Reference compound 3 and general structures of galactose mimics synthesized. Minimum
and maximum IC50 (µM) values, considering the standard deviations, are indicated for each family of
compounds. Two independent determinations were performed, except for 3 where three independent
measurements were done.
Compound 39 , obtained as secondary product from Michael additions and
nucleophilic substitutions, showed a comparable binding affinity as GalNAc (figure
22) in the competitive target-based assay. However, Biacore monitoring of the direct
interaction between 39 and the immobilized H1-CRD did not show a comparable
increase of the binding affinity. Since hexitol 39 has two pairs of free 3,4-hydroxyls in
equatorial and axial arrangement, the difference may come from a local
concentration effect which could convert two weak binders into one highly improved
binder.[34,36,45]
O
HO
HO
S
O
HO
OH
S
39
IC50 (µM) 94    18
O
HO
HO
OH
AcHN OH
GalNAc
IC50 (µM) 78    5
Figure 22: IC50 (µM) values obtained from the competitive target-based assay. The values are the
media ± standard deviation of two independent determinations.
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In general, galactose mimics modified at the 6-position by hydrophobic groups
showed only a modest improvement of the binding affinity for H1-CRD relative to Gal.
However, bulky groups in the 6-position did not interfere with the binding indicating
that this position can be used to link the targeting device with a possible drug.
1.27 Galactose derivatives and mimics thereof modified only at their 2-
position.
To investigate the role that modifications at the 2-position of the galactose moiety
may play, two families of derivatives were synthesized (figure 23).
O
HO
HO
N3
OCH3
NH
O
NH2
O
HO
HO
N3
OCH3
NH
O
NH2
O
HO
HO
N3
OCH3
NH
O
NH2
98 
IC50 (µM)  401
KD (µM) 1120
99 
IC50 (µM)  71   32
KD (µM) 134
100
IC50 (µM)  385   61
KD (µM) 1268
O
HO
HO
N3
46
IC50 (µM)  248   41
KD (µM) 855
O
HO
HO
OH
O
OCH3
NN
N
R
66 to 75
IC50 (µM)  592 to 
1209
Figure 23: Two families of galactose derivatives modified at the 2-position and galactose mimic
46.
Compounds 66 to 75 were obtained by 1,3-dipolar cycloadditions performed on an
azido group at the C-2’ linked to the 2-OH of the sugar scaffold. They do not show
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improved binding affinity in the competitive assay and the Biacore experiments.
Derivative 72 was the only member of this group to show a binding affinity (IC50 (µM)
= 110 ± 13) comparable to the one of GalNAc. However, a different binding mode
was found by biosensor studies of the direct interaction between this compound and
the immobilized monomer of H1-CRD.
2-N-acyl derivatives of a methyl 6-azido-β-D-galactopyranoside were synthesized on
solid phase by amino acid coupling at the N -2-position of the sugar moiety.
Compounds 98-100 showed improved binding affinities for the H1-CRD relative to
methyl β-D-galactopyranoside (figure 23). Whereas derivatives acylated with glycine
(98) or valine (1 0 0) experienced only a modest improvement of their binding
affinities, the 2-(2-amino propionamido) derivative 99 achieved a binding affinity
approximately 1.5 to 2-fold better than GalNAc and 12-fold better than methyl β-D-
galactopyranoside. Even though the galactose mimic 46 containing an azido
functionality at the 6-position, competed 2 to 3 times better for binding to the H1-CRD
relative to 3, the 6-azido group present also in derivatives 98-100 does not contribute
to the binding.
N-acyl coupled chains appear to improve the binding affinity for the receptor
depending on the size of the acyl group. The propionamido derivative displayed the
lowest IC50 value and therefore the optimal chain length studied. It is possible that
such N-acyl derivatives allow establishing an optimal interaction with His 256,
through H-bond formation with the hydrogen of the nitrogen of the N-acyl group.  This
interaction is known for being responsible for the preferential binding of GalNAc with
respect to Gal.  2-N -acyl derivatives are an excellent starting point for the
development of novel high affinity ligands for the H1-CRD.
1.28 Monosaccharides mimics modified simultaneously at their 2- and 6-
positions.
Methyl β-D-galactosamine-derivatives modified at the 2- and 6-positions were
synthesized to elucidate the hypothesis of an added effect on the binding affinity. A
collection of ten di-substituted galactose mimics was synthesized on solid phase with
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excellent yields. Amino acids were first coupled with the N -2-position of a
galactosamine mimic and modified Huisgen 1,3-dipolar cycloadditions were
performed at the 6-position of the monosaccharide mimic.
Results from the competitive target-based assay indicated that all the derivatives
synthesized were better binders for the H1-CRD than methyl β-D-galactopyranoside.
However, all di-substituted compounds showed very similar IC50 values to their
parent derivatives N-acyl monosubstituted (98-100). Improved binding due to the
additional 6-substitution could not be observed. The better-defined orientation of the
monosaccharide in the binding pocket, after establishing additional interactions
through its 2-N-substituent, could be the reason for the loss of a complementary 6-
interaction. In addition, this hypothesis may also explain the behavior observed in the
preliminary IC50 determination for compound 69 relative to 68 (figure 24). In the
presence of the substitution in 2-position, compound 68 did not showed an improved
binding affinity compared to Gal. Lacking good interactions with the protein in the
region of the 2-position of Gal, the substituent at the 6-position in 69 could improve
binding.
O
HO
HO
OH
O
OCH3
NN
N
S
O
HO
HO
O
O
OCH3
NN
N
S
O
68 
IC50 (µM) 952
69 
IC50 (µM) 592
Figure 24: Influence of the 6 position in a weak binder.
Since none of the substituents employed at the 6-position interfered with the binding,
a collection of eight derivatives obtained by amino acid coupling with alanine (99 and
110
104-110), with similar or slightly improved binding affinities than GalNAc was
obtained for the H1-CRD (figure 25).
O
HO
HO
N
OCH3
NH
NN
R
O
NH2
104 to 110
IC50 (µM) 155 to 30
O
HO
HO
N3
OCH3
NH
O
NH2
99
IC50 (µM) 71    32
Figure 25: High affinity galactose mimics synthesized for the H1-CRD.
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Outlook.
The results obtained in this thesis may be applied to produce a new generation of
ligands for the H1-CRD.
First, the synthesis of three 2-substituted galactose derivatives (figure 26) may be
envisaged.
O
HO
HO
R1
OCH3
NH
O
112
O
HO
HO
R1
OCH3
NH
O
R2
113
O
HO
HO
R1
OCH3
O
114
Figure 26: Further exploration of the binding site; R1: OH, N3; R
2: H, CH3, OH.
The influence of the one-carbon extension of the N-acyl chain of 99 on the binding
affinity could be studied with compound 112. Between the propionamido derivative
99 and the valine-derivatized compound 100 exists a space to be analyzed for
determining the real optimal length preferred for the N-acyl chain. Moreover, the
absence or replacement of the α-amino group on the N-acyl chains (113) would allow
further exploration of the binding site and the type of established interactions.
Substituents as H, CH3 and OH are suggested in order to determine whether
hydrophobic interactions or H-bond formation are preferred. Additionally, compound
114 will help to establish if the N-acyl derivatives have a preferred binding relative to
their O-counterparts due to specific interactions with His 256.
Second, compound 99 could be employed to synthesize a triantennary ligand[36] for
the H1-CRD. Determination of the IC50 value of the novel multivalent ligand in a
competitive assay and comparison with a triantennary galactose ligand would be of
high interest for the development of liver targeting strategies. Additionally, a
comparative study of its cellular uptake by the hepatocytes would also be required.
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Experimental
General
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer.
Assignments of 1H and 13C NMR spectra were achieved using 2D methods (COSY,
HSQC). Chemical shifts are expressed in ppm using residual CHCl3, CHD2OD and
HDO as references. Optical rotations were measured using Perkin-Elmer
Polarimeters 241 and 341. ESI-MS and LC-MS analyses were carried out with a
Waters micromass ZQ spectrometer equipped with ELS detector (waters 2420) and
photodiode array detector (waters 2996). All spectra were recorded in positive mode.
The LC-MS was equipped with an analytical SunFireTM column from Waters C18 (3.5
µm, 2.1 x 50 mm) and 0.2 mL volume. The mobile phase was CH3CN/H2O with
additional 0.2% formic acid, using a flow rate of 0.5mL/min. The linear gradient run
from 5% to 95% acetonitrile in 7 min followed by 2 min at 95% before returning to the
initial conditions in another 2 min. IR spectra were obtained with a Perkin-Elmer
Spectrum One FT-IR spectrometer. Elemental analyses were carried out with a
Perkin-Elmer 240 analyzer. Reactions were monitored by TLC using glass plates
coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or a
developing solution (0.02M solution of ammonium cerium sulfate dihydrate and
ammonium molybdate tetrahydrate in 10% H2SO4). Column chromatography was
performed on silica gel (Fluka 60). Reversed- phase chromatography was done on
LiChroprep RP 18 (Merck). Methanol (MeOH) was dried by refluxing with sodium
methoxide. Pyridine (Py) was freshly distilled over CaH2. Tetrahydrofuran (THF) was
dried by refluxing with sodium and benzophenone. N,N’-dimethylformamide (DMF)
was distilled under vacuum and immediately stored over activated molecular sieves 4
Å. Acetonitrile (CH3CN), dichloroethane (DCE), dichloromethane (DCM), dioxane and
hexane were dried by filtration over Al2O3 (Fluka, Brockmann activity I).
Petroleumether (PE) was distilled over CaCl2. Ethyl acetate and tert-butanol were
used without further purification. Molecular sieves type 3 Å and 4 Å were activated in
vacuum at 600°C immediately before use. As support for the solid phase synthesis,
aminomethylated polystyrene lanterns (Mimotopes SynPhase, D series) were
employed. The average loading of each lantern was 35 µmol.
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Ninhydrin test for primary amines.
A washed piece of lantern is treated with 6 drops of solution A and 2 drops of solution
B and heated for 10 min at 100°C. Blue staining indicates the presence of  primary
amines.
Solution A: Solution 1: Phenol (40 g) is dissolved in abs. EtOH (10 mL), stirred with
Amberlite MB-3 mixed bed resin (4 g) for 45 min and filtered. Solution 2: KCN (1.3 g)
is dissolved in H2O (2 mL) and diluted with pyridine (100 mL, freshly distilled from
ninhydrin). The solution is stirred over Amberlite MB-3 mixed bed resin (4 g) for 45
min and filtered. Solutions 1 and 2 are mixed to obtain solution A.
Solution B: Ninhydrin (2.5 g) dissolved in abs. EtOH (50 mL).
Determination of the loading capacity.
An aminomethylated lantern (Mimotopes SynPhaseTM, D series) was left for 15 min in
DMF and then treated with 20% Et3N in DMF (3 x 10 min) for activation. The lantern
was then washed with DMF (3 x 10 min) and DCM (3 x 10 min). A suspension of
Fmoc-succinimidyl carbonate (150 mg, 0.445 mmol) in dry THF (540 µL) was
prepared. 457 µL (0.376 mmol of Fmoc-succinimidyl carbonate) of the solution and
DIPEA (43 µL, 0.25 mmol) were combined in a well of a 96-well plate. The lantern
was added and the plate was left in the shaker at r.t. After 3 h the ninhydrin test[94] for
primary amines was negative. The lantern was washed with THF (2 x 10 min), DMF
(2 x 10 min) and DCM (2 x 10 min). The lantern was added to a 10 mL volumetric
flask filled with 20% piperidine in DMF and left in the shaker at r.t. for 30 min. 0.5 mL
of the resulting solution were diluted in a second volumetric flask (10 mL) with 20%
piperidine in DMF. An UV scan between 190 nm and 400 nm was performed with a
Perkin-Elmer Lambda 2 UV/VIS spectrophotometer. The absorption at 300 nm of two
measurements was used for determination of the loading capacity with the following
formula:
  
€ 
Loading (µmol) = 200• A300nm
7.8
A1 = 1.428;
A2 = 1.459.
Loading capacity: 37 ± 0.6 µmol.
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Synthesis of the linkers
Allyl 4-formyl-benzoate (1), (CR 1).
Cesium fluoride-celite was formed by adding CsF (5.04 g, 33.2 mmol) to a
suspension of celite (3.01 g) in H2O (100 mL). After stirring at r.t. for 40 min, the
solvent was evaporated under reduced pressure and the solid residue washed with
CH3CN (30 mL). 4-Dimethoxymethyl-benzoic acid (2.17 g, 11.1 mmol), was dissolved
under argon in CH3CN (300 mL). Dry CsF-celite (2.52 g of CsF, 16.6 mmol) was
added to the solution followed by allyl bromide (1.92 mL, 22.2 mmol). The mixture
was refluxed at 95°C for 20 h. After cooling to r.t., the solvent was evaporated under
reduced pressure, the residue was taken up in EtOAc (20 mL), filtered and the filtrate
concentrated. Purification was done by silica gel chromatography (PE/EA 6:1, +1%
Et3N) to obtain 1 (1.94 g, 93%) as white solid. 
1H NMR (500 MHz, CDCl3): δ 4.85 (m,
2H, CH2CHCH2O), 5.32 (d, J  = 10.4 Hz, 1H, Ha of CH2CHCH2O), 5.42 (d, J  =
17.2 Hz, 1H, Hb of CH2CHCH2O), 6.04 (m, 1H, CH2CHCH2O), 7.95, 8.21 (m, 4H,
C6H4), 10.10 (s, 1H, COH); 
13C NMR (125 MHz, CDCl3): δ 66.26 (CH2CHCH2O),
118.95 (CH2CHCH2O), 129.65, 130.37, 131.91, 135.25, 139.32 (7C, CH2CHCH2O,
C6H4), 191.74 (COH).
Allyl 4-dimethoxymethyl-benzoate (2), (CR 2).
Compound 1 (576 mg, 3.03 mmol) was dissolved in MeOH (30 mL) under argon.
Trimethyl orthoformate was added to the solution. A catalytic amount of p-toluene
sulfonic acid monohydrate (57.6 mg/mL in 0.50 mL MeOH) was added and stirring
continued for 30 min. The reaction was quenched by neutralization with Et3N (10 mL)
and the solvents were evaporated under reduced pressure. Purification by silica gel
chromatography (PE/EA 8:1, +1% Et3N) yielded 2 (698 mg, 97%) as colorless oil.
1H NMR (500 MHz, CDCl3): δ 3.33 (s, 6H, 2OCH3), 4.83 (m, 2H, CH2CHCH2O), 5.30
(m, 1H, Ha of CH2CHCH2O), 5.43 (m, 2H, Hb of CH2CHCH2O, CH(OCH3)2), 6.05 (m,
1H, CH2CHCH2O), 7.54, 8.07 (m, 4H, C6H4); 
13C NMR (125 MHz, CDCl3): δ 53.05
(OCH3), 66.00 (CH2CHCH2O), 102.73 (CH(OCH3)2), 118.70 (CH2CHCH2O), 127.22,
130.00, 132.60, 143.41 (7C, CH2CHCH2O, C6H4); MS (ESI): Calcd for C13H16O4 M
+:
236.10; Found m/z: 236.03; IR (NaCl) ν 1722 vs (CO) (cm-1).
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Synthesis of hexitols as mimics of galactose for modifications at the 6-position
3,4,6-Tri-O-acetyl-1,5-anhydro-2-deoxy-D-lyxo-hexitol (4), (CRIV 1).
3,4,6-Tri-O-acetyl-D-galactal (5.45 g, 20.0 mmol) was dissolved in MeOH (20 mL)
under argon. Palladium on activated charcoal (10%, 250 mg) was added. The
mixture was stirred vigorously under an atmosphere of H2 at r.t. for 15 h. The
reaction was diluted with DCM (30 mL) under argon and then filtered through a pad
of celite. The filtrate was concentrated under reduced pressure to obtain 4 (5.40 g,
99%) as colourless oil. The product was used in the following step without further
purification. 1H NMR (500 MHz, CDCl3): δ 1.69 (m, 1H, H-2a), 2.01-2.15 (m, 10H,
3CH3, H-2b), 3.58 (t, J1a,1b = 12.2 Hz, 1H, H-1a), 3.75 (t, J5,6a = J5,6b = 6.4 Hz, 1H, H-
5), 4.06-4.14 (m, 3H, H-6, H-1b), 4.99 (m, 1H, H-3), 5.30 (d, J3,4  = 1.4 Hz, 1H, H-4);
13C NMR (125 MHz, CDCl3): δ 20.70, 20.84, 20.97 (3CH3), 26.38 (C-2), 62.55 (C-6),
65.86 (C-1), 66.89 (C-4), 69.66 (C-3), 74.86 (C-5), 170.03, 170.27, 170.48 (3CO).
1,5-Anhydro-2-deoxy-D-lyxo-hexitol (3), (CRIV 2).
Compound 4 (5.40 g, 19.7 mmol) was dissolved in MeOH (120 mL) under argon.
Sodium methoxide was added to the solution in small aliquots until the pH of the
reaction was slightly basic (pH 8-9). Then the mixture was stirred at r.t. for 4h. The
reaction was neutralized by addition of amberlyste 15 ion-exchange resin and filtered
through a pad of celite. The mixture was concentrated under reduced pressure to
give 3 (2.85 g, quantitative), which was used without further purification in the next
step. 1H NMR (500 MHz, CD3OD): δ 1.62, 1.94 (m, 2H, H-2), 3.35 (m, 1H, H-5), 3.46
(m, 1H, H-1a), 3.62-3.77 (m, 4H, H-3, H-4, H-6), 3.98 (m, 1H, H-1b); 13C NMR
(125 MHz, CD3OD): δ 30.46 (C-2), 63.84 (C-6), 67.42 (C-1), 70.16 (C-4), 71.15 (C-3),
81.29 (C-5); Anal. calcd for C6H12O4: C 48.64; H 8.16; Found: C 48.86; H 8.07.
1,5-Anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)diphenylsilyl]-D-lyxo-hexitol (5),
(CRIV 3).
Dry hexitol 3 (2.92 g, 19.7 mmol) was suspended in DCM (60 mL) under argon. To
this suspension tert-butyl diphenylchlorosilane (5.6 mL, 22 mmol), DMAP (96 mg,
0.79 mmol) and Et3N (3.0 mL, 23 mmol) were added. The reaction was vigorously
stirred at r.t. for 24 h. The reaction was driven to completion by repeated additions of
TBDPS (total 2.0 mL, 7.9 mmol) and Et3N (total 0.80 mL, 6.1 mmol). The solvent was
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evaporated under reduced pressure and the residue was taken up in DCM (20 mL).
The organic phase was washed with water (15 mL) and brine (2 x 15 mL). The
combined organic layers were dried with Na2SO4, filtered and the solvent evaporated
under reduced pressure. Purification by silica gel chromatography (PE/EA 2:1 to 1:1)
afforded 5 (5.81 g, 76%) as white foam.   
€ 
[α]
D
21 +3.4 (c = 1.00, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.06 (s, 9H, C(CH3)3), 1.74, 1.85 (m, 1H, H-2), 2.54 (d, J4,OH =
5.6 Hz, 1H, OH-4), 2.77 (d, J3,OH = 9.5 Hz, 1H, OH-3), 3.36 (m, 2H, H-1a, H-5), 3.85
(m, 2H, H-6), 3.98 (m, 2H, H-1b, H-4), 7.38-7.45, 7.66-7.71 (m, 10H, 2C6H5);
13C NMR (125 MHz, CDCl3): δ 19.17 (C(CH3)3), 26.81 (3C, C(CH3)3), 29.68 (C-2),
63.73 (C-6), 64.99 (C-1), 68.78 (C-4), 69.50 (C-3), 78.32 (C-5), 127.76, 127.77,
129.82, 132.93, 133.08, 135.54, 135.62 (12C, 2C6H5); Anal. calcd for C22H30O4Si: C
68.36; H 7.82; Found: C 68.00; H 7.83.
3,4-O-[(1RS)-4-(Allyl carboxylate)-benzylidene]-1,5-anhydro-2-deoxy-6-O-[(1,1-
dimethylethyl)diphenylsilyl]-D-lyxo-hexitol (6a/b), (CRIV 4a/b), (a:b 3:2).
General procedure for methods A and B.
A soxhlet extractor containing activated powdered molecular sieves (3 Å) was
conditioned at 95°C with dry CH3CN (58 mL) for 20 h under argon. After cooling to
r.t., dry 5 (1.2 eq) was added, followed by a solution of 1 or 2 (1 eq) in CH3CN (2
mL). Toluene-4-sulfonicacid monohydrate (14.5 mg/mL in CH3CN, 0.05 eq) was
added to the mixture. The reaction was refluxed at 100°C under argon for 48 h. After
cooling to r.t., the mixture was quenched by dropwise addition of Et3N until pH 7 and
concentrated under reduced pressure. Purification by silica gel chromatography
(PE/EA/Et3N 8:1, +1%) afforded a mixture of isomers 6a/b.
Method A.
According to the general procedure 5 (170 mg, 43.8 µmol) was reacted with 1 (69
mg, 36 µmol) to afford 6a/b (134 mg, 67%).
Method B.
According to the general procedure 5 (125 mg, 32.3 µmol) was reacted with 2 (64
mg, 27 µmol) to afford 6a/b (141 mg, 94%). 1H NMR (500 MHz, CDCl3): δ 1.00 (s, 9H
of 6a, C(CH3)3), 1.07 (s, 9H of 6b, C(CH3)3), 1.89 (m, 1H of 6b, H-2a),1.90-1.95 (m,
2H of 6a, H-2; 1H of 6b, H-2b), 3.38-3.46 (m, 1H of 6a, H-1a; 1H of 6b, H-1a), 3.74
(t, J5,6a = J5,6b = 6.5 Hz, 1H of 6a, H-5), 3.82 (t, J5,6a = J5,6b = 6.3 Hz, 1H of 6b, H-5),
3.83-4.02 (m, 3H of 6a, H-1b, H6; 3H of 6b, H-1b, H6), 4.24 (d, J3,4 = 5.0 Hz, 1H of
117
6a, H-4), 4.29 (d, J3,4 = 6.0 Hz, 1H of 6b, H-4), 4.42, 4.54 (m, 1H of 6a, H-3; 1H of 6b,
H-3), 4.83 (m, 2H of 6a, CH2CHCH2O; 2H of 6b, CH2CHCH2O), 5.30 (m, 1H of 6a,
Ha of CH2CHCH2O; 1H of 6b , Ha of CH 2CHCH2O), 5.41 (m, 1H of 6a , Hb of
CH2CHCH2O; 1H of 6b, Hb of CH2CHCH2O), 5.91 (s, 1H of 6b, CHO2), 6.04 (m, 1H
of 6a, CH2CHCH2O; 1H of 6b, CH2CHCH2O), 6.22 (s, 1H of 6a, CHO2), 7.28-7.42,
7.54-7.71, 8.06 (m, 14H of 6a, 2C6H5, C6H4; 14H of 6b, 2C6H5, C6H4); 
13C NMR (125
MHz, CDCl3): δ 19.21, 19.28 (C(CH3)3, 6a/b), 26.72, 26.82 (6C, C(CH3)3, 6a/b),
27.29, 29.16 (C-2, 6a/b), 63.10, 63.21, 63.37, 64.07, 65.60 (C-1, 6a/b; C-6, 6a/b),
65.60 (CH2CHCH2O, 6a/b), 71.69 (C-3, 6b), 72.03 (C-4, 6a), 74.15 (C-4, 6b), 75.33
(C-3, 6a) 75.33 (C-5, 6b), 76.28 (C-5, 6a), 101.98 (CHO2, 6a), 102.92 (CHO2, 6b),
118.24 (CH2CHCH2O, 6a/b), 126.17, 126.63, 127.62, 127.67, 129.67, 129.69,
129.73, 130.51, 130.73, 132.19, 133.24, 133.41, 133.48, 135.52, 135.57, 135.59,
135.64, 142.94, 144.41 (38C, CH2CHCH2O, 6a/b; 2C6H5, 6a/b; C6H4, 6a/b), 165.97,
165.98 (CO, 6a/b); Missing signals are due to overlapping or low resolution. MS
(ESI): Calcd for C33H38NaO6Si [M+Na]
+: 581.23; Found m/z: 581.22; IR (NaCl)
ν 1723 vs (CO) (cm-1); Anal. Calcd for C33H38O6Si: C 70.94; H 6.85; Found: C 70.85;
H 6.94.
1,5-Anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)diphenylsilyl]-3,4-O-[(1RS)-4-
(triethylammonium carboxylate)-benzylidene]-D-lyxo-hexitol (7a/b), (CRIV 5a/b),
(a:b 1:1).
6a/b (1.41 g, 2.52 mmol) was dissolved in THF (21 mL) under argon. Acetylacetone
(3.9 mL, 38 mmol) was added and the mixture was degassed by bubbling argon
during 2 h. Triphenylphosphine (858 mg, 3.27 mmol) and Pd(PPh3)4 (581 mg, 0.503
mmol) were added with light exclusion. The reaction was stirred at r.t. for 21 h. After
diluting with DCM (15 mL), the solution was filtered over a pad of celite and
concentrated under reduced pressure. Purification by silica gel chromatography
(DCM/MeOH 20:1, +1% Et3N) afforded 7a/b (1.38 g, 88%) as isomeric mixture.
1H NMR (500 MHz, CDCl3): δ 1.00, 1.06  (2s, 9H of 7a, C(CH3)3; 9H of 7b, C(CH3)3),
1.29 (m, 9H of 7a, (CH3CH2)3N
+H; 9H of 7b, (CH3CH2)3N
+H), 1.80, 1.91 (m, 2H of 7a,
H-2; 2H of 7b, H-2),3.09 (m, 6H of 7a, (CH3CH2)3N
+H; 6H of 7b, (CH3CH2)3N
+H),
3.37-3.46 (m, 1H of 7a, H-1a; 1H of 7b, H-1a), 3.72, 3.83 (t, J5,6a = J5,6b = 6.0 Hz, 1H
of 7a, H-5; 1H of 7b, H-5), 3.85-4.02 (m, 3H of 7a, H-1b, H6; 3H of 7b, H-1b, H6),
4.27 (d, J3,4 = 4.1 Hz, 1H of 7a, H-4; 1H of 7b, H-4), 4.39, 4.53 (m, 1H of 7a, H-3; 1H
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of 7b, H-3), 5.90, 6.21 (s, 1H of 7a, CHO2; 1H of 7b, CHO2), 7.26-7.41, 7.47-7.52,
7.63-7.71, 8.08 (m, 14H of 7a, 2C6H5, C6H4; 14H of 7 b, 2C6H5, C6H4); 
13C NMR
(125 MHz, CDCl3): δ 8.73 (CH3CH2NH
+, 7a/b), 19.17, 19.26 (C(CH3)3, 7a/b), 26.81
(6C, C(CH3)3, 7a/b), 29.45 (C-2, 7a/b), 45.08 (CH3CH2NH
+, 7a/b), 63.21, 63.27,
63.46, 64.07 (C-1, 7a/b; C-6, 7a/b), 71.44 (C-3, 7b), 72.01 (C-4, 7a), 72.63 (C-3, 7a),
74.04 (C-4, 7b), 76.46 (C-5, 7a/b), 102.59 (CHO2, 7a), 103.59 (CHO2, 7b), 125.58,
126.07, 127.62, 127.65, 129.48, 129.54, 129.62, 133.16, 133.54, 135.52, 135.57,
135.61, 137.01, 141.47 (36C, 2C6H5, 7a/b; C6H4, 7a/b), 172.28 (CO, 7a/b); Missing
signals are due to overlapping or low resolution. MS (ESI): Calcd for C30H34NaO6Si
[M+Na]+: 541.20; Found m/z: 541.22; IR (NaCl) ν 1600 s (CO) (cm-1).
1,5-Anhydro-2-deoxy-3,4-O-[(1RS)-4-(triethylammonium carboxylate)-
benzylidene]-D-lyxo-hexitol (8a/b), (CR IV 7), (a:b 1:1).
7 a / b  (245 mg, 0.395 mmol) was dissolved in THF (4 mL) and 1 M
tetrabutylammonium fluoride solution in THF (0.79 mL, 0.79 mmol) was added. The
mixture was stirred at r.t. for 22 h. The solvent was evaporated under reduced
pressure. Purification by silica gel chromatography (DCM/MeOH 9:1, +1% Et3N) gave
8a/b (151 mg, quantitative) as yellowish foam. 1H NMR (500 MHz, CDCl3): δ 1.29 (m,
9H of 8a, (CH3CH2)3NH
+; 9H of 8b, (CH3CH2)3NH
+),1.88-1.92 (m, 2H of 8a, H-2; 2H
of 8b, H-2), 3.05 (m, 6H of 8a, (CH3CH2)3NH
+; 6H of 8b, (CH3CH2)3NH
+), 3.37-3.50
(m, 1H of 8a, H-1a; 1H of 8b, H-1a), 3.64 (m, 1H of 8a, H-5), 3.74-3.83 (m, 1H of 8a,
H6a;  2H of 8b, H-5, H6a), 3.89-3.95 (m, 1H of 8a, H-6b; 1H of 8b, H-6b), 3.99-4.07
(m, 2H of 8a, H-1b, H-4; 1H of 8b, H-1b), 4.12 (m, 1H of 8b, H-4), 4.37 (m, 1H of 8b,
H-3), 4.52 (m, 1H of 8a, H-3), 5.86, 6.17 (s, 1H of 8a, CHO2; 1H of 8b, CHO2), 7.40,
7.49, 8.05 (m, 4H of 8a, C6H4; 4H of 8b, C6H4) 
 13C NMR (125 MHz, CDCl3): δ 8.72
(CH3CH2)3NH
+, 8a/b), 29.18, 29.69 (C-2, 8a/b), 45.02 (CH3CH2)3NH
+, 8a/b), 63.10,
63.38, 63.46, 64.04 (C-1, 8a/b; C-6, 8a/b), 71.74 (C-3, 8b), 72.86, 72.96 (C-3, 8a; C-
4, 8a), 74.79 (C-4, 8b), 75.40, 76.56 (C-5, 8a/b), 102.72 (CHO2, 8a), 103.94 (CHO2,
8b), 125.63, 126.19, 129.56, 129.59, 137.28, 137.45, 139.60, 141.09 (12C, C6H5,
8a/b), 171.98, 171.99 (CO, 8a/b); Missing signals are due to overlapping or low
resolution.
119
1,5-Anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)diphenylsilyl]-3,4-O-
isopropylidene-D-lyxo-hexitol (9), (CRV 2).
Compound 5 (1.00 g, 2.59 mmol) was dissolved in CH3CN (53 mL) under argon. 2,2-
dimethoxypropane (635 µL, 5.18 mmol) was added followed by camphor sulfonic
acid in CH3CN (1.0 mL, 21.5 mg/mL). After stirring the reaction vigorously at r.t. for
62 h, it was quenched by addition of Et3N (30 mL). The solvents were evaporated
and the resulting syrup was purified by silica gel chromatography (PE/EA 8:1, +1%
Et3N) to afford 9 (1.01 g, 92%) as white foam.   
€ 
[α]
D
21 +4.1 (c = 0.70, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.05 (s, 9H, C(CH3)3), 1.36,1.52 (2s, 6H, C(CH3)2), 1.75-1.87
(m, 2H, H-2), 3.36 (td, J1a,1b = 11.2 Hz, J1a,2a = J1a,2b = 2.9 Hz, 1H, H-1a), 3.73 (m,
1H, H-5), 3.84 (dd, J5,6a = 5.8 Hz, J6a,6b = 9.7 Hz, 1H, H-6a), 3.86-3.94 (m, 2H, H-1b,
H-6b), 4.25 (m, 2H, H-3, H-4), 7.35-7.43, 7.67-7.72 (m, 10H, 2C6H5); 
13C NMR
(125 MHz, CDCl3): δ 19.41 (C(CH3)3), 26.38, 26.94, 28.37  (5C, C(CH3)2, C(CH3)3),
29.81 (C-2), 63.32 (C-6), 63.97 (C-1), 71.67, 71.85 (C-3, C-4), 75.96 (C-5), 108.98
(C(CH3)2), 127.72, 127.81, 129.75, 129.78, 133.64, 133.77, 135,72,135.81 (12C,
2C6H5); Anal. calcd for C25H34O4Si: C 70.38; H 8.03; Found: C 70.31; H 8.00.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-D-lyxo-hexitol (10), (CRV 3).
Compound 9  (1.01 g, 2.36 mmol) was dissolved in THF (50 mL) and 1 M
tetrabutylammonium fluoride solution in THF (4.75 mL, 4.75 mmol) was added. The
mixture was stirred at r.t. for 1 h. The solvent was evaporated under reduced
pressure. Purification by silica gel chromatography (PE/EA 2:3, +1% Et3N) gave 10
(430 mg, 97%) as white foam.   
€ 
[α]
D
21 -2.9 (c = 0.45, CHCl3); 
1H NMR (500 MHz,
CDCl3): δ 1.32, 1.50 (2s, 6H, C(CH3)2), 1.78, 1.86 (m, 2H, H-2), 2.37 (t, J6a,OH-6 =
J 6b,OH-6 = 8.5 Hz, OH-6), 3.40 (ddd, J1a,1b = 11.5 Hz , J1a,2a = 10.9 Hz, J1a,2b = 2.9 Hz,
1H, H-1a), 3.68 (m, 1H, H-5), 3.75, 3.90 (m, 2H, H-6), 3.90 (m, 1H, H-6b), 3.99 (dt,
J1a,1b = 11.6 Hz, J1b,2a = J1b,2b = 4.4 Hz, 1H, H-1b), 4.05 (dd, J3,4 = 5.6 Hz, J4,5 =
2.0 Hz, 1H, H-4), 4.26 (m, 1H, H-3); 13C NMR (125 MHz, CDCl3): δ 19.26 (C(CH3)3),
26.28, 28.09 (C(CH3)2), 29.30 (C-2), 63.53 (C-6), 63.71 (C-1), 71.81 (C-3), 72.95 (C-
4), 75.62 (C-5), 109.40 (C(CH3)2); Anal. calcd for C9H16O4: C 57.43; H 8.57; Found: C
57.10; H 8.67.
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6-S-Acetyl-1,5-anhydro-2-deoxy-3,4-O-isopropylidene-6-thio-D-lyxo-hexitol (11),
(CRV 4).
Compound 10 (372mg, 1.98 mmol) was dissolved under argon in THF (14.5 mL). To
this solution triphenylphosphine (652 mg, 2.49 mmol) was added at -10°C followed
by dropwise addition of DEAD (387 µL, 2.49 mmol). After stirring for 10 min,
thiolacetic acid (185 µL, 2.49 mmol) was slowly added and stirring continued for 10
min at -10°C. Then the reaction was warmed to r.t.. After stirring for 39 h, the solvent
was evaporated under reduced pressure and the residue was purified by silica gel
chromatography (PE/EA 4:1, +0.5% Et3N) to afford 11 (340 mg, 70%) as colorless
oil.   
€ 
[α]
D
21 +52.7 (c = 0.62, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.34, 1.51 (2s, 6H,
C(CH3)2), 1.75, 1.83 (m, 2H, H-2), 2.34 (s, 3H, SAc), 3.10 (dd, J5,6a = 8.8 Hz, J6a,6b =
13.9 Hz, 1H, H-6a), 3.24 (dd, J5,6b = 4.7 Hz , J6a,6b = 13.9 Hz, 1H, H-6b), 3.37 (m, 1H,
H-1a), 3.60 (m, 1H, H-5), 3.95 (dt, J1a,1b  = 11.6 Hz, J1a,2a  = J1a,2b = 4.5 Hz, 1H, H-1b),
4.07 (dd, J3,4 = 5.5 Hz, J4,5  = 1.9 Hz, 1H, H-4), 4.23 (m, 1H, H-3); 
13C NMR
(125 MHz, CDCl3): δ 26.23, 28.04  (C(CH3)2), 28.97 (C-2), 30.56 (COCH3), 30.94 (C-
6), 63.84 (C-1), 71.65 (C-3), 73.24 (C-4), 74.31 (C-5), 109.12 (C(CH3)2), 195.89
(CO); IR (NaCl) ν 1694 vs (CO) (cm-1); Anal. calcd for C11H18O4S: C 53.64; H 7.37;
Found: C 53.54; H 7.22.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-O-methanesulfonyl-D-lyxo-hexitol
(40), (CRVII 1).
Compound 10 (183 mg, 0.970 mmol) was dissolved in pyridine (87 mL).
Methanesulfonyl chloride (0.15 mL, 1.9 mmol) was added dropwise at 0°C. After 15
min the reaction was warmed to r.t. and stirred for 1 h. The reaction was diluted with
EtOAc (50 mL) and extracted with 1 N HCl (2 x 50 mL), saturated aqueous NaHCO3
(2 x 50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, filtered and
concentrated. Silica gel chromatography (PE/EA 2:1, +1% Et3N) of the residue gave
40 (249 mg, 96%) as white foam.   
€ 
[α]
D
21 +10.6 (c = 0.42, CHCl3); 
1H NMR (500 MHz,
CDCl3): δ 1.32, 1.51 (2s, 6H, C(CH3)2), 1.80 (m, 1H, H-2a), 1.88 (m,1H, H-2b), 3.06
(s, 3H, SCH3), 3.44 (td, J1a,1b = 11.2 Hz, J1a,2a = J1a,2b = 3.0 Hz, 1H, H-1a), 3.92 (m,
1H, H-5), 3.99 (m, 1H, H-1b), 4.05 (d, J3,4  = 5.6 Hz, 1H, H-4), 4.31 (m, 1H, H-3), 4.39
(m, 1H, H-6); 13C NMR (125 MHz, CDCl3): δ 26.13, 27.82 (C(CH3)2), 28.65 (C-2),
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63.29 (C-1), 69.93 (C-6), 71.39 (C-3), 71.64 (C-4), 73.14 (C-5), 109.58 (C(CH3)2); MS
(ESI): Calcd for C10H18NaO6S [M+Na]
+: 289.07; Found m/z: 288.99;
1,5-Anhydro-6-azido-2-deoxy-3,4-O-isopropylidene-D-lyxo-hexitol (41), (CRVII
2).
Compound 40 (365 mg, 1.37 mmol) was dissolved in dry DMF (55 mL) under argon.
Sodium azide (446 mg, 6.86 mmol) was added followed by 15-crown-5 (0.11 mL,
0.55 mmol). The reaction was vigorously stirred under argon at 100°C for 3 days.
The reaction mixture was then diluted at 0°C with EtOAc (30 mL) and washed with
ice-cold water (2 x 30 mL) followed by extraction of the aqueous layer with EtOAc (4
x 40 mL). The combined organic phases were dried with Na2SO4, filtered,
concentrated and the resulting syrup was purified by silica gel chromatography
(PE/EA 8:1, +1% Et3N) to afford 41 (233 mg, 80%) as white solid.   
€ 
[α]
D
21 +9.2 (c = 0.97,
CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.34, 1.52 (2s, 6H, C(CH3)2), 1.78 (m, 1H, H-
2a), 1.88 (m, 1H, H-2b), 3.37-3.45 (m, 2H, H-1a, H-6a), 3.53 (m, 1H, H-6b), 3.73 (m,
1H, H-5), 3.99 (m, 2H, H-1b, H-4), 4.28 (m, 1H, H-3); 13C NMR (125 MHz, CDCl3): δ
26.21, 28.01 (C(CH3)2), 29.00 (C-2), 52.04 (C-6), 63.64 (C-1), 71.54 (C-3), 72.37 (C-
4), 74.49 (C-5), 109.39 (C(CH3)2); MS (ESI): Calcd for C9H15N3NaO3 [ M+Na]
+:
236.10; Found m/z: 235.95; IR (NaCl) ν 2099 s (-N=N+-N-) (cm-1);
1,5-Anhydro-6-azido-2-deoxy-D-lyxo-hexitol (46), (CRVII 3).
Hexitol 41  (90 mg, 0.42 mmol) was stirred at 85°C in 80% aqueous AcOH (19 mL)
for 3 h. After cooling to r.t., the solvent was coevaporated with toluene. Purification by
silica gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1],
followed by filtration through Gelman Acrodisc (0.2 µm) gave 46 (71 mg, 96%) as a
white powder after a final liophilization from H2O/dioxane (1:1).   
€ 
[α]
D
21 +0.6 (c = 0.76,
MeOH); 1H NMR (500 MHz, CDCl3): δ 1.80-1.88 (m, 2H, H-2), 2.13 (m, 2H, OH-3,
OH-4), 3.37 (dd, J5,6a = 4.4 Hz, J6a,6b = 12.6 Hz, 1H,  H-6a), 3.44 (m, 2H, H-1a, H-5),
3.60 (dd, J5,6b = 7.5 Hz, J6a,6b = 12.5 Hz, 1H, H-6b), 3.76 (m, 2H, H-3, H-4), 4.05 (dd,
J1a,1b = 11.7 Hz, J1a,2a = J1a,2b = 4.3 Hz, 1H, H-1b); 
13C NMR (125 MHz, CDCl3): δ
29.64 (C-2), 52.42 (C-6), 63.32 (C-1), 69.54 (2C, C-3, C-4), 77.71 (C-5); MS (ESI):
Calcd for C6H11N3NaO3 [M+Na]
+: 196.07; Found m/z: 195.87; IR (NaCl) ν 2099 s
(-N=N+-N-) (cm-1);
122
3,4-O-[(1RS)-4-(Allyl carboxylate)-benzylidene]-1,5-anhydro-6-azido-2-deoxy-D-
lyxo-hexitol (47a/b), (CRVII 4a/b), (a:b 1:1).
A soxhlet extractor with activated powdered molecular sieves (3 Å, was conditioned
at 95°C with dry CH3CN (65 mL) for 20 h under argon. After cooling to r.t., dry 46
(164 mg, 0.947 mmol) and  2 (193 mg, 0.816 mmol), both dissolved in CH3CN (5
mL), were added. Toluene-4-sulfonicacid monohydrate (0.73 mL of 11 mg/mL
solution in CH3CN) was added to the mixture. The mixture was refluxed at 105 °C.
After 20 h no more 2 was detected by TLC but instead 1 (the aldehyde form).
Additional 0.7 eq of 2 (135 mg, 0.571 mmol) were added and the reaction was stirred
for another 16 h. After cooling to r.t., the reaction was quenched by addition of Et3N
until pH 7 and the mixture was concentrated under reduced pressure. Purification by
silica gel chromatography (PE/EA 8:1 to 4:1, +1% Et3N) afforded 47a/b (124 mg,
44%). It was possible to separate the two isomers from the 1:1 mixture. 47a:   
€ 
[α]
D
21
+51.4 (c = 0.53, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.87-2.04 (m, 2H, H-2), 3.39-
3.48 (m, 2H, H-1a, H-6a), 3.66-3.74 (m, 2H, H-5, H-6b), 3.99 (m, 1H, H-4), 4.09 (m,
1H, H-1b), 4.57 (m, 1H, H-3), 4.83 (m, 2H, CH2CHCH2O), 5.29 (m, 1H, Ha of
CH2CHCH2O), 5.41 (m, 1H, Hb of CH2CHCH2O), 6.04 (m, 1H, CH2CHCH2O), 6.21
(s, 1H, CHO2), 7.51, 8.07 (m, 4H, C6H4); 
13C NMR (125 MHz, CDCl3): δ 26.74 (C-2),
52.23 (C-6), 63.97 (C-1), 65.66 (CH2CHCH2O), 72.63, 72.88 (C-3, C-4), 75.26 (C-5),
102.21 (CHO2), 118.33 (CH2CHCH2O), 126.17, 129.83, 130.79, 143.77 (6C, C6H4),
132.16 (CH2CHCH2O); IR (NaCl) ν 2104 s (-N=N
+-N-), 1720 vs (CO) (cm-1). 47b:   
€ 
[α]
D
21
-40.6 (c = 0.98, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.81 (m, 1H, H-2a), 1.95 (m,
1H, H-2b), 3.45 (dd, J5,6a = 4.8 Hz, J6a,6b = 12.8 Hz, 1H, H-6a), 3.54 (td, J1a,1b = 11.8
Hz, J1a,2a = J1a,2b = 3.7 Hz, H-1a), 3.66 (dd, J5,6b = 8.0 Hz, J6a,6b = 12.7 Hz, 1H, H-6b),
3.81 (m, 1H, H-5), 4.03 (m, 1H, H-1b), 4.12 (m, 1H, H-4), 4.46 (m, 1H, H-3), 4.83 (m,
2H, CH2CHCH2O), 5.29 (m, 1H, Ha of CH 2CHCH2O), 5.41 (m, 1H, Hb of
CH2CHCH2O), 5.92 (s, 1H, CHO2), 6.04 (m, 1H, CH2CHCH2O), 7.61, 8.09 (m, 4H,
C6H4); 
13C NMR (125 MHz, CDCl3): δ 28.42 (C-2), 51.90 (C-6), 63.22 (C-1), 65.65
(CH2CHCH2O), 71.81 (C-3), 73.96 (C-5), 74.49 (C-4), 103.29 (CHO2), 118.28
(CH2CHCH2O), 126.72, 129.80, 131.02, 142.41 (6C, C6H4), 132.16 (CH2CHCH2O),
165.90 (CO); IR (NaCl) ν 2103 s (-N=N+-N-), 1721 vs (CO) (cm-1).
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1,5-Anhydro-6-azido-2-deoxy-3,4-O-[(1RS)-4-(triethylammonium carboxylate)-
benzylidene]-D-lyxo-hexitol (49a/b), (CRVII 7), (a:b 1:1).
To a solution of 47a/b (114 mg, 0.330 mmol) in H2O/dioxane (1:1, 11 mL) was added
lithium hydroxide (80.6 mg, 3.30 mmol). The reaction was stirred at r.t. for 17 h. The
solvents were evaporated under reduced pressure. Purification by silica gel
chromatography (DCM/MeOH 20:1 to 9:1, +1% Et3N) afforded the two isomers 49a/b
(103 mg, 77%). 1H NMR (500 MHz, CDCl3): δ 1.33 (m, 9H of 49a, (CH3CH2)3NH
+; 9H
of 49b, (CH3CH2)3NH
+), 1.95 (m, 2H of 49a, H-2; 2H of 49b, H-2), 3.10 (m, 6H of
49a, (CH3CH2)3NH
+; 6H of 49b, (CH3CH2)3NH
+), 3.37-3.51 (m, 2H of 49a, H-1a, H-
6a; 2H of 49b, H-1a, H-6a), 3.52-3.70 (m, 1H of 49a, H-6b; 2H of 49b, H-5, H-6b),
3.80 (m, 1H of 49a, H-5), 3.98-4.09 (m, 2H of 49a, H-1b, H-4; 2H of 49b, H-1b, H-4),
4.42 (m, 1H of 49b, H-3), 4.53 (m, 1H of 49a, H-3), 5.90 (s, 1H of 49b, CHO2), 6.19
(s, 1H of 49a, CHO2), 7.43, 7.53, 8.07 (m, 4H of 49a, C6H4; 4H of 49b , C6H4);
13C NMR (125 MHz, CDCl3): δ 8.64 ((CH3CH2)3NH
+, 49a/b),28.61, 29.70 (C-2,
49a/b), 45.18 ((CH3CH2)3NH
+, 49a/b), 52.37, 52.94 (C-6, 49a/b), 63.27, 63.98 (C-1,
49a/b), 71.61 (C-3, 49b), 72.55, 72.73 (C-3, 49a; C-4, 49a), 74.01 (C-5, 49b), 74.41
(C-4, 49b), 75.38 (C-5, 49a), 102.73, 103.88 (CHO2, 49a/b), 125.65, 126.26, 129.68,
136.46, 136.68, 139.80, 141.28 (12C, C6H4, 49a/b ); MS (ESI): Calcd for
C14H15N3NaO5 [M+Na]
+: 328.09; Found m/z: 328.09; IR (NaCl) ν 2104 s (-N=N+-N-),
1705 vs (CO) (cm-1).
Galacto-mimics modified at the 6-position.
General procedure for S-deacetylations and Michael addition or nucleophilic
substitution (from 11).
Compound 11 (1.0 eq, 60 mg scale) was dissolved in freshly degassed DMF (1.9
mL) under argon. The solution was again degassed by bubbling argon through it for
40 min. Hydrazine acetate (1.16 eq) was added quickly under flowing argon. After
stirring the mixture for 4 h at r.t., freshly degassed Et3N (1.30 eq) was added. After
10-15 min, the corresponding α,β-unsaturated ketone or α-halo ketone (1.50 eq) was
added to the mixture. For solid reagents a solution in DMF (200 mg/mL) was
prepared and degassed prior to its addition. After 24 h to 6 d (depending on the
reactants), the mixture was diluted with EtOAc (5 mL) and extracted with 1 N HCl (3
mL) and saturated aqueous NaHCO3 (2 x 3 mL). The organic layer was dried with
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Na2SO4, filtered and concentrated. Purifications were done by silica gel
chromatography (PE/EA 4:1 to 2:1, +0.5% Et3N).
Bis [1,5-anhydro-3,4-O-isopropylidene-D-lyxo-hexitol-6-yl]-disulphide (15), (CRV
6).
Obtained as secondary product due to oxidation during Michael additions and
nucleophilic substitutions from 11. Separated during purification processes of such
reactions.   
€ 
[α]
D
21 -97.1 (c = 0.54, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.33, 1.50 (2s,
6H, C(CH3)2), 1.67-1.88 (m, 2H, H-2), 2.95-3.05 (m, 2H, H-6), 3.41 (m, 1H, H-1a),
3.84 (m, 1H, H-5), 3.97 (m, 1H, H-1b), 4.12 (d, J3,4 = 5.6 Hz, 1H, H-4), 4.27 (m, 1H,
H-3); 13C NMR (125 MHz, CDCl3): δ 26.23, 28.06  (4C, C(CH3)2), 29.04 (C-2), 40.02
(C-6), 63.85 (C-1), 71.68 (C-3), 72.91 (C-4), 73.79 (C-5), 109.04, 109.60 (C(CH3)2);
MS (ESI): Calcd for C18H30NaO6S2 [M+Na]
+: 445.11; Found m/z: 445.00; Anal. calcd
for C18H30O6S2: C 53.18; H 7.44; Found : C 53.49; H 7.36.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(1RS)-3-oxo-cyclohexyl]-6-thio-
D-lyxo-hexitol (16a/b), (CRV5a/b), (a:b 1:1).
According to the general procedure, 11 (60.5 mg, 0.246 mmol) was deprotected with
hydrazine acetate (26.4 mg, 0.287 mmol) and reacted with 2-cyclohexen-1-one
(36 µL, 0.38 mmol) for 75 h. After work-up and chromatographic purification 16a/b
(38 mg, 51%) was obtained as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.34,
1.52 (2s, 6H of 16a, C(CH3)2; 6H of 16b, C(CH3)2), 1.71-1.87, 2.12-2.18, 2.29-2.42,
2.73-2.82  (m, 11H of 16a, H-2, H-6a, 8H of C6H9; 11H of 16b, H-2, H-6a, 8H of
C6H9), 2.91 (m, 1H of 16a, H-6b; 1H of 16b, H-6b), 3.16 (m, 1H of 16a, H-1’; 1H of
16b, H-1’), 3.39 (m, 1H of 16a, H-1a; 1H of 16b, H-1a), 3.64 (m, 1H of 16a, H-5; 1H
of 16b, H-5), 3.97 (m, 1H of 16a, H-1b; 1H of 16b, H-1b), 4.12 (m, 1H of 16a, H-4; 1H
of 16b, H-4), 4.26 (m, 1H of 16a, H-3; 1H of 16b, H-3); 13C NMR (125 MHz, CDCl3): δ
24.20, 24.22 (CH2, 16a/b), 26.23, 26.26 (C(CH3)2, 16a/b), 28.09 (C(CH3)2, 16a/b),
29.05, 29.07 (C-2, 16a/b), 31.76, 31.86, 31.92, 31.99 (C-6, 16a/b; CH2, 16a/b),
41.04, 41.05 (CH2, 16a/b), 43.59, 43.68 (C-1’, 16a/b), 48.28, 48.47 (CH2, 16a/b),
63.97, 64.01 (C-1, 16a/b), 71.79 (C-3, 16a/b), 72.93, 72.99 (C-4, 16a/b), 75.81,
75.82 (C-5, 16a/b), 109.15, 109.13 (C(CH3)2, 16a/b), 208.92, 208.99 (CO, 16a/b);
Missing signals are due to overlapping or low resolution. IR (NaCl) ν 1715 vs (CO)
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(cm-1); Anal. calcd for C15H24O4S: C 59.97; H 8.05; O 21.30; Found: C 59.94; H 8.10;
O 21.44.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(1RS)-3-oxo-cyclopentyl]-6-
thio-D-lyxo-hexitol (17a/b), (CRV 9a/b), (a:b 1:1).
According to the general procedure, 11 (299 mg, 1.22 mmol) was deprotected with
hydrazine acetate (130 mg, 1.41 mmol) and reacted with 2-cyclopenten-1-one (157
µL, 1.83 mmol) for 5 d. After work-up and purification 17a/b (52 mg, 14%) was
obtained as colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.35, 1.53 (2s, 6H of 17a,
C(CH3)2; 6H of 17b, C(CH3)2), 1.74-1.88 (m, 2H of 17a, H-2; 2H of 17b, H-2), 1.97,
2.18-2.27, 2.38-2.50, 2.64 (m, 6H of 17a, 6H of C5H7; 6H of 17b, 6H of C5H7), 2.82,
2.93 (m, 2H of 17a, H-6; 2H of 17b, H-6), 3.40 (m, 1H of 17a, H-1a; 1H of 17b, H-1a),
3.58 (m, 1H of 17a, H-1’; 1H of 17b, H-1’), 3.67 (m, 1H of 17a, H-5; 1H of 17b, H-5),
3.98 (m, 1H of 17a, H1b; 1H of 17b, H1b), 4.12 (d, J3,4 = 3.9 Hz, 1H of 17a, H-4; 1H
of 17b, H-4), 4.27 (m, 1H of 17a, H-3; 1H of 17b, H-3); 13C NMR (125 MHz, CDCl3): δ
24.20, 24.22 (CH2, 17a/b), 26.25, 28.08  (C(CH3)2, 17a/b), 29.02 (C-2, 17a/b), 29.98,
30.07 (CH2, 17a/b), 32.64, 32.70 (CH2, 17a/b), 37.19 (C-6, 17a/b), 41.24 (C-1’,
17a/b), 45.81, 45.95 (CH2, 17a/b), 63.90 (C-1, 17a/b), 71.69 (C-3, 17a/b), 72.94,
72.97 (C-4, 17a/b), 75.66, 75.74 (C-5, 17a/b), 109.08, (C(CH3)2, 17a/b); Missing
signals are due to overlapping or low resolution. MS (ESI): Calcd for C14H22NaO4S
[M+Na]+: 309.11; Found m/z: 309.16; IR (NaCl) ν 1744 vs (CO) (cm-1).
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(1RS)-2-oxo-cyclohexyl]-6-thio-
D-lyxo-hexitol (18a/b), (CRV 14a/b), (a:b 1:1).
According to the general procedure, 11 (155 mg, 0.629 mmol) was deprotected with
hydrazine acetate (68 mg, 0.74 mmol) and reacted with 2-chlorocyclohexanone (110
µL, 0.944 mmol) for 32 h. After work-up and purification as in the general procedure,
an additional purification by silica gel chromatography was applied [a) Hexane, b)
PE/EA 2:1, +0.5% Et3N], 18a/b (148 mg, 78%) was obtained as colorless oil.
1H NMR (500 MHz, CDCl3): δ 1.31, 1.49 (s, 6H of 18a, C(CH3)2; 6H of 18b, C(CH3)2),
1.65, 1.70-1.90, 1.95, 2.03, 2.15-2.26  (m, 10H of 18a, H-2, 8H of C6H9; 10H of 18b,
H-2, 8H of C6H9), 2.70 (m, 1H of 18a, H-6a; 1H of 18b, H-6a), 2.82-2.99 (m, 1H of
18a, H-6b; 1H of 18b, H-6b), 3.33-3.46 (m, 2H of 18a, H-1a, H-1’; 2H of 18b, H-1a,
H-1’), 3.61 (m, 1H of 18a, H-5), 3.66 (m, 1H of 18b, H-5), 3.94 (m, 1H of 18a, H1b;
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1H of 18b, H1b), 4.04 (m, 1H of 18a, H-4; 1H of 18b, H-4), 4.22 (m, 1H of 18a, H-3;
1H of 18b, H-3); 13C NMR (125 MHz, CDCl3): δ 21.86, 21.90, 26.27, 26.96, 26.99,
28.09, 29.07, 29.11, 33.08, 33.25, 33.28, 34.12, 37.88 (18C, C-2, 18a/b; C-6, 18a/b;
5CH2 of C6H9, 18a/b; C(CH3)2, 18a/b), 52.35, 52.84 (C-1’, 18a/b), 63.87, 63.92 (C-1,
18a/b), 71.67, 71.69 (C-3, 18a/b), 73.04, 73.19 (C-4, 18a/b), 74.23 (C-5, 18b), 74.91
(C-5, 18a), 109.02 (C(CH3)2, 18a/b), 208.39, 208.42 (CO, 18a/b); Missing signals are
due to overlapping or low resolution. MS (ESI): Calcd for C15H24NaO4S [M+Na]
+:
323.13; Found m/z: 323.10; IR (NaCl) ν 1704 vs (CO) (cm-1).
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(1RS)-2-oxo-cyclopentyl]-6-
thio-D-lyxo-hexitol (19a/b), (CRV 10a/b), (a:b 1:1).
According to the general procedure, 11 (90.6 mg, 0.368 mmol) was deprotected with
hydrazine acetate (39.6 mg, 0.430 mmol) and reacted with 2-chloropentan-1-one (57
µL, 0.56 mmol) for 25 h. After work-up and purification 19a/b (80 mg, 76%) was
obtained as colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.32, 1.50 (s, 6H of 19a,
C(CH3)2; 6H of 19b, C(CH3)2), 1.62-1.91, 2.04-2.29, 2.45, 2.83-2.94  (m, 8H of 19a,
H-2, 6H of C5H7; 8H of 19b, H-2, 6H of C5H7), 3.09 (m, 1H of 19a, H-6a; 2H of 19b,
H-6a, H-6b), 3.27 (m, 1H of 19a, H-6b), 3.40 (m, 1H of 19a, H-1’; 1H of 19b, H-1’),
3.67 (m, 1H of 19a, H-1a; 1H of 19b, H-1a), 3.74 (m, 1H of 19a, H-5), 3.94 (m, 1H of
19b, H-5), 4.03 (m, 1H of 19a, H-1b; 1H of 19b, H-1b), 4.23 (m, 1H of 19a, H-4, 1H of
19b, H-4), 4.26 (m, 1H of 19a, H-3; 1H of 19b, H-3); 13C NMR (125 MHz, CDCl3): δ
20.38, 20.45 (CH2, 19a/b), 26.26, 28.10 (C(CH3)2, 19a/b), 29.07, 29.12 (C-2, 19a/b),
30.27, 30.34, 32.48, 32.52 (CH2, 19a/b), 36.00, 36.03 (C-6, 19a/b), 47.40, 48.17 (C-
1’, 19a/b), 63.84, 63.95 (C-1, 19a/b), 71.69 (C-3, 19a/b), 73.14, 73.20 (C-4, 19a/b),
74.02, 75.40 (C-5, 19a/b), 109.03 (C(CH3)2, 19a/b), 214.03, 214.34 (CO, 19a/b);
Missing signals are due to overlapping or low resolution. MS (ESI): Calcd for
C14H22NaO4S [M+Na]
+: 309.11; Found m/z: 309.10; IR (NaCl) ν 1731 vs (CO) (cm-1);
Anal. calcd for C15H24O4S: C 58.72; H 7.74; Found: C 58.83, H 7.70.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-(2-oxo-2-phenyl-ethyl)-6-thio-D-
lyxo-hexitol (20), (CRV 17).
According to the general procedure, 11 (121 mg, 0.492 mmol) was deprotected with
hydrazine acetate (55 mg, 0.59 mmol) and reacted with 2-chloroacetophenone (114
mg, 0.738 mmol) for 24 h. After work-up and purification 20 (122 mg, 77%) was
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obtained.   
€ 
[α]
D
21 +10.7 (c = 0.28, CHCl3);
 1H NMR (500 MHz, CDCl3): δ 1.31, 1.49 (2s,
6H, C(CH3)2), 1.67-1.84 (m, 2H, H-2), 2.81 (dd, J5,6a = 5.3 Hz, J6a,6b = 14.0 Hz, 1H, H-
6a), 2.95 (dd, J5,6b = 8.2 Hz, J6a,6b = 14.0 Hz, 1H, H-6b), 3.35 (td, J1a,1b = 11.2 Hz,
J1a,2a = J1a,2b =  2.7 Hz, 1H, H-1a), 3.71 (m, 1H, H-5), 3.92 (m, 3H, H-1b, H-1’), 4.06
(d, J3,4 = 4.3 Hz, 1H, H-4), 4.24 (m, 1H, H-3), 7.47, 7.57, 7.97 (m, 5H, C6H5);
13C NMR (125 MHz, CDCl3): δ 26.23, 28.08 (C(CH3)2), 29.04 (C-2), 33.80 (C-6),
38.16 (C-1’), 63.82 (C-1), 71.67 (C-3), 73.13 (C-4), 74.86 (C-5), 109.04 (C(CH3)2),
128.68, 128.73, 133.40, 135.35 (6C, C6H5), 194.72 (CO); MS (ESI): Calcd for
C17H22NaO4S [M+Na]
+: 345.11; Found m/z: 345.08; IR (NaCl) ν 1674 vs (CO) (cm-1);
Anal. calcd for C17H22O4S + 0.25 H2O: C 62.46, H 6.94; Found: C 62.49, H 6.66.
1,5-Anhydro-2-deoxy-6-S-[2-(4-fluorophenyl)-2-oxo-ethyl]-3,4-O-isopropylidene-
6-thio-D-lyxo-hexitol (21), (CRV 18).
According to the general procedure, 11 (113 mg, 0.460 mmol) was deprotected with
hydrazine acetate (50 mg, 0.54 mmol) and reacted with 2-chloro-4’-
fluoroacetophenone (120 mg, 0.689 mmol) for 24 h. After work-up and purification 21
(105 mg, 67%) was obtained as white solid.   
€ 
[α]
D
21 +8.1 (c = 1.08, CHCl3);
 1H NMR
(500 MHz, CDCl3): δ 1.31, 1.50 (2s, 6H, C(CH3)2), 1.70-1.86 (m, 2H, H-2), 2.80 (dd,
J5,6a = 5.2 Hz, J6a,6b = 13.9 Hz, 1H, H-6a), 2.95 (dd, J5,6b = 8.3 Hz, J6a,6b = 13.9 Hz, 1H,
H-6b), 3.36 (td, J1a,1b = 11.0 Hz, J1a,2a = J1a,2b =  2.8 Hz, 1H, H-1a), 3.71 (m, 1H, H-5),
3.89 (m, 3H, H-1b, H-1’), 4.06 (m, 1H, H-4), 4.24 (m, 1H, H-3), 7.14, 8.01 (m, 4H,
C6H4); 
13C NMR (125 MHz, CDCl3): δ 26.24, 28.07 (C(CH3)2), 29.02 (C-2), 33.82 (C-
6), 38.05 (C-1’), 63.82 (C-1), 71.67 (C-3), 73.16 (C-4), 74.87 (C-5), 109.08 (C(CH3)2),
115.74, 115.92, 131.41, 131.49, 131.72 (6C, C6H4), 193.20 (CO); MS (ESI): Calcd for
C17H21FNaO4S [M+Na]
+: 363.10; Found m/z: 363.06; IR (NaCl) ν 1674 vs (CO)
(cm-1); Anal. calcd for C17H21FO4S: C 59.98; H 6.22; Found: C 60.19; H 6.39.
1,5-Anhydro-6-S-[2-(4-chlorophenyl)-2-oxo-ethyl]-2-deoxy-3,4-O-
isopropylidene-6-thio-D-lyxo-hexitol (22), (CRV 19).
According to the general procedure, 11 (77 mg, 0.31 mmol) was deprotected with
hydrazine acetate (34 mg, 0.37 mmol) and reacted with 2-bromo-4’-
chloroacetophenone (112 mg, 0.470 mmol) for 24 h. After work-up and purification 22
(105 mg, 94%) was obtained as colorless oil.   
€ 
[α]
D
21 +3.1 (c = 0.40, CHCl3);
 1H NMR
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(500 MHz, CDCl3): δ 1.31, 1.49 (2s, 6H, C(CH3)2), 1.72-1.81 (m, 2H, H-2), 2.78 (m,
1H, H-6a), 2.94 (m, 1H, H-6b), 3.35 (m, 1H, H-1a), 3.70 (m, 1H,  H-5), 3.89 (m, 3H,
H-1b, H-1’), 4.05 (m, 1H, H-4), 4.18 (m, 1H, H-3), 7.44, 7.91 (m, 4H, C6H4); 
13C NMR
(125 MHz, CDCl3): δ 26.23, 28.06 (C(CH3)2), 29.00 (C-2), 33.80 (C-6), 38.04 (C-1’),
63.80 (C-1), 71.66 (C-3), 73.15 (C-4), 74.88 (C-5), 109.07 (C(CH3)2), 129.01, 130.18,
133.63, 139.86 (6C, C6H4), 193.50 (CO); MS (ESI): Calcd for C17H21ClNaO4S
[M+Na]+: 379.07; Found m/z: 379.01; IR (NaCl) ν 1674 vs (CO) (cm-1); Anal. calcd
for C17H21ClO4S: C 57.22; H 5.93; Found: C 57.34; H 5.95.
1,5-Anhydro-2-deoxy-6-S-[2-(2,5-dimethoxy-phenyl)-2-oxo-ethyl]-3,4-O-
isopropylidene-6-thio-D-lyxo-hexitol (23), (CRV 23).
According to the general procedure, 11 (66 mg, 0.27 mmol) was deprotected with
hydrazine acetate (29 mg, 0.32 mmol) and reacted with 2-bromo-2’,5’-dimethoxy-
acetophenone (108 mg, 0.404 mmol) for 22 h. After work-up and purification 23 (78
mg, 75%) was obtained as colorless oil.   
€ 
[α]
D
21 +10.6 (c = 0.40, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.31, 1.49 (2s, 6H, C(CH3)2), 1.74 (m, 1H, H-2a), 1.83 (m, 1H,
H-2b), 2.78 (dd, J5,6a = 5.8 Hz, J6a,6b = 13.8 Hz, 1H, H-6a), 2.86 (dd, J5,6b = 7.9 Hz,
J6a,6b = 13.8 Hz, 1H, H-6b), 3.36 (m, 1H, H-1a), 3.68 (m, 1H, H-5), 3.80, 3.87 (2s, 6H,
2OCH3), 3.95 (m, 3H, H-1b, H-1’), 4.07 (m, 1H, H-4), 4.22 (m, 1H, H-3), 6.91, 7.05,
7.36 (m, 3H, C6H3); 
13C NMR (125 MHz, CDCl3): δ 26.09, 26.21 (C(CH3)2), 29.13 (C-
2), 33.47 (C-6), 43.02 (C-1’), 55.84 (OCH3), 56.13 (OCH3), 63.88 (C-1), 71.69 (C-3),
73.02 (C-4), 74.61 (C-5), 108.97(C(CH3)2), 113.17, 114.56, 120.91, 126.16, 153.28,
153.58  (C6H3), 195.69 (CO); MS (ESI): Calcd for C19H26NaO6S [M+Na]
+: 405.13;
Found m/z: 405.03; IR (NaCl) ν 1674 vs (CO) (cm-1); Anal. calcd for C19H26O6S: C
59.67; H 6.85; Found : C 59.69; H 6.85.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-(2-napht-2’-yl-2-oxo-ethyl)-6-
thio-D-lyxo-hexitol (24), (CRV 24).
According to the general procedure, 11 (64 mg, 0.26 mmol) was deprotected with
hydrazine acetate (29 mg, 0.31 mmol) and reacted with 2-bromo-2’-acetonaphtone
(99 mg, 0.39 mmol) for 25 h. After work-up and purification according to the general
procedure an additional purification by silica gel chromatography (PE/EA 4:1, +0.5%
Et3N) was done and 24 (59 mg, 60%) was obtained as colorless oil.   
€ 
[α]
D
21 +6.5 (c =
129
0.58, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.31, 1.44 (2s, 6H, C(CH3)2), 1.71-1.84
(m, 2H, H-2), 2.85 (dd, J5,6a = 5.0 Hz, J6a,6b = 13.6 Hz, 1H, H-6a), 3.00 (dd, J5,6b =
8.2 Hz, J6a,6b = 13.7 Hz, 1H, H-6b), 3.36 (m, 1H, H-1a), 3.75 (m, 1H,  H-5), 3.92 (m,
1H, H-1b), 4.06 (m, 3H, H-4, H-1’), 4.24 (m, 1H, H-3), 7.59, 7.81-8.04, 8.50 (m, 7H,
C10H7); 
13C NMR (125 MHz, CDCl3): δ 26.24, 28.09 (C(CH3)2), 29.06 (C-2), 33.88 (C-
6), 38.27 (C-1’), 63.85 (C-1), 71.68 (C-3), 73.17 (C-4), 74.96 (C-5), 109.06 (C(CH3)2),
124.27, 126.88, 127.81, 128.58, 128.70, 129.66, 130.57, 132.49, 132.68, 135.71
(C10H7), 194.75 (CO); MS (ESI): Calcd for C21H24NaO4S [M+Na]
+: 395.13; Found
m/z: 395.03; IR (NaCl) ν 1674 vs (CO) (cm-1). Anal. calcd for C21H24O4S: C 66.12; H
6.61; Found : C 66.28; H 6.54.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(2RS)-1-oxo-indan-2yl]-6-thio-
D-lyxo-hexitol (25a/b), (CRV 26a/b) (a:b 1:1).
According to the general procedure, 11 (107 mg, 0.434 mmol) was deprotected with
hydrazine acetate (48 mg, 0.52 mmol) and reacted with 2-bromo-1-indanone (153
mg, 0.651 mmol) for 26 h. After work-up and purification according to the general
procedure an additional purification by silica gel chromatography (PE/EA 4:1, +0.5%
Et3N) was done and 25a/b (95 mg, 65%) was obtained as colorless oil. 
1H NMR
(500 MHz, CDCl3): δ 1.32, 1.33, 1.50 (4s, 6H of 25a, C(CH3)2; 6H of 25b, C(CH3)2),
1.72-1.88 (m, 2H of 25a, H-2; 2H of 25b, H-2), 2.96-3.02 (m, 2H of 25a, H-6a, H-3’a;
2H of 25b, H-6a, H-3’a), 3.14 (dd, J5,6b = 5.4 Hz, J6a,6b = 13.9 Hz, 1H of 25a, H-6b),
3.22 (dd, J5,6b = 8.2 Hz, J6a,6b = 13.7 Hz, 1H of 25b, H-6b), 3.34 (m, 1H of 25b, H-1a),
3.43 (m, 1H of 25a , H-1a), 3.60 (m, 1H of 25a, H-3’b; 1H of 25b, H-3’b), 3.71-3.78
(m, 1H of 25a, H-2’; 2H of 25b, H-5, H-2’), 3.86 (m, 1H of 25a, H-5; 1H of 25b, H-1b),
3.98 (m, 1H of 25a, H-1b), 4.14 (m, 1H of 25a, H-4; 1H of 25b, H-4), 4.26 (m, 1H of
25a, H-3; 1H of 25b, H-3), 7.39, 7.52, 7.77 (m, 4H of 25a, C6H4; 4H of 25b, C6H4);
13C NMR (125 MHz, CDCl3): δ 26.25, 28.08 (4C, C(CH3)2, 25a/b), 29.02, 29.11 (C-2,
25a/b), 32.45, 32.52 (C-6, 25a/b), 34.48, 34.60 (C-3’, 25a/b), 45.61, 46.44 (C-2’,
25a/b), 63.72, 63.92 (C-1, 25a/b), 71.69 (C-3, 25a/b), 73.18 (C-4, 25a/b), 74.33 (C-5,
25a), 75.56 (C-5, 25b), 109.03 (C(CH3)2, 25a/b), 124.59, 124.65, 126.35, 126.39,
127.81, 127.87, 135.14, 135.19, 135.25, 152.04 (12C, C6H4, 25a/b), 203.13, 203.38
(CO, 25a/b); Missing signals are due to overlapping or low resolution. MS (ESI):
Calcd for C18H22NaO4S [M+Na]
+: 357.11; Found m/z: 357.06; IR (NaCl) ν 1713
130
vs (CO) (cm-1); Anal. calcd for C18H22O4S + 0.25 H2O: C 63.79; H 6.69; Found : C
64.11; H 6.81.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(1RS)-3-(4-methoxy-phenyl)-3-
oxo-1-phenyl-propyl]-6-thio-D-lyxo-hexitol (26),(CRV 11a/b), (a:b 1:1).
According to the general procedure, 11 (271 mg, 1.10 mmol) was deprotected with
hydrazine acetate (119 mg, 1.28 mmol) and reacted with 4’-methoxychalcone (408
mg, 1.66 mmol) for 6 d. After work-up and purification 26a/b (98 mg, 28%) was
obtained. 1H NMR (500 MHz, CDCl3): δ 1.30, 1.38, 1.47, 1.51 (4s, 6H of 26a,
C(CH3)2; 6H of 26b, C(CH3)2), 1.71-1.80 (m, 2H of 26a, H-2; 2H of 26b, H-2), 2.61-
2.76 (m, 2H of 26a, H-6; 2H of 26b, H-6), 3.30 (m, 1H of 26a, H-1a; 1H of 26b, H-1a),
3.44-3.54 (m, 3H of 26a, H-5, H-2’; 3H of 26b, H-5, H-2’), 3.86 (s, 3H of 26a, OCH3;
3H of 26b, OCH3), 3.92 (m, 1H of 26a, H-1b; 1H of 26b, H-1b), 4.04 (d, J3,4 = 4.6 Hz,
1H of 26a, H-4), 4.15 (d, J3,4 = 3.8 Hz, 1H of 26b, H-4), 4.20 (m, 1H of 26a, H-3; 1H
of 26b, H-3), 4.63 (m, 1H of 26a, H-1’; 1H of 26b, H-1’), 6.90, 7.21, 7.30, 7.43, 7.89
(m, 9H of 26a, C6H5, C6H4; 9H of 26b, C6H5, C6H4); 
13C NMR (125 MHz, CDCl3): δ
26.18, 26.31, 28.01, 28.15  (C(CH3)2, 26a/b), 28.96, 29.05 (C-2, 26a/b), 32.44, 32.52
(C-6, 26a/b), 44.79, 44.87, 44.93 (4C, C-1’, 26a/b; C-2’, 26a/b), 55.49 (OCH3,
26a/b), 63.79, 63.90 (C-1, 26a/b), 71.61, 71.66 (C-3, 26a/b), 72.53, 72.78 (C-4,
26a/b), 74.76, 74.95 (C-5, 26a/b), 108.92, 109.00 (C(CH3)2, 26a/b), 113.76, 125.31,
127.30, 127.94, 127.97, 128.24, 128.55, 129.05, 129.92, 130.41, 142.14, 163.61
(C6H5, 26a/b ; C6H4, 26a/b), 195.35 (CO, 26a/b); Missing signals are due to
overlapping or low resolution. IR (NaCl) ν 1601 vs (CO) (cm-1); Anal. calcd for
C25H30O5S + 0.25 H2O: C 67.17; H 6.82; Found: C 66.95; H 6.54.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-S-[(1RS)-2-oxo-1,2-diphenyl-
ethyl]-6-thio-D-lyxo-hexitol (27a/b), (CRV 25a/b) (a:b 1:1).
According to the general procedure, 11 (63 mg, 0.26 mmol) was deprotected with
hydrazine acetate (29 mg, 0.31 mmol) and reacted with desylchloride (89 mg, 0.38
mmol) for 23 h. After work-up and purification according to the general procedure an
additional purification by silica gel chromatography (PE/EA 4:1, +0.5% Et3N) was
done and 27a/b (67 mg, 66%) was obtained as white solid. 1H NMR (500 MHz,
CDCl3): δ 1.30, 1.31, 1.48, 1.50 (4s, 6H of 27a, C(CH3)2; 6H of 27b, C(CH3)2), 1.68-
1.78 (m, 2H of 27a, H-2; 2H of 27b), 2.67 (m, 1H of 27a, H-6a), 2.77-2.87 (m, 2H of
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27b, H-6), 2.93 (m, 1H of 27a, H-6b), 3.25-3.32 (m, 1H of 27a, H-1a; 1H of 27b, H-
1a), 3.51 (t, J5,6a  = J5,6b = 7.0 Hz, 1H of 27b, H-5), 3.65 (m, 1H of 27a, H-5), 3.77 (m,
1H of 27a, H-1b), 3.90 (m, 1H of 27b, H-1b), 4.02 (d, J3,4 = 5.5 Hz, 1H of 27a, H-4),
4.09 (d, J3,4 = 5.5 Hz, 1H of 27b, H-4), 4.21 (m, 1H of 27a, H-3; 1H of 27b, H-3),
7.26-7.33, 7.38-7.41, 7.44-7.52, 7.94-7.98 (m, 10H of 27a, 2C6H5; 10H of 27b ,
2C6H5); 
13C NMR (125 MHz, CDCl3): δ 26.24, 26.31, 28.01, 28.05 (C(CH3)2, 27a/b),
28.78 (C-2, 27a/b), 32.37, 32.96 (C-6, 27a/b), 56.35, 56.50 (C-1’, 27a/b), 63.51,
63.68 (C-1, 27a/b), 71.60, 71.63 (C-3, 27a/b), 72.72, 73.41 (C-4, 27a/b), 75.14,
76.43 (C-5, 27a/b), 109.01, 109.04 (C(CH3)2, 27a/b), 127.92, 128.02, 128.55,
128.58, 128.77, 128.88, 128.92, 128.97, 129.04, 133.15, 133.26, 133.81, 136.91,
137.05 (24C, 2C6H5, 27a/b), 195.22, 195.41 (CO, 27a/b); Missing signals are due to
overlapping or low resolution. MS (ESI): Calcd for C23H26NaO4S [M+Na]
+: 421.14;
Found m/z: 421.06; IR (NaCl) ν 1683 vs (CO) (cm-1); Anal. calcd for C23H26O4S: C
69.32, H 6.58; Found : C 69.13, H 6.79.
1,5-Anhydro-2-deoxy-6-S-[(1RS)-3-oxo-cyclohexyl]-6-thio-D-lyxo-hexitol (28a/b),
(CRV 8a/b) (a:b 1:1).
16a/b (28.9 mg, 0.096 mmol) was stirred overnight at 95°C in 80% aqueous AcOH
(2.5 mL). After cooling to r.t., the solvent was coevaporated with toluene. Purification
by silica gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1],
followed by filtration through Gelman Acrodisc (0.2 µm) gave 28a/b (18 mg, 72%) as
a white powder after a final lyophilization from dioxane/H2O (1:1). 
1H NMR (500 MHz,
CDCl3): δ 1.68-1.80  (m, 4H of 28a, H-2, 2H of C6H9; 4H of 28b, H-2, 2H of C6H9),
2.06 (d, J4,OH = 7.1 Hz, 1H of 28a, OH-4; 1H of 28b, OH-4), 2.10-2.22, 2.29-2.45,
2.70-2.79 (m, 8H of 28a, OH-3, H-6a, 6H of C6H9; 8H of 28b, OH-3, H-6a, 6H of
C6H9), 2.87 (m, 1H of 28a, H-6b; 1H of 28b, H-6b), 3.16 (m, 1H of 28a, H-1’; 1H of
28b, H-1’), 3.34-3.44 (m, 2H of 28a, H-1a, H-5; 2H of 28b, H-1a, H-5), 3.71 (m, 1H of
28a, H-3; 1H of 28b, H-3), 3.87 (m, 1H of 28a, H-4; 1H of 28b, H-4), 4.00 (m, 1H of
28a, H-1b; 1H of 28b, H-1b); 13C NMR (125 MHz, CDCl3): δ 24.51 (CH2, 28a/b),
29.78, 30.11 (C-2, 28a/b), 31.58, 31.78, 32.00 (C-6, CH2, 28a/b), 41.31 (CH2, 28a/b),
43.97 (C-1’, 28a/b), 48.27, 48.63 (CH2, 28a/b), 66.52 (C-1, 28a/b), 69.57, 69.76 (4C,
C-3, C-4, 28a/b), 78.96, 79.15 (C-5, 28a/b), 209.38 (CO, 28a/b); Missing signals are
due to overlapping or low resolution. Anal. calcd for C12H20O4S: C 55.36; H 7.74;
Found: C 55.54; H 8.03.
132
1,5-Anhydro-2-deoxy-6-S-[(1RS)-2-oxo-cyclohexyl]-6-thio-D-lyxo-hexitol (29a/b),
(CRV 16a/b), (a:b 1:1).
18a/b (130 mg, 0.434 mmol) was stirred at 90°C in 80% aqueous AcOH (19 mL) for 4
h. After cooling to r.t., the solvent was coevaporated with toluene. Purification by
silica gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1],
followed by filtration through Gelman Acrodisc (0.2 µm) gave 29a/b (66 mg, 59%) as
colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.65-2.02, 2.14-2.26, 2.62-2.95 (m, 14H of
29a, H-2, H-6, OH-3, OH-4, 8H of C6H9; 14H of 29b, H-2, H-6, OH-3, OH-4, 8H of
C6H9), 3.32-3.43 (m, 3H of 29a, H-1a, H-5, H-1’; 3H of 29b, H-1a, H-5, H-1’), 3.68 (m,
1H of 29a, H-3; 1H of 29b, H-3), 3.82 (m, 1H of 29a, H-4; 1H of 29b, H-4), 3.97 (m,
1H of 29a, H1b; 1H of 29b, H1b); 13C NMR (125 MHz, CDCl3): δ 21.90, 22.00 (CH2 of
C6H9, 29a/b), 26.91 (C-2, 29a/b), 29.33, 29.36, 32.26, 32.64, 33.08, 33.23, 37.96,
38.03 (C-6, 29a/b; CH2 of C6H9, 29a/b), 52.46, 52.85 (C-1’, 29a/b), 66.11 (C-1,
29a/b), 69.19, 69.34, 69.37 (C-3, 29a/b; C-4, 29a/b), 77.93, 78.18 (C-5, 29b),
208.78, 208.85 (CO, 29a/b); Missing signals are due to overlapping or low resolution.
MS (ESI): Calcd for C12H20NaO4S [M+Na]
+: 283.10; Found m/z: 283.06; IR (NaCl)
ν 1699 vs (CO) (cm-1); Anal. calcd for C12H20O4S + 0.25 H2O: C 54.42; H 7.80;
Found: C 54.56; H 7.66.
1,5-Anhydro-2-deoxy-6-S-[(1RS)-2-oxo-cyclopentyl]-6-thio-D-lyxo-hexitol
(30a/b), (CRV 12a/b), (a:b 1:1).
19a/b (114 mg, 0.397 mmol) was stirred at 90°C in 80% aqueous AcOH (18 mL) for 4
h. After cooling to r.t., the solvent was coevaporated with toluene. Purification by
silica gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1],
followed by filtration through Gelman Acrodisc (0.2 µm) to obtain 30a/b (83 mg, 85%)
as colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.72-1.96, 2.03-2.47, 2.67 (m, 8H of
30a, H-2, 6H of C5H7; 8H of 30b, H-2, 6H of C5H7), 2.75-2.88 (m, 1H of 30a, H-6a;
2H of 30b, H-6), 3.07 (m, 1H of 30a, H-6b), 3.21 (m, 1H of 30a, H-1’; 1H of 30b, H-
1’), 3.36-3.47 (m, 2H of 30a, H-1a, H-5; 2H of 30b, H-1a, H-5), 3.69 (m, 1H of 30a, H-
3; 1H of 30b, H-3), 3.86 (m, 1H of 30a, H-4; 1H of 30b, H-4), 3.98 (m, 1H of 30a,
H1b; 1H of 30b, H1b); 13C NMR (125 MHz, CDCl3): δ 20.34 (CH2 of C5H7, 30a/b),
29.31, 29.32 (C-2, 30a/b), 30.23, 30.27 (CH2 of C5H7, 30a/b), 31.64, 31.91 (C-6,
30a/b), 36.09 (CH2 of C5H7, 30a/b), 47.58, 48.04 (C-1’, 30a/b), 66.10, 66.18 (C-1,
30a/b), 69.19, 69.35, 69.38 (4C, C-3, C-4, 30a/b), 77.94, 78.64 (C-5, 30a/b), 214.61,
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215.14 (CO, 30a/b), Missing signals are due to overlapping or low resolution. MS
(ESI): Calcd for C11H18NaO4S [M+Na]
+: 269.08; Found m/z: 269.00; IR (NaCl) ν 1728
vs (CO) (cm-1); Anal. calcd for C11H18O4S: C 53.64; H 7.37; Found : C 53.73; H 7.35.
1,5-Anhydro-2-deoxy-6-S-[2-oxo-2phenyl-ethyl]-6-thio-D-lyxo-hexitol (31), (CRV
20).
20 (106 mg, 0.329 mmol) was stirred at 95°C in 80% aqueous AcOH (15 mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) gave 31 (89 mg, 95%) as white
powder after a final lyophilization from dioxane.   
€ 
[α]
D
21 +3.7 (c = 0.56, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.71-1.83 (m, 2H, H-2), 2.43 (d, J3,OH = 7.5 Hz, 1H, OH-3), 2.60
(d, J4,OH = 6.6 Hz, 1H, OH-4), 2.75 (dd, J5,6a = 6.4 Hz, J6a,6b = 13.9 Hz, 1H, H-6a), 2.91
(dd, J5,6b = 6.8 Hz, J6a,6b = 13.6 Hz, 1H, H-6b), 3.34-3.43 (m, 2H, H-1a, H-5), 3.68 (m,
1H, H-3), 3.86-3.95 (m, 4H, H-1b, H-4, H-1’), 7.47, 7.58, 7.96 (m, 5H, C6H5);
13C NMR (125 MHz, CDCl3): δ 29.41 (C-2), 33.11 (C-6), 38.10 (C-1’), 66.06 (C-1),
69.30, 69.37 (C-3, C-4), 78.30 (C-5), 128.76, 133.61, 135.15 (6C, C6H5), 194.92
(CO); MS (ESI): Calcd for C14H18NaO4S [M+Na]
+: 305.08; Found m/z: 304.99; IR
(NaCl) ν 1668 vs (CO) (cm-1); Anal. calcd for C14H18O4S + 0.25 H2O: C 58.62; H 6.50;
Found: C 58.92; H 6.38.
1,5-Anhydro-2-deoxy-6-S-[2-(4-fluorophenyl)-2-oxo-ethyl]-6-thio-D-lyxo-hexitol
(32), (CRV 21).
21 (91 mg, 0.27 mmol) was stirred at 95°C in 80% aqueous AcOH (12 mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) gave 32 (65 mg, 80%) as white
powder after a final lyophilization from dioxane.   
€ 
[α]
D
21 +1.6 (c = 0.34, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.69-1.83 (m, 2H, H-2), 2.39 (s, 1H, OH-3), 2.55 (d, J4,OH = 6.0
Hz, 1H, OH-4), 2.74 (dd, J5,6a = 6.2 Hz, J6a,6b = 13.9 Hz, 1H, H-6a), 2.90 (dd, J5,6b =
7.3 Hz, J6a,6b = 13.9 Hz, 1H, H-6b), 3.39 (m, 2H, H-1a, H-5), 3.69 (m, 1H, H-3), 3.85
(s, 1H, H-4), 3.88 (s, 2H, H-1’), 3.96 (m, 1H, H-1b), 7.14, 8.00 (m, 4H, C6H4);
13C NMR (125 MHz, CDCl3): δ 29.36 (C-2), 33.15 (C-6), 38.01 (C-1’), 66.07 (C-1),
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69.31, 69.42 (C-3, C-4), 78.31 (C-5), 115.83, 116.00, 131.46, 131.53 (6C, C6H4),
193.37 (CO); MS (ESI): Calcd for C14H17FO4NaS [M+Na]
+:323.07; Found: 323.01; IR
(NaCl) ν 1674 vs (CO) (cm-1); Anal. calcd for C14H17FO4S: C 55.99; H 5.70; Found :
C 56.01; H 5.77.
1,5-Anhydro-2-deoxy-6-S-[2-(4-chlorophenyl)-2-oxo-ethyl]-6-thio-D-lyxo-hexitol
(33), (CRV 22).
22 (83 mg, 0.23 mmol) was stirred at 85°C in 80% aqueous AcOH (10 mL) for 6 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) gave 33 (51 mg, 69%) as white
powder after a final lyophilization from dioxane.   
€ 
[α]
D
21 +0.5 (c = 0.35, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.71-1.83 (m, 2H, H-2), 2.70 (m, 3H, H-6a, 2OH), 2.90 (dd, J5,6b
= 6.4 Hz, J6a,6b = 12.9 Hz, 1H, H-6b), 3.38 (m, 2H, H-1a, H-5), 3.68 (m, 1H, H-3), 3.83
(s, 1H, H-4), 3.86 (s, 2H, H-1’), 3.92 (m, 1H, H1-b), 7.43, 7.89 (m, 4H, C6H4);
13C NMR (125 MHz, CDCl3): δ 29.29 (C-2), 33.19 (C-6), 38.03 (C-1’), 66.06 (C-1),
69.32, 69.46 (C-3, C-4), 78.32 (C-5), 129.08, 130.19, 133.44, 140.07 (6C, C6H4Cl),
193.70 (CO); MS (ESI): Calcd for C14H17ClO4NaS [M+Na]
+: 339.04; Found: 338.94;
IR (NaCl) ν 1668 vs (CO) (cm-1); Anal. calcd for C14H17ClO4S: C 53.08; H 5.41;
Found : C 52.86; H 5.45.
1,5-Anhydro-2-deoxy-6-S-[2-(2,5-dimethoxy-phenyl)-2-oxo-ethyl]-6-thio-D-lyxo-
hexitol (34), (CRV 27).
23 (61 mg, 0.16 mmol) was stirred at 90°C in 80% aqueous AcOH (7 mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) gave 34 (42 mg, 78%) as colorless oil.
  
€ 
[α]
D
21 +1.8 (c = 0.98, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.75-1.83 (m, 2H, H-2),
2.45 (m, 1H, OH-3), 2.64 (d, J4,OH = 6.1 Hz,  1H, OH-4), 2.71 (dd, J5,6a = 7.0 Hz, J6a,6b
= 13.7 Hz, 1H, H-6a), 2.84 (dd, J5,6b = 6.8 Hz, J6a,6b = 13.7 Hz, 1H, H-6b), 3.38 (m,
2H, H-1a, H-5), 3.67 (m, 1H,  H-3), 3.79 (s, 3H, OCH3), 3.87 (s, 4H, H-4, OCH3),
3.91-3.98 (m, 3H, H-1b, H-1’), 6.91, 7.06, 7.36 (m, 3H, C6H3); 
13C NMR (125 MHz,
CDCl3): δ 29.50 (C-2), 32.77 (C-6), 43.03 (C-1’), 55.85, 56.16 (2OCH3), 66.10 (C-1),
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69.14, 69.33 (C-3, C-4), 78.10 (C-5), 113.24, 114.50, 121.27, 125.86, 153.41, 153.60
(C6H3); MS (ESI): Calcd for C16H22NaO6S [M+Na]
+: 365.10; Found m/z: 365.04; IR
(NaCl) ν 1661 vs (CO) (cm-1); Anal. calcd for C16H22O6S: C 56.13; H 6.48; Found : C
56.12; H 6.40.
1,5-Anhydro-2-deoxy-6-S-(2-napht-2’yl-2-oxo-ethyl)-6-thio-D-lyxo-hexitol (35),
(CRV 28).
24 (50 mg, 0.133 mmol) was stirred at 90°C in 80% aqueous AcOH (6 mL) for 6 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) afforded 35 (33 mg, 76%) as white
solid.   
€ 
[α]
D
21 +4.1 (c = 0.26, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.75-1.83 (m, 2H, H-
2), 2.33 (d, J3,OH = 8.3 Hz, 1H, OH-3), 2.55 (d, J4,OH = 6.5 Hz, 1H, OH-4), 2.80 (dd,
J5,6a = 6.4 Hz, J6a 6b = 13.9 Hz, 1H, H-6a), 2.95 (dd, J5,6b = 7.1 Hz, J6a,6b = 13.9 Hz, 1H,
H-6b), 3.38 (m, 1H, H-1a), 3.45 (m, 1H,  H-5), 3.69 (m, 1H, H-3), 3.87 (s, 1H, H-4),
3.94 (dd, J1a,1b = 11.8 Hz, J1b,2a = J1b,2b = 4.8 Hz, 1H, H-1b), 4.04 (m, 2H, H-1’), 7.55-
7.63, 7.90, 7.97, 8.02, 8.50 (m, 7H, C10H7); 
13C NMR (125 MHz, CDCl3): δ 29.44 (C-
2), 33.16 (C-6), 38.22 (C-1’), 66.08 (C-1), 69.22 (C-3, C-4), 78.37 (C-5), 124.21,
126.96, 127.83, 128.68, 128.82, 129.69, 130.68, 132.48, 135.79 (10C, C10H7),
194.93 (CO); MS (ESI): Calcd for C18H20NaO4S [M+Na]
+: 355.10; Found m/z:
355.02; IR (NaCl) ν 1668 vs (CO) (cm-1); Anal. calcd for C18H20O4S: C 65.04; H 6.06;
Found : C 65.26; H 6.23.
1,5-Anhydro-2-deoxy-6-S-[(2RS)-1-oxo-indan-2yl]-6-thio-D-lyxo-hexitol (36 a/b),
(CRV 30a/b), (a:b 1:1).
25a/b  (65 mg, 0.19 mmol) was stirred at 95°C in 80% aqueous AcOH (10mL) for 6 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) gave 36a/b (37 mg, 64%) as colorless
oil. 1H NMR (500 MHz, CDCl3): δ 1.66-1.86 (m, 2H of 36a, H-2; 2H of 36b, H-2), 2.41
(m, 1H of 36a, OH-3; 1H of 36b, OH-3), 2.68, 2.78 (d, J4,OH = 6.1 Hz, 1H of 36a, OH-
4; 1H of 36b, OH-4), 2.90-2.99 (m, 2H of 36a, H-6a, H-3’a; 2H of 36b, H-6a, H-3’a),
3.07 (dd, J5,6b = 6.4 Hz, J6a,6b = 13.7 Hz, 1H of 36a, H-6b), 3.25 (dd, J5,6b = 6.5 Hz,
J6a,6b = 13.4 Hz, 1H of 36b, H-6b), 3.35-3.48 (m, 1H of 36a, H-1a; 2H of 36b, H-1a,
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H-5), 3.54 (m, 1H of 36a, H-5), 3.58-3.64 (m, 1H of 36a, H-3’b; 1H of 36b, H-3’b),
3.71-3.77 (m, 2H of 36a, H-3, H-2’; 2H of 36b, H-3, H-2’), 3.89-4.00 (m, 2H of 36a, H-
1b, H-4; 2H of 36b, H-1b, H-4), 7.38-7.44, 7.62, 7.78 (m, 4H of 36a, C6H4; 4H of 36b,
C6H4); 
13C NMR (125 MHz, CDCl3): δ 29.48 (C-2, 36a/b), 31.36, 32.05 (C-6, 36a/b),
34.28, 34.57 (C-3’, 36a/b), 45.72, 46.34 (C-2’, 36a/b), 65.99, 66.14 (C-1, 36a/b),
68.94, 69.25, 69.31, 69.37 (C-3, 36a/b; C-4, 36a/b), 78.20,78.61 (C-5, 36a/b),
124.72,124.79, 126.36, 126.41, 127.04,127.94, 127.99, 135.05, 135.43, 152.08 (12C,
C6H4, 36a/b); Missing signals are due to overlapping or low resolution. MS (ESI):
Calcd for C15H18NaO4S [M+Na]
+: 317.08; Found m/z: 317.06; IR (NaCl) ν 1694 vs
(CO) (cm-1) Anal. calcd for C15H18O4S + 0.25 H2O: C 60.28; H 6.23; Found : C 60.27;
H 6.18.
1,5-Anhydro-2-deoxy-6-S-[(1RS)-3-(4-methoxy-phenyl)-3-oxo-1-phenyl-propyl]-
6-thio-D-lyxo-hexitol (37a/b), (CRV 13a/b), (a:b 1:1).
26a/b (129 mg, 0.293 mmol) was stirred at 80°C in 80% aqueous AcOH (13 mL) for 3
h. After cooling to r.t., the solvent was coevaporated with toluene. Purification by
silica gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1],
followed by filtration through Gelman Acrodisc (0.2 µm) gave 37a/b (99.5 mg, 85%)
as a white solid. 1H NMR (500 MHz, CD3OD): δ 0.98, 1.24-1.34 (m, 2H of 37a, H-2;
2H of 37b, H-2), 2.00-2.11 (m, 2H of 37a, H-6; 2H of 37b, H-6), 2.51 (t, 1H of 37a,
J5,6a = J5,6b = 6.9 Hz, H-5), 2.63 (t, 1H of 37b, J5,6a = J5,6b = 6.9 Hz, H-5), 2.69-2.82 (m,
1H of 37a, H-1a; 1H of 37b, H-1a), 2.93-3.04 (m, 3H of 37a, H-3, H-2’; 3H of 37b, H-
3, H-2’), 3.17 (m, 1H of 37a, H-4; 1H of 37b, H-4), 3.27-3.35 (m, 1H of 37a, H-1b; 1H
of 37b, H-1b), 4.01 (m, 1H of 37a, H-1’; 1H of 37b, H-1’), 4.33 (s, 3H of 37a, OCH3;
3H of 37b, OCH3), 6.43, 6.66, 6.75, 6.88, 7.38 (m, 9H of 37a, C6H5, C6H4; 9H of 37b,
C6H5, C6H4); 
13C NMR (125 MHz, CD3OD): δ 30.16, 30.20 (C-2, 37a/b), 33.32, 33.89
(C-6, 37a/b), 46.05, 46.12 (C-2’, 37a/b), 46.83, 47.30 (C-1’, 37a/b), 56.49 (OCH3,
37a/b), 67.48 (C-1, 37a/b), 70.42, 70.49  (C-4, 37a/b), 71.24 (C-3, 37a/b), 79.95,
80.17 (C-5, 37a/b), 115.33, 128.72, 129.57, 129.58, 129.92, 131.54, 132.13, 144.05,
144.35, 165.82 (24C, C6H5, 37a/b; C6H4, 37a/b), 198.38 (CO, 37a/b); Missing signals
are due to overlapping or low resolution. MS (ESI): Calcd for C22H26NaO5S [M+Na]
+:
425.14; Found m/z: 425.14; IR (NaCl) ν 1599 vs (CO) (cm-1); Anal. calcd for
C22H26O5S + 0.25 H2O: C 64.92; H 6.56; Found: C 64.93; H 6.41.
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1,5-Anhydro-2-deoxy-6-S-[(1RS)-2-oxo-1,2-diphenyl-ethyl]-6-thio-D-lyxo-hexitol
(38a/b), (CRV 29a/b), (a:b 1:1).
27a/b (39 mg, 0.099 mmol) was stirred at 90°C in 80% aqueous AcOH (5 mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 20:1 b) Hexane c) DCM/MeOH 20:1], followed
by filtration through Gelman Acrodisc (0.2 µm) yielded 38a/b (23 mg, 66%) as
colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.71-1.78 (m, 2H of 38a, H-2; 2H of 38b,
H-2), 2.23 (m, 2H of 38a, OH-3, OH-4; 1H of 38b, OH-3), 2.52 (d, J4,OH = 6.2 Hz, 1H
of 38b, OH-4), 2.65  (m, 1H of 38a, H-6a), 2.74 (m, 1H of 38b, H-6a), 2.81-2.89 (m,
1H of 38a, H-6b; 1H of 38b, H-6b), 3.22-3.36 (m, 2H of 38a, H-1a, H-5; 2H of 38b, H-
1a, H-5), 3.62 (m, 1H of 38a, H-3; 1H of 38b, H-3), 3.80-3.92 (m, 2H of 38a, H-1b, H-
4; 2H of 38b, H-1b, H-4), 7.26-7.53, 7.96 (m, 10H of 38a, 2C6H5; 10H of 38b, 2C6H5);
13C NMR (125 MHz, CDCl3): δ 29.33, 29.39 (C-2, 38a/b), 32.10, 32.51 (C-6, 38a/b),
56.23, 56.49 (C-1’, 38a/b), 65.89, 66.04 (C-1, 38a/b), 69.19, 69.21, 69.28, 69.79 (C-
3, 38a/b; C-4, 38a/b), 78.15, 79.26 (C-5, 38a/b), 118.72, 128.07, 128.14, 128.63,
128.67, 128.81, 128.97, 129.05, 133.32, 133.41, 135.57, 135.62, 136.71 (24C,
4C6H5, 38a/b), 195.28, 195.41 (CO, 38a/b); Missing signals are due to overlapping or
low resolution. MS (ESI): Calcd for C20H22NaO4S [M+Na]
+: 381.11; Found m/z:
381.06; IR (NaCl) ν 1668 vs (CO) (cm-1); Anal. calcd for C20H22O4S + 0.25 H2O: C
65.37; H 6.31; Found : C 65.61; H 6.54.
Bis [1,5-anhydro-D-lyxo-hexitol-6-yl]-disulphide (39), (CRV 31).
15 (278 mg, 0.683 mmol) was stirred at 80°C in 80% aqueous AcOH (30 mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 9:1 b) Hexane c) DCM/MeOH 9:1], followed by
filtration through Gelman Acrodisc (0.2 µm) yielded 39 (156 mg, 70%) as a white
solid.   
€ 
[α]
D
21 +9.4 (c = 0.60, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.60 (m, 1H, H-2a),
1.88 (m, 1H, H-2b), 2.94 (m, 2H, H-6), 3.45 (m, 1H, H-1a), 3.54 (t, J5,6a = J5,6b =
6.6 Hz, 1H, H-5), 3.69 (m, 1H, H-3), 3.77 (s, 1H, H-4), 3.95 (m, 1H, H-1b); 13C NMR
(125 MHz, CD3OD): δ 30.20 (C-2), 41.82 (C-6), 67.50 (C-1), 70.80, 71.21 (C-3, C-4),
79.14 (C-5); MS (ESI): Calcd for C12H22O6NaS2 [M+Na]
+: 349.08; Found m/z: 348.96;
Anal. calcd for C12H22O6S2: C 44.16; H 6.79; Found : C 44.17; H 6.87.
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1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-{4-(napht-2-yl)-[1,2,3]-triazol-1-yl}-
D-lyxo-hexitol (42), (CRVII 9).
41 (20 mg, 0.094 mmol) was dissolved in H2O/t-BuOH (1:1) (1.7 mL) with vigorous
stirring. 1-Ethynyl-naphtalene (13.7 µL, 0.094 mmol) was added followed by sodium
ascorbate as a freshly prepared solution (93 µL, 20 mg/mL in H2O/t-BuOH 1:1) and
finally CuSO4⋅5H2O also as a freshly prepared solution (23 µL, 10 mg/mL in H2O).
The reaction was stirred at r.t. Additions of fresh sodium ascorbate and copper
sulfate solutions (equal amounts to the initial one) were performed every 4 to 6 h
during 4 days. When no more changes were detected according to TLC, one eq of
alkyne was added (this was repeated twice). After 4 days the reaction was
concentrated under reduced pressure. Purification by silica gel chromatography
(PE/EA 2:1, +1% Et3N) gave 42 (31 mg, 91%) as white solid.   
€ 
[α]
D
21 -10.0 (c = 0.91,
CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.38, 1.58 (2s, 6H, C(CH3)2), 1.79-1.92 (m, 2H,
H-2), 3.41 (m, 1H, H-1a), 3.98 (m, 1H, H-1b), 4.09 (m, 2H, H-4, H-5), 4.33 (m, 1H, H-
3), 4.66 (dd, J5,6a = 8.5 Hz, J6a,6b = 14.2 Hz, 1H, H-6a), 4.78 (dd, J5,6b = 4.2 Hz, J6a,6b =
14.2 Hz, 1H, H-6b), 7.52, 7.75, 7.89, 8.40 (m, 8H, C2HN3, C10H7);
 13C NMR
(125 MHz, CDCl3): δ 26.16, 27.93, 28.60 (C-2, C(CH3)2), 51.70 (C-6), 63.42 (C-1),
71.44 (C-3), 72.18 (C-4), 73.96 (C-5), 109.53 (C(CH3)2), 124.30, 125.37, 125.92,
126.53, 127.13, 128.10, 128.42, 128.77, 131.04, 133.86, 146.49 (12C, C2HN3,
C10H7); MS (ESI): Calcd for C21H24N3O3 [M+H]
+: 366.18; Found m/z: 366.20; Anal.
calcd for C21H23N3O3 + 0.17 H2O: C 68.46; H 6.37; N 11.37 Found : C 68.79; H 6.69;
N 10.83.
1,5-Anhydro-2-deoxy-3,4-O-isopropylidene-6-{4-(3-trifluoromethyl-phenyl)-
[1,2,3]-triazol-1-yl}-D-lyxo-hexitol  (43), (CR VII 11).
41 (21 mg, 0.10 mmol) was dissolved in H2O/t-BuOH (1:1) (1.7 mL) with vigorous
stirring. 3-Ethynyl-α,α,α-trifluorotoluene (15 µL, 0.10 mmol) was added followed by
sodium ascorbate as a freshly prepared solution (50 µL, 20 mg/mL in H2O/t-BuOH
1:1) and finally CuSO4⋅5H2O also as a freshly prepared solution (25 µL, 10 mg/mL in
H2O). The reaction was stirred at r.t. Identical additions of fresh sodium ascorbate
and copper sulfate solutions as the initial one, were performed every 3 h along the
whole reaction time. When no more changes were detected according to TLC, one
eq of alkyne was added (this was repeated once). After 48 h, a catalytic amount of
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CuCl was added and the reaction left overnight. The mixture was concentrated under
reduced pressure. Purification by silica gel chromatography (PE/EA 2:1, +1% Et3N)
gave 43 (25 mg, 67%) as white solid.   
€ 
[α]
D
21 +6.6 (c = 1.25, CHCl3); 
1H NMR (500 MHz,
CDCl3): δ 1.37, 1.57 (2s, 6H, C(CH3)2), 1.80-1.92 (m, 2H, H-2), 3.38 (m, 1H, H-1a),
3.96-4.06 (m, 3H, H-1b, H-4, H-5), 4.32 (m, 1H, H-3), 4.58 (dd, J5,6a = 8.8 Hz, J6a,6b =
14.2 Hz, 1H, H-6a), 4.72 (dd, J5,6b = 3.7 Hz, J6a,6b = 14.2 Hz, 1H, H-6b), 7.55, 7.75,
7.98, 8.02, 8.08 (m, 5H, C2HN3, C6H4); 
13C NMR (125 MHz, CDCl3): δ 26.29, 28.07
(C(CH3)2), 28.70 (C-2), 52.06 (C-6), 63.56 (C-1), 71.60 (C-3), 72.37 (C-4), 74.09 (C-
5), 109.73 (C(CH3)2), 122.02, 122.61, 129.48, 131.68, 146.34 (9C, C2HN3 , C7H4F3);
MS (ESI): Calcd for C18H21F3N3O3 [M+H]
+: 384.15; Found m/z: 384.19.
1,5-Anhydro-2-deoxy-6-{4-(napht-2-yl)-[1,2,3]-triazol-1-yl}-D-lyxo-hexitol (44),
(CRVII 10).
42 (25 mg, 0.68 mmol) was stirred at 95°C in 80% aqueous AcOH (3mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 9:1 b) Hexane c) DCM/MeOH 9:1], followed by
filtration through Gelman Acrodisc (0.2 µm) gave 44 (19 mg, 95%) as white powder
after a final lyophilization from H2O/dioxane (1:1).   
€ 
[α]
D
21 +11.5 (c = 0.95, MeOH); 1H
NMR (500 MHz, CD3OD): δ 1.62 (m, 1H, H-2a), 1.98 (m, 1H, H-2b), 3.42 (t, J1a,2a =
J1b,2b = 12.0 Hz, 1H, H-1a), 3.73 (m, 1H, H-3), 3.79 (m, 1H, H-4), 3.86 (t, J5,6a = J5,6b =
4.1 Hz, 1H, H-5), 3.97 (m, 1H, H-1b), 4.68-4.76 (m, 2H, H-6), 7.54, 7.68, 7.93, 8.24
(m, 8H, C2HN3, C10H7); 
13C NMR (125 MHz, CD3OD): δ 29.74 (C-2), 53.23 (C-6),
66.98 (C-1), 69.93 (C-4), 70.36 (C-3), 78.74 (C-5), 126.10, 126.17, 126.21, 126.40,
127.14, 128.37, 129.08, 129.54, 130.10, 132.46, 135.39, 147.38 (C2HN3 , C10H7); MS
(ESI): Calcd for C18H20N3O3 [ M+H]
+: 326.15; Found m/z: 326.15; Anal. calcd for
C18H19N3O3 + 0.17 H2O: C 65.84; H 6.04; Found : C 66.16; H 6.45.
1,5-Anhydro-2-deoxy-6-{4-(3-trifluoromethyl-phenyl)-[1,2,3]-triazol-1-yl}-D-lyxo-
hexitol (45), (CRVII 12).
43 (25 mg, 0.065 mmol) was stirred at 80°C in 80% aqueous AcOH (3mL) for 4 h.
After cooling to r.t., the solvent was coevaporated with toluene. Purification by silica
gel chromatography [a) DCM/MeOH 9:1 b) Hexane c) DCM/MeOH 9:1], followed by
filtration through Gelman Acrodisc (0.2 µm) gave 45 (22 mg, 100%) as white powder
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after a final lyophilization from H2O/dioxane (1:1).   
€ 
[α]
D
21 +6.1 (c = 1.10, MeOH);
1H NMR (500 MHz, CD3OD): δ 1.61 (m, 1H, H-2a), 1.97 (m, 1H, H-2b), 3.38 (m, 1H,
H-1a), 3.73 (m, 1H, H-3, H-4), 3.80 (m, 1H, H-5), 3.96 (m, 1H, H-1b), 4.61-4.70 (m,
2H, H-6), 7.63, 8.08, 8.14 (m, 4H, C6H4), 8.43 (s, 1H, C2HN3); 
13C NMR (125 MHz,
CD3OD): δ 29.73 (C-2), 53.31 (C-6), 66.97 (C-1), 69.91 (C-4), 70.37 (C-3), 78.68 (C-
5), 123.13, 130.13, 132.98, 147.11 (9C, C2HN3 , C7H4F3); MS (ESI): Calcd for
C15H17F3N3O3 [M+H]
+: 344.12; Found m/z: 344.12; Anal. calcd for C15H16 F3N3O3 +
0.1 H2O: C 52.20; H 4.73; Found : C 52.49; H 4.91.
3,4-O-[(1RS)-4-(Allyl carboxylate)-benzylidene]-1,5-anhydro-6-azido-2-deoxy-6-
{4-(tiophen-3-yl)- [1,2,3]-triazol-1-yl}-D-lyxo-hexitol (48a/b), (CR VII 5a/b), (a:b:
1:1).
47a/b (25 mg, 0.073 mmol) was dissolved in H2O/t-BuOH (1:1) (1.35 mL) with
vigorous stirring. 3-Ethynyl-tiophene (72 µL, 0.073 mmol) was added followed by
sodium ascorbate as a freshly prepared solution (144 µL, 10 mg/mL in H2O/t-BuOH
1:1) and finally CuSO4⋅5H2O also as a freshly prepared solution (18.2 µL, 10 mg/mL
in H2O). The reaction was stirred at r.t. and three additional portions of freshly
prepared sodium ascorbate and copper sulfate solutions (same quantities as the
initial addition) were added during a period of 40 h. The reaction was concentrated
under reduced pressure. Purification by silica gel chromatography (PE/EA 2:1 to 1:1,
+1% Et3N) gave 48a/b 1:1 (26.1 mg, 79%) as colorless oil. The two isomers could be
separated. 48a:   
€ 
[α]
D
21 +31.2 (c = 0.34, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.90-
2.04 (m, 2H, H-2), 3.38 (dd, J1a,1b = 11.3 Hz, J1a,2a = J1a,2b = 3.1 Hz, 1H, H-1a) 3.99
(d, J3,4 = 5.1 Hz, 1H, H-4), 4.05 (m, 2H, H-1b, H-5), 4.57-4.66 (m, 2H, H-3, H-6a),
4.72 (dd, J5,6a = 4.4 Hz, J6a,6b = 14.2 Hz, 1H, H-6b), 4.84 (m, 2H, CH2CHCH2O), 5.30
(m, 1H, Ha of CH2CHCH2O), 5.42 (m, 1H, Hb of CH2CHCH2O), 6.01-6.09 (m, 1H,
CH2CHCH2O), 6.26 (s, 1H, CHO2), 7.38 (m, 2H, C4H3S), 7.52 (m, 2H, C6H4), 7.63 (m,
1H, C4H3S), 7.74 (s, 1H, C2HN3), 8.08 (m, 2H, C6H4); 
13C NMR (125 MHz, CDCl3): δ
26.60 (C-2), 51.64 (C-6), 63.95 (C-1), 65.71 (CH2CHCH2O), 72.21 (C-4), 72.88 (C-3),
74.77 (C-5), 102.41 (CHO2), 118.39 (CH2CHCH2O), 120.99, 121.19, 125.77, 126.16,
126.32, 129.91, 130.98, 143.56 (12C, C6H4, C4H3S, C2HN3), 132.12 (CH2CHCH2O),
165.80 (CO); IR (NaCl) ν 1716 vs (CO) (cm-1). 48b:   
€ 
[α]
D
21 -6.8 (c = 0.96, CHCl3); 
1H
NMR (500 MHz, CDCl3): δ 1.86 (m, 1H, H-2a), 1.96 (m, 1H, H-2b), 3.50 (m 1H, H-1a)
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4.01 (m, 1H, H-1b), 4.12 (m, 1H, H-5), 4.17 (d, J3,4 = 6.3 Hz, 1H, H-4), 4.50 (m, 1H,
H-3), 4.58 (dd, J5,6a = 8.6 Hz, J6a,6b = 14.3 Hz, 1H, H-6a), 4.76 (dd, J5,6b = 3.7 Hz,
J6a,6b = 14.3 Hz, 1H, H-6b), 4.84 (m, 2H, CH2CHCH2O), 5.30 (m, 1H, Ha of
CH2CHCH2O), 5.42 (m, 1H, Hb of CH2CHCH2O), 5.95 (s, 1H, CHO2), 6.01-6.09 (m,
1H, CH2CHCH2O), 7.38, 7.46 (m, 2H, C4H3S), 7.64 (m, 2H, C6H4), 7.68 (m, 1H,
C4H3S), 7.79 (s, 1H, C2HN3), 8.11 (m, 2H, C6H4); 
13C NMR (125 MHz, CDCl3): δ
27.79 (C-2), 51.66 (C-6), 63.03 (C-1), 65.69 (CH2CHCH2O), 71.90 (C-3), 73.54 (C-4),
74.25 (C-5), 103.40 (CHO2), 118.33 (CH2CHCH2O), 121.03, 121.26, 125.83, 126.31,
126.76, 129.83, 131.15, 131.85, 142.24, 143.78 (12C, C6H4, C4H3S, C2HN3), 132.13
(CH2CHCH2O), 165.86 (CO); MS (ESI): Calcd for C23H24N3O5S [M+H]
+: 454.14;
Found m/z: 454.15; IR (NaCl) ν 1715 vs (CO) (cm-1)
Synthesis on solid phase of:
1,5-Anhydro-2-deoxy-6-{4-(tiophen-3-yl)-[1,2,3]-triazole}-D-lyxo-hexitol (50),
(CRVII 8).
Aminomethylated polystyrene lanterns (Mimotopes SynphaseTM, D series) with a
loading capacity of 35 µmol, were used as solid support.
a) Lantern swelling and activation. The lanterns were immersed for 30 min in DMF,
then trested with 20% Et3N in DMF (3 x 10 min).
b) Standard washing procedure. The lanterns were washed with DMF (3 x 10 min)
and DCM (3 x 10 min).
c) Loading. The coupling solution consisted of 49 (69.5 mg, 3.3 eq x 35 µmol x 1.5
lantern) and HOBt (26.2 mg, 3.3 eq x 35 µmol x 1.5 lantern) in DMF (0.75 mL). Of the
coupling solution, 0.5 mL was pipetted in a 96-well plate followed by DIC (17.7 µL,
3.3 eq x 35 µmol). After 2 min of activation, the lantern was added and the plate left
at r.t. in the shaker during 21 h. The lantern was then washed with the above
washing procedure.
d) Triazole formation. To a well containing 0.45 mL of H2O/t-BuOH (1:1), 3-ethynyl-
tiophene (11.2 µL, 0.114 mmol) was added followed by freshly prepared sodium
ascorbate solution (20.0 µL, 113 mg/mL in H2O/t-BuOH 1:1), and freshly prepared
CuSO4⋅5H2O solution (10.0 µL, 28.5 mg/ml in H2O). The lantern was immersed in the
previous solution and the plate was left at r.t. in the shaker for 3 days. Regular
additions of freshly prepared sodium ascorbate and copper sulfate solutions (equal
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amounts as the initial addition) were performed three times per day. After 3 days of
reaction, the washing procedure was applied.
d) Cleavage from the solid phase. The lantern was treated with 80% aqueous AcOH
containing 2% TFA (2 mL) (2 x 15-20 h). The solvent was evaporated under reduced
pressure to provide 50 as a white solid in 58% yield considering the loading capacity
of one lantern. 1H NMR (500 MHz, CD3OD): δ 1.61 (m, 1H, H-2a), 1.95 (m, 1H, H-
2b), 3.39 (m, 1H, H-1a), 3.68-3.79 (m, 3H, H-3, H-4, H-5), 3.95 (m, 1H, H-1b), 4.58-
4.66 (m, 2H, H-6), 7.49, 7.74 (m, 3H, C4H3S), 8.18 (s, 1H, C2HN3),
 13C NMR
(125 MHz, CD3OD): δ 30.13 (C-2), 53.60 (C-6), 67.36 (C-1), 70.32 (C-4), 70.77 (C-3),
79.14 (C-5), 122.51, 122.49, 127.12, 128.02, 133.25, 145.28 (C4H3S, C2HN3); MS
(ESI): Calcd for C12H16N3O3 [M+H]
+: 282.09; Found m/z: 281.83.
Synthesis of a library of derivates of methyl α-D-galactopyranoside.
Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-α-D-galactopyranoside (51),
(CRDM001).
To a suspension of methyl α-D-galactopyranoside (6.24 g, 32.1 mmol) in 120 mL of
dry DCM was added TBDPSCl (9.00 mL, 35.3 mmol). DMAP (157 mg, 1.28 mmol)
and Et3N (5.05 mL, 38.5 mmol) were added and the mixture was stirred under argon
at r.t.. During the reaction, the pH was controlled and set to basic with Et3N until no
more starting material was detected by TLC. After 64 h the solvent was evaporated
and the crude material was redissolved in DCM (30 mL) and washed with water (2 x
20 mL). The organic layer was dried with Na2SO4, filtered and concentrated under
reduced pressure. After purification by silica gel chromatography (DCM/MeOH 20:1),
51 (15.1 g, quantitative) was obtained as yellow oil. 1H NMR (500 MHz, CDCl3): δ
1.07 (s, 9H, C(CH3)3), 2.06 (d, J2,OH = 9.4 Hz, 1H, OH-2), 2.60 (d, J3,OH = 5.4 Hz, 1H,
OH-3), 2.74 (d, J4,OH = 2.6 Hz, 1H, OH-4), 3.37 (s, 3H, OCH3), 3.72 (m, 1H, H-3), 3.77
(t, J5,6a = J5,6b = 5.5 Hz, 1H, H-5), 3.82 (m, 1H, H-2), 3.87 (dd, J5,6a = 5.1 Hz, J6a,6b =
10.6 Hz, 1H, H-6a), 3.92 (dd, J5,6b = 6.1 Hz, J6a,6b = 10.6 Hz, 1H, H-6b), 4.12 (s, 1H,
H-4), 4.80 (d, J1,2 = 3.9 Hz, 1H, H-1), 7.38-7.46, 7.67-7.71 (m, 10H, 2C6H5); 
 13C NMR
(125 MHz, CDCl3): δ 19.56 (C(CH3)3), 27.19  (3C, C(CH3)3), 55.78 (OCH3), 63.89 (C-
6), 69.80 (C-4), 70.14 (C-5), 70.33 (C-2), 71.87 (C-3), 99.79 (C-1), 128.20, 130.30,
133.45, 135.97, 136.05 (12C, 2C6H5).
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Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-3,4-O-isopropylidene-α-D-
galactopyranoside (52), (CRDM002).
Compound 51 (1.09 g, 2.52 mmol) was dissolved under argon in dry CH3CN (50 mL).
2,2-Dimethoxypropane (0.46 mL, 3.78 mmol) was added dropwise with vigorous
stirring followed by toluene-4-sulfonicacid in acetonitrile (1.0 mL, 14.4 mg/mL, 75.6
µmol). After 24 h, 2,2-dimethoxypropane (93.0 µL, 0.756 mmol) was added, and
stirring was continued for additional 5 h. After neutralizing the reaction with Et3N, the
solution was concentrated under reduced pressure. The residue was purified by silica
gel chromatography (PE/EA 2:1, +0.5% Et3N) to afford 52 (1.07 g, 89%) as yellow oil.
  
€ 
[α]
D
21 +63.2 (c = 0.57, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.06 (s, 9H, C(CH3)3),
1.34, 1.48 (2s, 6H, C(CH3)2), 2.31 (d, J2,OH = 6.9 Hz, 1H, OH-2), 3.42 (s, 3H, OCH3),
3.78 (m, 1H, H-2), 3.86 (dd, J5,6a = 6.6 Hz, J6a,6b = 10.1 Hz, 1H, H-6a), 3.93 (dd, J5,6b =
6.6 Hz, J6a,6b = 10.1 Hz, 1H, H-6b), 4.06 (td, J4,5 = 2.2 Hz, J5,6a = J5,6b = 6.6 Hz, 1H, H-
5), 4.19 (m, 1H, H-3), 4.28 (m, 1H, H-4), 4.73 (d, J1,2 = 3.8 Hz, 1H, H-1), 7.36-7.45,
7.71 (m, 10H, 2C6H5); 
13C NMR (125 MHz, CDCl3): δ  19.60 (C(CH3)3), 26.37
(C(CH3)2), 27.17 (3C, C(CH3)3), 28.25 (C(CH3)2), 55.75 (OCH3), 63.36 (C-6), 68.89
(C-5), 70.27 (C-2), 73.25 (C-4), 76.67 (C-3), 98.92 (C-1), 109.81 (C(CH3)2), 128.02,
128.07, 130.07, 133.82, 133.92, 136.03, 136.06 (12C, 2C6H5).
(2RS)-2-(2-Bromoethoxy)-tetrahydro-2H-pyran (53), (CRDM006).
To a stirred mixture of 2-bromoethanol (1.60 mL, 21.4 mmol) and 3,4-dihydro-2H-
pyran (3.00 mL, 32.2 mmol) in dry DCM (115 mL) pyridinium p-toluenesulfonate was
added (0.54 g, 2.14 mmol) under argon. After stirring at r.t. for 2 h, the solution was
washed with water (2 x 50 mL), dried over Na2SO4, filtered and concentrated under
reduced pressure at rt. The residue was purified by silica gel chromatography (PE/EA
10:1) and 53 was obtained  (4.60 g, quantitative) as colorless liquid. 1H NMR
(500 MHz, CDCl3): δ 1.52-1.89 (m, 6H, H-3, H-4, H-5), 3.49-3.55 (m, 3H, H-2’, H-6a),
3.77 (dt, J1’a,1’b = 11.3 Hz, J1’a,2’a = J1’a, 2’b = 6.3 Hz, 1H, H-1’a), 3.90 (m, 1H, H-6b),
4.02 (dt, J1’a,1’b = 11.3 Hz, J1’b,2’a = J1’b,2’b = 6.3 Hz, 1H, H-1’b), 4.68 (t, J = 3.5 Hz, 1H,
H-2), 13C NMR (125 MHz, CDCl3): δ 19.65, 25.75, 30.82 (C-3, C-4, C-5), 31.26 (C-2’),
62.68 (C-6), 67.93 (C-1’), 99.34 (C-2).
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Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-O-[(2RS)-(2-ethoxy-tetrahydro-
2H-pyran)-2’-O-yl]-3,4-O-isopropylidene-α-D-galactopyranoside (54a/b),
(CRDM007a/b) (a:b 1:1).
NaH (313 mg of 55% NaH in oil, 7.20 mmol) was washed with hexane (3 x 10 mL)
under argon and immediately dried in high vacuum. After suspending the NaH in dry
DMF (30 mL), 52 (1.45 g, 2.87 mmol) dissolved in DMF (10 mL) was slowly added
over 30 min at 0°C. Then a solution of 53 (900 mg, 4.31 mmol) in DMF (3 mL) was
added during 15 min. After 1 h at 0°C, the reaction was warmed to r.t.. When no
more gas evolution was detected, the reaction mixture was heated to 40°C. After 29
h the reaction was quenched by addition of saturated aqueous NH4Cl until pH 7,
extracted with DCM (2 x 40 mL) and washed with water (2 x 30 mL). After drying with
Na2SO4 and filtering, the organic layer was concentrated under reduced pressure
and the residue purified by silica gel chromatography (PE/EA 4:1 to 2:1, +0.5% Et3N).
54  (620 mg, 50%) was afforded as an isomeric mixture. 1H NMR (500 MHz, CDCl3):
δ 1.06 (s, 9H of 54a, C(CH3)3; 9H of 54b, C(CH3)3), 1.34 (s, 3H of 54a, C(CH3)2; 3H
of 54b, C(CH3)2), 1.52 (s, 5H of 54a, C(CH3)2, 2H of C5H9O; 5H of 54b, C(CH3)2, 2H
of C5H9O), 1.55-1.62, 1.68-1.74, 1.79-1.83  (m, 4H of 54a, 4H of C5H9O; 4H of 54b,
4H of C5H9O), 3.37 (s, 3H of 54a, OCH3; 3H of 54b, OCH3), 3.46 (m, 1H of 54a, 1H
of C5H9O; 1H of 54b, 1H of C5H9O), 3.55 (m, 1H of 54a, H-2; 1H of 54b, H-2), 3.60-
3.67, 3.80-3.98 (m, 7H of 54a, H-6, H-1’, H-2’, 1H of C5H9O; 7H of 54b, H-6, H-1’, H-
2’, 1H of C5H9O), 4.04 (t, J5,6a = J5,6b = 6.6 Hz, 1H of 54a, H-5; 1H of 54b, H-5), 4.25-
4.28 (m, 2H of 54a, H-3, H-4; 2H of 54b, H-3, H-4), 4.64 (m, 1H of 54a, CHO of
C5H9O; 1H of 54b, CHO of C5H9O), 4.79 (d, J1,2 = 3.5 Hz, 1H of 54a, H-1; 1H of 54b,
H-1), 7.36-7.44, 7.70-7.72 (m, 10H of 54a, 2C6H5; 10H of 54b, 2C6H5); 
13C NMR
(125 MHz, CDCl3): δ  19.59, 19.95 (C(CH3)3, 54a/b), 25.83  (CH2 of C5H9O, 54a/b),
26.75, 26.78 (C(CH3)2, 54a/b), 27.15 (C(CH3)3, 54a/b), 28.73 (C(CH3)2, 54a/b), 30.09
(CH2 of C5H9O, 54a/b), 30.94, 31.01 (2CH2 of C5H9O, 54a/b), 55.77 (OCH3, 54a/b),
62.48, 62.71, 63.50, 67.09, 67.41 (OCH2, 54a/b; CH2 of C5H9O, 54a/b), 68.12 (C-5,
54a/b), 70.61, 71.02 (C-6, 54a/b), 76.51, 76.42, 73.67 (4C, C-3, 54a/b; C-4, 54a/b),
79.06, 78.90 (C-2, 54a/b), 99.15, 99.55, 98.74, 98.78 (4C, C-1, 54a/b; CH of C5H9O,
54a/b), 109.39 (C(CH3)2), 128.02, 128.07, 130.08, 131.09, 133.94, 136.07 (24C,
2C6H5, 54a/b); Missing signals are due to overlaping or low resolution. Anal. calcd for
C33H48O8Si + 0.25 H2O: C 65.46, H 8.08; Found: C 65.14, H 8.05.
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Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-O-(2-hydroxyethyl)-3,4-O-
isopropylidene-α-D-galactopyranoside (55), (CRDM008).
Dry 54a/b (1.66 g, 2.76 mmol) was dissolved under argon in MeOH (22 mL) and
PPTS (251 mg, 0.138 mmol) was added. The mixture was stirred at 55°C for 5 h and
then left at r.t. overnight. The reaction was neutralized by addition of Et3N (pH 7). The
solvents were evaporated and the residue was purified by silica gel chromatography
(PE/EA 2:1to 4:3, +0.5% Et3N) to obtain 55 (83%) as yellowish oil.   
€ 
[α]
D
21 +58.7 (c =
1.05, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.06 (s, 9H, C(CH3)3), 1.34, 1.52 (2s, 6H,
C(CH3)2), 3.38 (s, 3H, OCH3), 3.50 (dd, J1,2 = 3.5 Hz, J2,3 = 7.6 Hz, 1H, H-2), 3.72-
3.81 (m, 4H, H-1’, H-2’), 3.87 (dd, J5,6a = 6.5 Hz, J6a,6b = 9.9 Hz, 1H, H-6a), 3.95 (dd,
J5,6b = 6.9 Hz, J6a,6b = 9.9 Hz, 1H, H-6b), 4.25-4.31 (m, 2H, H-3, H-4), 4.77 (d, J1,2 =
3.5 Hz, 1H, H-1), 7.36-7.45, 7.69-7.74 (m, 10H, 2C6H5); 
13C NMR (125 MHz, CDCl3):
δ 19.60 (C(CH3)3), 26.60 (C(CH3)2), 27.16 (3C, C(CH3)3), 28.57 (C(CH3)2), 55.78
(OCH3), 62.36 (C-2’), 63.24 (C-6), 68.18 (C-5), 73.09 (C-1’), 73.61 (C-4), 76.04 (C-3),
79.37 (C-2), 98.24 (C-1), 109.69 (C(CH3)2), 128.03, 128.08, 130.10, 133.76, 133.87,
136.01, 136.05 (12C, 2C6H5); Missing signals are due to overlapping or low
resolution. Anal. calcd for C28H40O7Si + 0.25 H2O: C 64.53, H 7.83; Found: C 64.48,
H 7.90.
Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-3,4-O-isopropylidene-2-O-[(2-
methanesulfonyloxy)ethyl]-α-D-galactopyranoside (56), (CRDM009).
Galactoside 55(1.15 g, 2.22 mmol) was dissolved in pyridine (20 mL). Then mesyl
chloride (0.35 mL, 4.52 mmol) was added dropwise at 0°C. After 15 min the reaction
was warmed to r.t. and stirring continued for 3 h. The reaction was diluted with EtOAc
(30 mL) and extracted with 1 N HCl (2 x 15 mL), saturated aqueous NaHCO3 (2 x 20
mL) and brine (20 mL). The organic layer was dried with Na2SO4, filtered and
concentrated. Silica gel chromatography (PE/EA 2:1, +0.5% Et3N) of the residue
gave 56 (1.22 g, 92%) as a white solid.   
€ 
[α]
D
21 +59.8 (c = 0.58, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.06 (s, 9H, C(CH3)3), 1.33, 1.51 (2s, 6H, C(CH3)2), 3.08 (s, 3H,
SCH3), 3.36 (s, 3H, OCH3), 3.48 (m, 1H, H-2), 3.85-3.90 (m, 2H, H-6a, 1H of CH2),
3.94-4.04 (m, 3H, H-5, H-6b, 1H of CH2), 4.10-4.14 (m, 1H, H-3), 4.23-4.28 (m, 1H,
H-4), 4.39 (m, 2H, CH2), 4.76 (d, J1,2 = 3.3 Hz, 1H, H-1), 7.36-7.44, 7.66-7.74 (m,
10H, 2C6H5); 
13C NMR (125 MHz, CDCl3): δ 19.60 (C(CH3)3), 26.71 (C(CH3)2), 27.16
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(3C, C(CH3)3), 28.78 (C(CH3)2), 38.06 (SCH3), 55.72 (OCH3), 63.25 (C-6), 68.11 (C-
5), 69.16, 69.81 (2CH2), 73.66 (C-4), 76.17 (C-3), 79.42 (C-2), 98.32 (C-1), 109.59
(C(CH3)2), 128.04, 128.10, 130.12, 133.76, 133.86, 136.01, 136.04 (12C, 2C6H5).
Anal. calcd for C29H42O9SSi + 0.5 H2O: C 57.69, H 7.18; Found: C 57.60, H 6.93.
Methyl 2-O-(2-azidoethyl)-6-O-[(1,1-dimethylethyl)diphenylsilyl]-3,4-O-
isopropylidene-α-D-galactopyranoside (57), (CRDM010).
Compound 56  (613 mg, 1.03 mmol) was dissolved under argon in dry DMF (40 mL).
Sodium azide (336 mg, 5.16 mmol) was added and the reaction was vigorously
stirred under argon at r.t. overnight. Then it was heated to 50°C for 6 h. The reaction
mixture was diluted at 0°C with EtOAc and washed with ice cold water (2 x 40 mL)
followed by extraction of the aqueous layer with EtOAc (3 x 40 mL). The combined
organic phases were dried with Na2SO4, filtered, concentrated and the resulting
syrup was purified by silica gel chromatography (PE/EA 8:1, +0.5% Et3N) to afford 57
(558 mg, quantitative) as a white foam.   
€ 
[α]
D
21 +50.8 (c = 0.41, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.06 (s, 9H, C(CH3)3), 1.34, 1.51 (2s, 6H, C(CH3)2), 3.29-3.33
(m, 1H, H-2’a), 3.38 (s, 3H, OCH3), 3.47-3.53 (m, 2H, H-2, H-2’b), 3.76 (m, 1H, H-
1’a), 3.87  (dd, J5,6 = 6.5 Hz, J6a,6b = 9.9 Hz, 1H, H-6a), 3.96 (m, 2H, H-6b, H-1’b),
4.05 (td, J4,5 = 1.4 Hz, J5,6 = 6.5 Hz, 1H, H-5), 4.27 (m, 2H, H-3, H-4), 4.77 (d, J1,2 =
3.5 Hz, 1H, H-1), 7.36-7.44, 7.70 (m, 10H, 2C6H5); 
13C NMR (125 MHz, CDCl3): δ
21.77 (C(CH3)3), 28.90 (C(CH3)2), 29.33 (3C, C(CH3)3), 30.94 (C(CH3)2), 53.29 (C-2’),
58.03 (OCH3), 65.47 (C-6), 70.29 (C-5), 72.71 (C-1’), 75.86, 78.59 (C-3, C-4), 81.52
(C-2), 100.77 (C-1), 111.68 (C(CH3)2), 130.20, 130.26, 132.27, 135.97, 136.07,
138.19, 138.22 (12C, 2C6H5); IR (NaCl) ν 2103 s (-N=N
+-N-) (cm-1) ; Anal. calcd for
C28H39N3O6Si: C 62.08, H 7.26, N 7.76; Found: C 62.14, H 7.17, N 7.76.
Methyl 2-O-(2-azidoethyl)-α-D-galactopyranoside (58), (CRDM015).
Compound 57 (75.4 mg, 0.139 mmol) was stirred overnight at 50°C in 80% aqueous
AcOH (6 mL). After cooling to r.t., the solvent was coevaporated four times with
toluene. The crude material was dried at high vacuum and used without further
purification. It was dissolved in THF (3.7 mL) and 1 M tetrabutylammonium fluoride
solution in THF (0.28 mL, 0.28 mmol) was added. The mixture was stirred at r.t. for 2
h. The solvent was evaporated under reduced pressure. Purification by silica gel
chromatography (DCM/MeOH 20:1) gave 58 (40 mg, quantitative) as colourless oil.
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€ 
[α]
D
21 +116.0 (c = 0.45, CHCl3);
 1H NMR (500 MHz, CDCl3): δ 2.46 (s, 1H, OH-6), 2.97
(s, 1H, OH-3), 3.04 (s, 1H, OH-4), 3.40-3.44 (m, 4H, H-2’a, OCH3), 3.51-3.56 (m, 1H,
H-2’b) 3.71-3.77  (m, 2H, H-2, H-1’a), 3.82-3.93 (m, 3H, H-5, H-6a, H-1’b), 3.96-4.01
(m, 2H, H-3, H-6b), 4.13 (d, J3,4 = 2.8 Hz, 1H, H-4), 4.95 (d, J1,2 = 3.5 Hz, 1H, H-1);
13C NMR (125 MHz, CDCl3): δ 51.02 (C-2’), 55.47 (OCH3), 63.26 (C-6), 69.07, 69.11
(C-3, C-5), 69.79 (C-1’), 70.61 (C-4), 77.98 (C-2), 97.72 (C-1); MS (ESI): Calcd for
C9H17N3NaO6 [M+Na]
+: 286.10; Found m/z: 286.04; IR (NaCl) ν 2100 s (-N=N+-N-)
(cm-1).
General procedure for the synthesis of 1,4-disubstituted-[1,2,3]-triazoles from
57.
57 (0.154 mmol) was dissolved in H2O/t-BuOH (1:1) (1.0 mL) with vigorous stirring.
The corresponding alkyne was added (1.0 eq), followed by sodium ascorbate (0.10
eq) as a freshly prepared solution (30 mg/mL in H2O/t-BuOH 1:1) and CuSO4⋅5H2O
(0.01 eq) also as a freshly prepared solution (30 mg/mL in H2O). All reactions were
carried out at r.t. and followed by TLC. Regular additions of freshly prepared
solutions of sodium ascorbate and copper sulfate were done every 6 to 8 h. When no
further changes were detected by TLC, alkyne (0.5 eq each time) was also added.
This process was repeated according to TLC results until completion was achieved
or no further changes were detected. The total amounts required for each alkyne are
given in the individual descriptions of the compounds synthesized.  Ice-cold water
was added to the reaction mixture and the aqueous phase was extracted with EtOAc
(3 x 3 mL). The organic phase was dried with Na2SO4, filtered and concentrated. The
product was purified by silica gel chromatography (PE/EA 2:1 gradient to 1:4, +1%
Et3N).
Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-O-{2-[4-(1-hydroxy-1-methyl-
ethyl)-[1,2,3]-triazol-1-yl]-ethyl}-3,4-O-isopropylidene-α-D-galactopyranoside
(62), (CRDM020).
According to the general procedure, 57 (40 mg, 0.074 mmol) was reacted with 2-
methyl-3-butin-2-ol (21.6 µL, 0.148 mmol) for 3 d to obtain 62 (37 mg, 81%) as white
solid.   
€ 
[α]
D
21 +53.9 (c = 0.97, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.05 (s, 9H,
C(CH3)3), 1.32, 1.46 (2s, 6H, C(CH3)2), 1.63, 1.64 (s, 6H, C[(CH3)2OH]), 3.34 (s, 3H,
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OCH3), 3.40 (dd, J1,2 = 3.5 Hz, J2,3 = 7.8 Hz, 1H, H-2), 3.85 (dd, J5,6 = 6.5 Hz, J6a,6b =
10.0 Hz, 1H, H-6a), 3.93 (dd, J5,6 = 6.8 Hz, J6a,6b = 10.0 Hz, 1H, H-6b), 3.99-4.02 (m,
3H, H-5, H-2’), 4.22 (dd, J2,3 = 7.7 Hz, J3,4 = 5.5 Hz, 1H, H-3), 4.27 (dd, J3,4 = 5.5 Hz,
J4,5 = 2.3 Hz, 1H, H-4), 4.54-4.56 (m, 2H, H-1’), 4.67 (d, J1,2 = 3.5 Hz, 1H, H-1), 7.35-
7.44, 7.68-7.72 (m, 11H, 2C6H5, C2HN3); 
13C NMR (125 MHz, CDCl3): δ 19.19
(C(CH3)3), 26.29 (C(CH3)2), 26.76 (3C, C(CH3)3), 28.39 (C(CH3)2), 30.37, 30.43
(C[(CH3)2OH ]),50.17 (C-2’), 55.41 (OCH3), 62.80 (C-6), 67.71 (C-5), 68.39
(C[(CH3)2OH]),69.39 (C-1’), 73.23 (C-4), 75.44 (C-3), 79.13 (C-2), 97.66 (C-1),
109.23 (C(CH3)2), 120.56, 127.64, 127.69, 129.72, 133.33, 133.43, 135.60, 155.36
(14C, 2C6H5, C2HN3); Anal. calcd for C33H47N3O7Si + 0.5 H2O: C 62.44, H 7.62;
Found: C 62.55, H 7.77.
Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-O-{2-[4-(thiophen-3-yl)-[1,2,3]-
triazol-1-yl]-ethyl}-3,4-O-isopropylidene-α-D-galactopyranoside (63), (CR VI 5).
According to the general procedure, 57 (77.0 mg, 0.142 mmol) was reacted with 3-
ethynyl thiophene (14.5 µL, 0.142 mmol) for 18 h to obtain 63 (89 mg, 97%) as white
solid.   
€ 
[α]
D
21 +55.0 (c = 0.66, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.05 (s, 9H,
C(CH3)3), 1.32, 1.42 (2s, 6H, C(CH3)2), 3.32 (s, 3H, OCH3), 3.43 (m, 1H, H-2), 3.85
(m, 1H, H-6a), 3.93 (m, 1H, H-6b), 4.02 (m, 3H, H-5, H-2’), 4.25 (m, 2H, H-3, H-4),
4.60 (m, 2H, H-1’), 4.67 (d, J1,2 = 3.2 Hz, 1H, H-1), 7.36-7.44, 7.69 (m, 13H, 2C6H5,
C4H3S), 8.01 (s, 1H, C2HN3); 
13C NMR (125 MHz, CDCl3): δ 19.19 (C(CH3)3), 26.29
(C(CH3)2), 26.75 (3C, C(CH3)3), 28.30 (C(CH3)2), 50.29 (C-2’), 55.39 (OCH3), 62.81
(C-6), 67.73 (C-5), 69.31 (C-1’), 73.23, 75.34 (C-3, C-4), 79.21 (C-2), 97.50 (C-1),
109.26 (C(CH3)2), 114.51, 115.86, 120.76, 121.10, 125.84, 126.18, 127.63, 127.68,
129.71, 132.14, 133.33, 133.42, 135.59, 135.62, 143.83  (18C, 2C6H5, C4H3S,
C2HN3).
Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-O-{2-[4-(3-amino-phenyl)-[1,2,3]-
triazol-1-yl]-ethyl}-3,4-O-isopropylidene-α-D-galactopyranoside (64), (CR VI 4).
According to the general procedure, 57 (78.2 mg, 0.144 mmol) was reacted with 3-
ethynyl aniline (15.1 µL, 0.144 mmol) for 42 h to obtain 64 (94 mg, 98%) as white
solid.   
€ 
[α]
D
21 +84.3 (c = 0.26, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.05 (s, 9H,
C(CH3)3), 1.32, 1.42 (2s, 6H, C(CH3)2), 3.31 (s, 3H, OCH3), 3.42 (dd, J1,2 = 3.4 Hz,
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J2,3 = 7.5 Hz, 1H, H-2), (dd, J5,6a = 6.5 Hz, J6a,6b = 10.0 Hz, 1H, H-6a), 3.93 (dd, J5,6b =
6.8 Hz, J6a,6b = 9.9 Hz, 1H, H-6b), 4.02 (m, 3H, H-5, H-2’), 4.26 (m, 2H, H-3, H-4),
4.60 (m, 2H, H-1’), 4.67 (d, J1,2 = 3.4 Hz, 1H, H-1), 6.65, 7.14-7.20, 7.29, 7.35-7.44,
7.69 (m, 14H, 2C6H5, C6H4), 8.06 (s, 1H, C2HN3); 
13C NMR (125 MHz, CDCl3): δ
19.20 (C(CH3)3), 26.30 (C(CH3)2), 26.76 (3C, C(CH3)3), 28.32 (C(CH3)2), 50.31 (C-2’),
55.42 (OCH3), 62.83 (C-6), 67.73 (C-5), 69.32 (C-1’), 73.24, 75.36 (C-3, C-4), 79.22
(C-2), 97.52 (C-1), 109.27 (C(CH3)2), 112.19, 114.75, 116.04, 121.30, 127.64,
127.69, 129.67, 129.71, 131.82, 133.36, 133.45, 135.60, 135.63, 146.87, 147.72
(20C, 2C6H5, C5H4, C2HN3).
Methyl 6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-O-{2-[4-(pyridin-3-yl)-[1,2,3]-
triazol-1-yl]-ethyl}-3,4-O-isopropylidene-α-D-galactopyranoside (65), (CR VI 3).
According to the general procedure, 57 (83.6 mg, 0.154 mmol) was reacted with 3-
ethynyl pyridine (32.5 mg, 0.309 mmol) for 28 h to obtain 65 (85 mg, 83%) as white
solid.   
€ 
[α]
D
21 +58.6 (c = 0.49, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.05 (s, 9H,
C(CH3)3), 1.32, 1.41 (2s, 6H, C(CH3)2), 3.32 (s, 3H, OCH3), 3.43 (dd, J1,2 = 3.4 Hz,
J2,3 = 7.6 Hz, 1H, H-2), 3.85 (dd, J5,6a = 6.5 Hz, J6a,6b = 10.0 Hz, 1H, H-6a), 3.93 (dd,
J5,6b = 6.8 Hz, J6a,6b = 10.0 Hz, 1H, H-6b), 4.04 (m, 3H, H-5, H-2’), 4.27 (m, 2H, H-3,
H-4), 4.64 (m, 2H, H-1’), 4.69 (d, J1,2 = 3.4 Hz, 1H, H-1), 7.35-7.43, 7.67-7.70, 8.22-
8.24, 9.02 (m, 10H, C6H5, C6H4N, C2HN3); 
13C NMR (125 MHz, CDCl3): δ 19.19
(C(CH3)3), 26.29 (C(CH3)2), 26.75 (3C, C(CH3)3), 28.34 (C(CH3)2), 50.44 (C-2’), 55.40
(OCH3), 62.79 (C-6), 67.71 (C-5), 69.18 (C-1’), 73.24, 75.30 (C-3, C-4), 79.32 (C-2),
97.45 (C-1), 109.29 (C(CH3)2), 116.50 (CH-triazole), 121.71, 123.76, 127.07, 127.64,
127.69, 128.05, 129.72, 132.87, 133.32, 133.42, 135.59, 135.62, 144.54, 147.04,
149.08, (18C, 2C6H5, C5H4N, C2HN3).
Methyl 2-O-{2-[4-(thiophen-3-yl)-[1,2,3]-triazol-1-yl]-ethyl}-α-D-
galactopyranoside (68), (CR VI 7) and Methyl 6-O-acetyl-2-O-{2-[4-(thiophen-3-
yl)-[1,2,3]-triazol-1-yl]-ethyl}-α-D-galactopyranoside (69), (CR VI 7b).
63 (78.9 mg, 0.121 mmol), was stirred in 80% aqueous AcOH (5.2 mL) at 80°C. After
cooling to r.t., the solvent was coevaporated five times with toluene. The crude
material was dried at high vacuum and used without further purification. It was
dissolved in THF (3.2 mL) and 1 M tetrabutylammonium fluoride solution in THF
(0.24 mL, 0.24 mmol) was added. The mixture was stirred for 2 h. The solvent was
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evaporated under reduced pressure. Purification by silica gel chromatography
(DCM/MeOH 20:1 to 9:1), followed by P2 size exclusion chromatography (sephadex
G-15 with H2O as eluent) gave 68 (21mg, 47%) as white powder after a final
lyophilization from H2O/dioxane (1:1). The acetylated product 69 (27 mg, 53%) was
also obtained as secondary product. 68:   
€ 
[α]
D
21 +82.3 (c = 0.38, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 2.89 (m, 1H, OH-6), 3.34 (s, 3H, OCH3), 3.62 (s, 1H, OH-4),
3.65 (dd, J1,2 = 3.6 Hz, J2,3 = 9.8 Hz, 1H, H-2), 3.78 (t, J5,6a = J5,6b = 4.8 Hz,1H, H-5),
3.80-3.97 (m, 4H, H-3, H-6, OH-3), 4.00 (m, 1H, H-2’a), 4.09 (m, 2H, H-4, H-2’b),
4.52-4.62 (m, 2H, H-1’), 4.82 (d, J1,2 = 3.5 Hz, 1H, H-1), 7.36-7.42, 7.66 (m, 3H,
C4H3S), 7.90 (s, 1H, C2HN3); 
13C NMR (125 MHz, CDCl3): δ  50.35 (C-2’), 55.34
(OCH3), 62.95 (C-6), 68.88, 68.94, 69.02 (C-3, C-5, C-1’), 70.54 (C-4), 78.05 (C-2),
97.64 (C-1), 120.87, 121.33, 125.74, 126.47, 131.54, 143.98  (6C, C4H3S, C2HN3);
MS (ESI): Calcd for C15H22N3O6S [M+H]
+: 372.12; Found m/z: 372.17; Anal. calcd for
C15H21N3O6S + 0.25 H2O: C 47.93, H 5.72, N 11.17; Found: C 47.85, H 5.66, N
10.92. 69:   
€ 
[α]
D
21 +104.5 (c = 1.01, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 2.07 (s, 3H,
Ac), 3.34 (s, 3H, OCH3), 3.66 (dd, J1,2 = 3.3 Hz, J2,3 = 9.1 Hz, 1H, H-2), 3.91-4.01 (m,
4H, H-3, H-4, H-5, H-2’a), 3.80-3.97 (m, 4H, H-3, H-6, OH-3), 4.08 (m, 1H, H-2’b),
4.24 (dd, J5,6a = 7.3 Hz, J6a,6b= 11.5 Hz, 1H, H-6a), 4.35 (dd, J5,6b = 5.3 Hz, J6a,6b=
11.6 Hz, 1H, H-6b), 4.40-4.62 (m, 2H, H-1’), 4.80 (d, J1,2 = 3.3 Hz, 1H, H-1), 7.36,
7.42, 7.65 (m, 3H, C4H3S), 7.89 (s, 1H, C2HN3); 
13C NMR (125 MHz, CDCl3): δ  20.87
(CH3-Ac), 50.31 (C-2’), 55.29 (OCH3), 63.35 (C-6), 67.63, 68.70, 68.96, 69.15 (C-3,
C-4, C-5, C-1’), 78.00 (C-2), 97.49 (C-1), 120.82, 121.18, 125.77, 126.43, 131.64,
143.00 (C4H3S, C2HN3), 171.08 (CO); MS (ESI): Calcd for C17H24N3O7S [M+H]
+:
414.13; Found m/z: 414.22; IR (NaCl) ν (cm-1) 1739 s (CO); Anal. calcd for
C17H23N3O7S + 0.25 H2O: C 49.39, H 5.61, N 10.16; Found: C 49.32, H 5.60, N 9.76.
Methyl 2-O-{2-[4-(1-hydroxy-1-methyl-ethyl)-[1,2,3]-triazol-1-yl]-ethyl-}α-D-
galactopyranoside (66), (CR VI 1) and Methyl 2-O-[2-(4-isopropenyl-[1,2,3]-
triazol-1-yl)-ethyl]-α-D-galactopyranoside (67), (CR VI 2).
According to the procedure described for 68, 62 (33 mg, 0.053 mmol) was stirred for
3 h in aqueous AcOH 80% (2.7 mL) and then reacted with 1 M tetrabutylammonium
fluoride solution in THF (22.4 µL, 22.4 µmol) for 3 h. After work-up and purification,
66 (2.2 mg, 12%) was obtained as colorless oil, and 67 (4.4 mg, 39%) as by product
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of 66 due to elimination under acidic conditions. 66:   
€ 
[α]
D
21 +35.4 (c = 0.22, CHCl3);
1H NMR (500 MHz, CD3OD): δ 1.59 (s, 6H, 2CH3), 3.36 (s, 3H, OCH3), 3.62 (dd, J1,2
= 3.7 Hz, J2,3 = 10.3 Hz, 1H, H-2), 3.67-3.74 (m, 2H, H-2, H-5, H-6), 3.80 (m, 1H, H-
3), 3.88 (d, J3,4 = 3.3 Hz, 1H, H-4), 4.03 (m, 2H, H-2’), 4.52-4.60 (m, 2H, H-1’), 4.80
(d, J1,2 = 3.7 Hz, 1H, H-1), 7.99 (s, 1H, C2HN3); 
13C NMR (125 MHz, CD3OD): δ 31.07
(2C, C[(CH3)2OH]),51.96 (C-2’), 55.91 (OCH3), 63.13 (C-6), 69.45 (C-1’), 70.49 (C-3),
71.97 (C-4), 72.55 (C-5), 79.19 (C-2), 99.64 (C-1), 119.36 (2C, C2HN3), 157.04
(C[(CH3)2OH]);MS (ESI): Calcd for C14H25N3NaO7 [ M+Na]
+: 370.16; Found m/z:
370.27; Anal. calcd for C14H25N3O7  + 0.25 H2O: C 47.79, H 7.30, N 11.94; Found: C
47.53, H 7.17 N 11.81. 67:   
€ 
[α]
D
21 +55.1 (c = 0.34, CHCl3); 
1H NMR (500 MHz, CDCl3):
δ 2.13 (s, 3H, CH3), 3.36 (s, 3H, OCH3), 3.66 (dd, J1,2 = 3.5 Hz, J2,3 = 9.7 Hz, 1H, H-
2), 3.79 (t, J5,6a = J5,6b = 4.9 Hz, 1H, H-5), 3.85-3.96 (m, 3H, H-3, H-6), 3.98-4.02 (m,
1H, H-2’a), 4.06-4.10 (m, 1H, H-2’b), 4.13 (d, 1H, J3,4 = 2.8 Hz, H-4), 4.50-4.61 (m,
2H, H-1’), 4.82 (d, J1,2 = 3.5 Hz, 1H, H-1), 5.10 (s, 1H, H-1”a), 5.68 (s, 1H, H-1”b),
7.74 (s, 1H, C2HN3); 
13C NMR (125 MHz, CDCl3): δ 20.62 (CCH3), 50.22 (C-2’), 55.32
(OCH3), 62.85 (C-6), 68.82, 69.07 (C3, C-5), 69.11 (C-1’), 70.41 (C-4), 78.19 (C-2),
97.72 (C-1), 112.61 (CH2CCH3), 120.94, 133.47 (C2HN3), 149.00 (CH2CCH3); MS
(ESI): Calcd for C14H23N3NaO6 [M+Na]
+: 352.15; Found m/z: 352.23.
Methyl 2-O-{2-[4-(3-amino-phenyl)-[1,2,3]-triazol-1-yl]-ethyl-}-α-D-
galactopyranoside (70), (CR VI 9).
According to the procedure described for 68, 64 (64 mg, 0.097 mmol) was stirred for
9 h in aqueous AcOH 80% (5 mL) and then reacted with 1 M tetrabutylammonium
fluoride solution in THF (0.20 mL, 0.20 mmol) overnight. After work-up and
purification, 70 (9 mg, 24%) was obtained as yellowish oil.   
€ 
[α]
D
21 +95.2 (c = 0.14,
MeOH); 1H NMR (500 MHz, CD3OD): δ 3.30 (s, 3H, OCH3), 3.63-3.73 (m, 4H, H-2,
H-5, H-6), 3.82 (dd, J2,3 = 10.0 Hz, J3,4 = 3.4 Hz, 1H, H-3), 3.88 (d, J3,4 = 3.3 Hz, 1H,
H-4), 4.03-4.10 (m, 2H, H-2’), 4.58-4.66 (m, 2H, H-1’), 4.77 (d, J1,2 = 3.6 Hz, 1H, H-1),
6.71, 7.11-7.19 (m, 4H, C6H4), 8.38 (s, 1H, C2HN3); 
13C NMR (125 MHz, CD3OD): δ
52.11 (C-2’), 55.88 (OCH3), 63.12 (C-6), 70.44 (C-1’), 70.92 (C-3), 71.55 (C-4), 72.53
(C-5), 79.14 (C-2), 99.50 (C-1), 113.76, 116.85, 116.90, 123.59, 131.07 (8C, C6H4,
C2HN3); Anal. calcd for C17H24N4O6 + 1.25 H2O: C 50.68, H 6.63, N 13.90; Found: C
50.63, H 6.34 N 13.90.
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Methyl 2-O-{2-[4-(pyridin-3-yl)-[1,2,3]-triazol-1-yl]-ethyl}-α-D-galactopyranoside
(71), (CR VI 8).
According to the procedure described for 68, 65 (78 mg, 0.12 mmol) was stirred
overnight in aqueous AcOH 80% (5.5 mL) and then reacted with 1 M
tetrabutylammonium fluoride solution in THF (0.24 mL, 0.24 mmol) for 2 h. After
work-up and purification, 71 (27 mg, 60%) was obtained as yellow solid.   
€ 
[α]
D
21 +177.4
(c = 0.12, CHCl3); 
1H NMR (500 MHz, CD3OD): δ 3.30 (s, 3H, OCH3), 3.63-3.74 (m,
4H, H-2, H-5, H-6), 3.83 (dd, J2,3 = 10.0 Hz, J3,4 = 3.0 Hz, 1H, H-3), 3.89 (d, J3,4 =
2.6 Hz, 1H, H-4), 4.05-4.12 (m, 2H, H-2’), 4.62-4.72 (m, 2H, H-1’), 4.80 (d, J1,2 =
3.5 Hz, 1H, H-1), 7.52, 8.28, 8.51, 8.64, 9.01 (m, 5H, C5H4N, C2HN3); 
13C NMR
(125 MHz, CD3OD): δ 52.56 (C-2’), 56.16 (OCH3), 63.45 (C-6), 70.54 (C-1’), 71.20
(C-3), 71.89 (C-4), 72.88 (C-5), 79.43 (C-2), 99.79 (C-1), 124.94, 126.37, 129.60,
135.60, 145.85, 147.95, 150.23  (C5H4N, C2HN3); MS (ESI): Calcd for C16H23N4O6
[M+H]+: 367.16; Found m/z: 367.09; Anal. calcd for C16H22N4O6 + 0.5 H2O: C 51.20,
H 6.18; Found: C 51.12, H 6.34.
General procedure for the synthesis of 1,4-disubstituted [1,2,3]-triazoles from
58.
Compound 58 (36.6 mg, 0.139 mmol) was dissolved in H2O/t-BuOH (1:1) (1.8 mL)
with vigorous stirring. The corresponding alkyne was added (1.0 eq), followed by
sodium ascorbate (0.10 eq) as freshly prepared solution (30 mg/mL in H2O/t-BuOH
1:1) and CuSO4⋅5H2O (0.01 eq) also as freshly prepared solution (20 mg/mL in H2O).
All reactions were carried out at r.t. and followed by TLC. Regular additions of freshly
prepared solutions of sodium ascorbate and copper sulfate were done every 6 to 8 h.
When no more changes were detected by TLC, alkyne (0.5 eq each time) was also
added. This process was repeated according to TLC results until completion was
achieved or no further changes were detected. The total amounts required for each
alkyne are given in the individual descriptions of the compounds synthesized. The
reaction mixture was concentrated under reduced pressure and the crude material
was purified by silica gel chromatography (DCM/MeOH 20:1 or 9:1), followed by P2
size exclusion chromatography (sephadex G-15 with H2O as eluent) or filtration
through Gelman Acrodiscs (0.2 µm).
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Methyl 2-O-{2-[4-(1-hydroxy-1-methyl-ethyl)-1,2,3-triazol-1-yl]-ethyl-}α-D-
galactopyranoside (66), (CR VI 1).
According to the general procedure, 58 (30.5 mg, 0.114 mmol) was reacted with 2-
methyl-3-butin-2-ol (16.5 µL, 0.171 mmol) for 48 h. After work-up and purification it
was lyophilized from H2O to obtain 66 (23 mg, 57%) as white solid. Analytical data
coincident  with data presented above for 66 in the synthesis of 1,4-disubstituted
1,2,3-triazoles from 57.
Methyl 2-O-[2-(4-methylaminomethyl-[1,2,3]-triazol-1-yl)-ethyl]-α-D-
galactopyranoside (72), (CRVI 10).
According to the general procedure, 58 (40.7 mg, 0.155 mmol) was reacted with N-
methyl propargylamine (13.5 µL, 0.155 mmol) for 42 h. After work-up it was purified
by RP chromatography (5% gradient MeOH in H2O) followed by P2 size exclusion
chromatography and a final lyophilization from H2O to obtain 72 (27 mg, 51%) as
pale green solid.   
€ 
[α]
D
21 +82.7 (c = 1.32, MeOH); 1H NMR (500 MHz, D2O): δ 2.72 (s,
3H, CH2NHCH3), 3.28 (s, 3H, OCH3), 3.57 (m, 1H, H-2), 3.69 (m, 2H, H-5, H-6a),
3.72-3.80 (m, 2H, H-3, H-6b), 3.91 (s, 1H, H-4), 4.10 (m, 2H, H-2’), 4.37 (s, 2H,
CH2NHCH3), 4.64 (m, 2H, H-1’), 4.86 (d, J1,2 = 2.6 Hz, 1H, H-1), 8.22 (s, 1H, C2HN3);
13C NMR (125 MHz, D2O): δ 32.33 (CH2NHCH3), 42.90 (CH2NHCH3), 50.96 (C-2’),
55.05 (OCH3), 61.49 (C-6), 68.99 (C-1’), 69.05, 69.52, 70.93 (C-3, C-4, C-5), 77.14
(C-2), 97.45 (C-1), 127.21, 138.24 (C2HN3); MS (ESI): Calcd for C13H25N4O6  [M+H]
+:
333.18; Found m/z: 333.09.
Methyl 2-O-{2-[4-(4-tolyl)-[1,2,3]-triazol-1-yl]-ethyl}-α-D-galactopyranoside (73),
(CR VI 12).
According to the general procedure, 58 (35.1 mg, 0.133 mmol) was reacted with 4-
ethynyltoluene (87.5 µL, 0.669 mmol) for 88 h. After work-up and purification 58 (13
mg, 37%) was recovered and 73 (18 mg, 57%) was obtained as white solid.   
€ 
[α]
D
21
+92.9 (c = 0.90, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 2.37 (s, 3H, CH3), 3.35 (s, 3H,
OCH3), 3.69 (m, 1H, H-2), 3.79 (m, 1H, H-5), 3.86 (m, 1H, H-6a), 3.95 (m, 2H, H-3,
H-6b), 4.03 (m, 1H, H-2’a), 4.12 (m, 2H, H-4, H-2’b), 4.23-4.65 (m, 2H, H-1’), 4.85 (d,
J1,2 = 3.4 Hz, 1H, H-1), 7.22, 7.70 (m, 4H, C6H4), 7.92 (s, 1H, C2HN3); 
13C NMR
(125 MHz, CDCl3): δ 21.30 (CH3), 50.34 (C-2’), 55.38 (OCH3), 63.25 (C-6), 68.79,
68.93 (C-3, C-5), 69.02 (C-1’), 70.76 (C-4), 78.13 (C-2), 97.64 (C-1), 125.63, 127.60,
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129.58, 138.18 (8C, C6H4, C2HN3); MS (ESI): Calcd for C18H26N3O6  [M+H]
+: 380.18;
Found m/z: 380.29; Anal. calcd for C18H25N3O6 : C 56.99, H 6.64; Found: C 57.20, H
6.72.
Methyl 2-O-{2-[4-(3-chloro-phenyl)-[1,2,3]-triazol-1-yl]-ethyl}-α-D-
galactopyranoside (74), (CR VI 11).
According to the general procedure, 58 (36.0 mg, 0.137 mmol) was reacted with 3-
chloro-1-ethynyl benzene (87.5 µL, 0.689 mmol) for 89 h. After work-up and
purification it was lyophilizated from dioxane to obtain 74 (38 mg, 74%) as white
powder.   
€ 
[α]
D
21 +95.6 (c = 0.32, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 3.39 (s, 3H,
OCH3), 3.70 (dd, J1,2 = 3.2 Hz, J2,3 = 9.9 Hz, 1H, H-2), 3.79 (m, 1H, H-5), 3.86 (dd,
J5,6a = 4.0 Hz, J6a,6b = 11.8 Hz, 1H, H-6a), 3.92-3.98 (m, 2H, H-3, H-6b), 4.03 (m, 1H,
H-2’a), 4.11 (m, 2H, H-4, H-2’b), 4.56-4.65 (m, 2H, H-1’), 4.89 (d, J1,2 = 3.1 Hz, 1H, H-
1), 7.32, 7.69, 7.80 (m, 4H, C6H4), 8.03 (s, 1H, C2HN3); 
13C NMR (125 MHz, CDCl3):
δ 50.47 (C-2’), 55.36 (OCH3), 63.20 (C-6), 68.88, 68.94, 69.05 (C-3, C-5, C-1’), 70.76
(C-4), 78.06 (C-2), 97.61 (C-1), 121.45, 123.75, 125.74, 128.24, 130.22, 132.20,
134.85 (8C, C6H4, C2HN3); MS (ESI): Calcd for C17H23ClN3O6  [M+H]
+: 400.13;
Found m/z: 400.21; Anal. calcd for C17H22ClN3O6 : C 51.07, H 5.55, N 10.51; Found:
C 51.15, H 5.61, N 9.95.
Methyl 2-O-{2-[4-(benzotriazol-1-ylmethyl)-[1,2,3]-triazol-1-yl]-ethyl}-α-D-
galactopyranoside (75), (CRVI 6).
According to the general procedure, 58 (36.6 mg, 0.139 mmol) was reacted with 1-
propargyl-1H-benzotriazole (22.5 mg, 0.139 mmol) for 21 h. After work-up and
purification it was lyophilized from H2O/dioxane (1:1) to obtain 75 (51 mg, 87%) as
white solid.   
€ 
[α]
D
21 +45.9 (c = 0.59, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 3.28 (s, 3H,
OCH3), 3.58 (dd, J1,2 = 3.6 Hz, J2,3 = 9.8 Hz, 1H, H-2), 3.74 (t, J5,6a = J5,6b = 4.8 Hz,
1H, H-5), 3.82-3.90 (m, 4H, H-3, H-6, H-2’a), 3.96 (m, 1H, H-2’b), 4.07 (d, J3,4 =
2.2 Hz, 1H, H-4), 4.46 (m, 1H, H-1’a), 4.54 (m, 1H, H-1’b), 4.74 (d, J1,2 = 3.6 Hz, 1H,
H-1), 7.35-7.48, 7.33, 7.93, 7.97 (m, 5H, C6H4N3, C2HN3); 
13C NMR (125 MHz,
CDCl3): δ 43.63 (CCH2N), 50.51 (C-2’), 55.24 (OCH3), 62.78 (C-6), 68.71, 68.91,
69.05 (C-3, C-5, C-1’), 70.59 (C-4), 77.80 (C-2), 97.59 (C-1), 110.13, 119.73, 124.42,
124.62, 127.89, 132.76, 141.81 (8C, C6H4N3, C2HN3); MS (ESI): Calcd for
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C18H24N6NaO6  [M+Na]
+: 443.17; Found m/z: 443.15; Anal. calcd for C18H24N6O6 +
0.25 H2O: C 50.88, H 5.75; Found: C 51.06, H 5.85.
Synthesis of scaffold 93 for solid phase synthesis
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-phthalimido-D-glucose (77), (CR III 2), (α:β 1:2).
To a stirred mixture of D-glucosamine hydrochloride (100 g, 464 mmol), water (1.2 L)
and sodium bicarbonate (78.0 g, 929 mmol) was added a solution of phthalic
anhydride (68.0 g, 459 mmol) in dioxane (900 mL). After 4 days the reaction was
acidified to pH 4-5 with 2 N HCl (90 mL). The solvents were evaporated under
reduced pressure.
The crude material (75.7 g, 168 mmol) was suspended in acetic anhydride (600 mL)
and sodium acetate (55.0 g, 670 mmol) was added. The mixture was refluxed at
140°C for 20 min. After cooling to r.t., the reaction was diluted with water (600 mL)
and neutralized with NaHCO3, followed by extraction with DCM (4 x 1 L). The
combined organic phases were dried with Na2SO4, filtered and concentrated under
reduced pressure. Purification of the residue by MPLC (PE/EA 3:2) gave 77 (55.4 g,
57%) as white foam.   
€ 
[α]
D
21 +71.4 (c = 0.98, CHCl3); 
1H NMR (500 MHz, CDCl3): δ
1.58, 1.87, 2.00, 2.04, 2.05, 2.06, 2.09, 2.13 (8s, 12H of 77α, 4Ac; 12H of 77β, 4Ac),
4.03 (m, 1H of 77β, H-5), 4.13 (m, 2H of 77α, H-5, H-6a; 1H of 77β, H-6a), 4.37 (m,
1H of 77α, H-6b; 1H of 77β, H-6b), 4.47 (dd, J1,2  = 8.9 Hz, J2,3  = 10.6 Hz, 1H of 77β,
H-2),  4.72 (dd, J1,2  = 3.3 Hz, J2,3  = 11.6 Hz, 1H of 77α, H-2), 5.15-5.24 (m, 1H of
77α, H-4; 1H of 77β, H-4), 5.89 (m, 1H of 77β, H-3), 6.29 (d, J1,2  = 3.4 Hz, 1H of
77α, H-1) 6.51-6.59 (m, 1H of 77α, H-3; 1H of 77β , H-1), 7.75, 7.86 (m, 4H of
77α, C6H4; 4H of 77β, C6H4); 
13C NMR (125 MHz, CDCl3): δ 20.41, 20.62, 20.66,
20.75, 20.78, 21.00 (8C, 4Ac, α/β), 52.81 (C-2, α), 53.50 (C-2, β), 61.53 (C-6, α/β),
67.00 (C-3, α), 68.29 (C-4, β), 69.38 (C-4, α), 70.18 (C-5, α), 70.51 (C-3, β), 72.54
(C-5, β), 89.77 (C-1, β), 90.53 (C-1, α), 123.75, 123.82, 131.22, 134.49, 134.51 (12C,
C6H4, α/β), 167.38, 168.65, 169.33, 169.49, 169.55, 169.79, 170.03, 170.67 (12C,
CO, α/β); Missing signals are due to overlapping or low resolution.
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3,4,6-Tri-O-acetyl-1-bromo-2-deoxy-2-phthalimido-D-glucose (78), (CR III 4), (α:β
1:4).
Compound 77 (10.2 g, 21.4 mmol) was dissolved under argon in DCM (150 mL). At
0°C a solution of 33% HBr in AcOH (30 mL, 0.17 mol) was added dropwise during 30
min. The reaction was stirred at r.t. for 5 h with light exclusion. The reaction was
quenched at 0°C with ice-cold saturated aqueous NaHCO3. The mixture was
extracted with DCM (4 x 200 mL) and the combined organic phases were dried with
Na2SO4, filtered and concentrated under reduced pressure. 78 (10.8 g, quantitative)
was obtained as the α/β-mixture (1:4) and used in the next step without further
purification.   
€ 
[α]
D
21 +70.4 (c = 0.99, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.87, 1.90,
2.04. 2.07, 2.12, 2.14 (6s, 9H of 78α, 3Ac; 9H of 78β, 3Ac), 3.97 (m, 1H of 78β, H-5),
4.19 (m, 1H of 78α, H-5; 1H of 78β, H-6a), 4.34 (dd, J5,6b = 4.7 Hz, J6a,6b = 12.5 Hz,
1H of 78β, H-6b), 4.44 (dd, J5,6a = J5,6b = 3.4 Hz, J6a,6b = 14.7 Hz, 2H of 78α, H-6),
4.61-4.70 (m, 1H of 78α, H-2; 1H of 78β, H-2), 5.16 (t, J3,4 = 9.4 Hz, 1H of 78α, H-4),
5.27 (m, 1H of 78β, H-4), 5.77 (m, 1H of 78β, H-3), 6.41 (d, J1,2  = 9.6 Hz, 1H of 78β,
H-1), 6.57 (d, J1,2  = 3.7 Hz, 1H of 78α, H-1), 6.66 (m, 1H of 78α, H-3), 7.77, 7.88 (m,
8H of 78α, C6H4; 8H of 78β, C6H4); 
13C NMR (125 MHz, CDCl3): δ 20.39, 20.59,
20.70, 20.78 (6C, 3Ac, α/β), 56.27 (C-2, α), 58.14 (C-2, β), 61.71 (C-6, α/β), 67.60
(C-3, α), 68.13 (C-4, β), 68.86 (C-4, α), 70.61 (C-3, β), 72.45 (C-5, α), 76.89 (C-5, β),
77.29 (C-1, β), 87.19 (C-1, α), 123.91, 134.60 (12C, C6H4, α/β), 169.32, 169.98,
170.68 (10C, 5CO, α/β); Missing signals due to overlapping or low resolution.
Methyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (79), (CRIII
5).
A mixture of CaSO4 (8.2 g, 60 mmol) and Ag2CO3 (6.7 g, 24 mmol) in MeOH (250
mL) was stirred with light exclusion for 30 min. A solution of compound 78 (10.1 g, 20
mmol) in MeOH (40 mL) was added. The mixture was stirred at r.t. for 23 h and then
filtered over a pad of celite. The solution was concentrated under reduced pressure
and the residue was redissolved in DCM (100 mL). The solution was extracted with
2% aqueous NH4OH (2 x 50 mL) and water (50 mL). The organic layer was dried
with Na2SO4, filtered and concentrated under reduced pressure. Purification by silica
gel chromatography (PE/EA 2:1) afforded 79 (7.90 g, 87%).  
€ 
[α]
D
21 +44.9 (c = 0.99,
CHCl3); 
1H NMR (500 MHz, CD3OD): δ 1.86, 2.03, 2.12 (3s, 9H, 3Ac), 3.45 (s, 3H,
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OCH3), 3.87 (m, 1H, H-5), 4.30 (d, J5,6a = J6a,6b = 8.9 Hz, 1H, H-6a), 4.34 (m, 2H, H-2,
H-6b), 5.18 (t, J3,4 = J4,5 = 9.7 Hz, 1H, H-4), 5.30 (d, J1,2 = 8.4 Hz, 1H, H-1), 5.78 (t,
J2,3 = J3,4 = 10.1 Hz, 1H, H-3), 7.74, 7.85 ( m, 4H, C6H4); 
13C NMR (125 MHz,
CD3OD): δ 18.34, 18.53, 18.67 (3C, 3Ac), 52.39 (C-2), 54.97 (OCH3), 59.85 (C-6),
66.84 (C-3), 68.67 (C-4), 69.73 (C-5), 96.93 (C-1), 121.51, 132.17 (6C, C6H4),
167.38, 168.08 (5C, CO); MS (ESI): Calcd for C21H23NNaO10 [ M+Na]
+: 472.12;
Found m/z: 472.15.
Methyl 2-deoxy-2-phthalimido-β-D-glucopyranoside (80) (CRIII 6).
Compound 79 (8.87 g, 19.7 mmol) was suspended in MeOH (200 mL) and NaOMe
was added until pH 9. The reaction was stirred overnight at r.t. After neutralization
with amberlyste 15 ion-exchange resin, the reaction was filtered over a pad of celite
and the solvent was evaporated. 80 (7.10 g, quantitative) was obtained as yellowish
oil and used in the next step without further purification.   
€ 
[α]
D
21 +5.2 (c = 1.08, CHCl3);
1H NMR (500 MHz, CDCl3): δ 3.38 (s, 3H, OCH3), 3.44 (m, 1H, H-5), 3.68 (t, J3,4 = J4,5
= 9.2 Hz, 1H, H-4), 3.88 (m, 2H, H-6), 4.06 (m, 1H, H-2), 4.27 (t, J2,3 = J3,4 = 9.2 Hz,
1H, H-3), 5.12 (d, J1,2 = 8.4 Hz, 1H, H-1), 7.69, 7.80 (m, 4H, C6H4);
 13C NMR
(125 MHz, CDCl3): δ 56.78, 56.91 (C-2, OCH3), 61.39 (C-6), 71.02 (C-3), 71.39 (C-4),
75.74 (C-5), 99.36 (C-1), 123.45, 131.73, 134.05 (6C, C6H4), 168.62 (2C, CO); MS
(ESI): Calcd for C15H17NNaO7 [M+Na]
+: 346.09; Found m/z: 346.00.
Methyl 2-deoxy-2-phthalimido-3,6-di-O-pivaloyl-β-D-glucopyranoside (81), (CR
III 7).
A solution of 80 (3.42 g, 11.0 mmol) in pyridine (67 mL) was cooled to -38°C. A
catalytic amount of DMAP was added to the solution. Pivaloyl chloride (3.4 mL, 28
mmol) was added during 30 min with vigorous stirring under argon. After 17 h the
reaction was warmed to 0°C and stirred for additional 2 h. The solvent was
evaporated and the residue dissolved in DCM (60 mL). The solution was extracted
with 0.1 N HCl (2 x 20 mL) and saturated aqueous NaHCO3 (30 mL). The organic
phase was dried with Na2SO4, filtered and concentrated under reduced pressure.
Purification by silica gel chromatography (PE/EA 4:1, +1% EtOH) gave 81 (3.62 g,
67%).  
€ 
[α]
D
21 -7.2 (c = 1.06, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.00, 1.26 (2s, 18H,
2C(CH3)3), 3.05 (s,1H, OH-4), 3.43 (s, 3H, OCH3), 3.59 (t, J3,4 = J4,5 = 8.9 Hz, 1H, H-
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4), 3.75 (m, 1H, H-5), 4.23 (t, J1,2 = J2,3= 10.0 Hz, 1H, H-2), 4.45 (m, 2H, H-6), 5.20
(d, J1,2 = 9.4 Hz, 1H, H-1), 5.59 (t, J2,3 = J3,4 = 10.0 Hz, 1H, H-3), 7.73, 7.79 (m, 4H,
C6H4); 
13C NMR (125 MHz, CD3OD): δ 26.83, 27.02, 27.23 (6C, 2C(CH3)3), 38.77,
38.98 (2C(CH3)3), 54.25 (C-2), 56.82 (OCH3), 63.22 (C-6), 70.59 (C-4), 73.32 (C-3),
74.38 (C-5), 98.98 (C-1), 123.52, 131.47, 134.26 (6C, C6H4), 178.98, 179.26 (2CO);
MS (ESI): Calcd for C25H33NNaO9 [M+Na]
+: 514.21; Found m/z: 514.23.
Methyl 2-deoxy-2-phthalimido-4,6-di-O-pivaloyl-β-D-galactopyranoside (82),
(CRIII 8).
A solution of 81 (2.73 g, 5.56 mmol) in DCE/pyridine (2:1, 49 mL) was cooled to 0°C.
A catalytic amount of DMAP was added under argon, followed by dropwise addition
of trifluoromethan sulfonic anhydride (1.5 mL, 8.3 mmol) during 40 min. The reaction
was stirred for 17 h, then water (5.5 mL) was added. The mixture was warmed to
80°C and stirred under argon for additional 5 h. After cooling to r.t., the reaction was
diluted with DCM ( 40 mL) and extracted with 5% HCl (2 x 40 mL), saturated
aqueous KHCO3 (2 x 40 mL) and water (40 mL). The organic phase was dried with
Na2SO4, filtered and concentrated under reduced pressure. Purification by silica gel
chromatography (PE/EA 5:1 to 3:1, +1% EtOH) gave 82 (1.61 g, 59%) as yellowish
oil.   
€ 
[α]
D
21 -9.7 (c = 0.92, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.21, 1.32 (2s, 18H,
2C(CH3)3), 3.45 (s, 3H, OCH3), 4.07 (m, 1H, H-5), 4.16 (m, 1H, H-6a), 4.24 (m, 1H,
H-6b), 4.34 (m, 1H, H-2), 4.63 (m, 1H, H-3), 5.18 (d, J1,2 = 8.4 Hz, 1H, H-1), 5.34 (m,
1H, H-4), 7.73, 7.84 (m, 4H, C6H4); 
13C NMR (125 MHz, CD3OD): δ 27.49, 27.59 (6C,
2C(CH3)3), 39.15, 39.78 (2C(CH3)3), 54.34 (C-2), 57.23 (OCH3), 62.11 (C-6), 68.57
(C-3), 69.71 (C-4), 71.53 (C-5), 99.94 (C-1), 132.17, 134.49 (6C, C6H4), 178.33,
179.33 (2CO); MS (ESI): Calcd for C25H33NNaO9 [ M+Na]
+: 514.21; Found m/z:
514.27.
Methyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-galactopyranoside (83a),
(CRIII 10).
Galactoside 82 (1.88 g, 3.82 mmol) was dissolved in MeOH (78 mL). A solution of
NaOMe in MeOH (0.5 M, 6.8 mL) was added and the reaction was stirred overnight
at r.t. After neutralization with amberlyste 15 ion-exchange resin and filtration over a
pad of celite, the solvent was evaporated under reduced pressure. The residue (1.27
g, 3.72 mmol) was suspended in acetic anhydride (80 mL) and sodium acetate (1.22
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g, 14.9 mmol) was added. The mixture was refluxed at 140°C for 15 min. After
cooling to r.t., the reaction was diluted with water (40 mL), neutralized with solid
NaHCO3 and  extracted with DCM (4 x 40 mL). The combined organic phases were
dried with Na2SO4, filtered and concentrated under reduced pressure. Purification by
silica gel chromatography (PE/EA 2:1) gave 83a (1.67 g, quantitative).   
€ 
[α]
D
21 +0.37 (c
= 0.74, CHCl3); 
1H NMR (500 MHz, CD3OD): δ 1.85, 2.07, 2.20 (3s, 9H, 3Ac), 3.46 (s,
3H, OCH3), 4.09 (t, J5,6a = J5,6b = 6.6 Hz, 1H, H-5), 4.19 (dd, J5,6a = 6.8 Hz, J6a,6b =
11.2 Hz, 1H, H-6a), 4.25 (dd, J5,6b = 6.6 Hz, J6a,6b = 11.2 Hz, 1H, H-6b), 4.53 (m, 1H,
H-2), 5.24 (d, J1,2  = 8.5 Hz, 1H, H-1), 5.48 (m, 1H, H-4), 5.79 (m, 1H, H-3), 7.74, 7.80
(m, 4H, C6H4); 
13C NMR (125 MHz, CD3OD): δ 20.93, 21.09 (3C, 3Ac), 51.71 (OCH3),
57.42 (C-2), 61.81 (C-6), 67.16 (C-4), 68.48 (C-3), 71.17 (C-5), 99.78 (C-1), 131.90,
134.68 (6C, C6H4), 170.26, 170.86 (5C, CO); MS (ESI): Calcd for C21H23NNaO10
[M+Na]+: 472.12; Found m/z: 472.13.
Methyl 2-deoxy-2-phthalimido-β-D-galactopyranoside (83), (CRIII 11).
83a (5.81 g, 12.9 mmol) was suspended in MeOH (230 mL) and NaOMe was added
until pH 9. The reaction was stirred overnight at r.t. After neutralization with
amberlyste 15 ion exchange resin, the reaction was filtered over celite and the
solvent was evaporated. 83 (4.34 g, quantitative) was obtained as white foam and
used in the next step without further purification.   
€ 
[α]
D
21 +1.6 (c = 0.99, MeOH); 1H
NMR (500 MHz, CD3OD): δ 3.38 (s, 3H, OCH3), 3.61 (m, 1H, H-5), 3.74-3.81 (m, 2H,
H-6), 3.92 (m, 1H, H-4), 4.31 (m, 1H, H-2), 4.38 (m, 1H, H-3), 5.00 (d, J1,2 = 8.3 Hz,
1H, H-1), 7.77-7.82 (m, 4H, C6H4); 
13C NMR (125 MHz, CD3OD): δ 55.42 (C-2), 56.93
(OCH3), 62.51 (C-6), 69.55 (C-3), 70.01 (C-4), 77.06 (C-5), 101.17 (C-1), 123.98,
124.26, 133.09, 135.45 (6C, C6H4), 169.80, 170.16 (2CO); MS (ESI): Calcd for
C15H17NNaO7 [M+Na]
+: 346.09; Found m/z: 346.02.
Methyl 2-deoxy-2-phthalimido-6-O-(toluene-4-sulfonyl)-β-D-galactopyranoside
(84), (CR III 33).
Compound 83 (40 mg, 0.12 mmol) was dissolved in DCM (0.3 mL). Dibutyltin oxide
(0.6 mg, 2.4 µmol) was added followed by tosyl chloride (24 mg, 0.12 mmol) and
Et3N (17 µL, 0.12 mmol). The reaction was stirred at r.t. for 4 h, then filtered and
concentrated in vacuo. Purification by silica gel chromatography (PE/EA 1:1,
DCM/MeOH 20:1) gave 84 (25.5 mg, 43%) as white solid, 84b (8 mg, 11%) (3,6-O-
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tosylated), and recovered 83 (11 mg, 28%). The product 84 was obtained in 60%
yield considering the starting material recovered. 84: 1H NMR (500 MHz, CD3OD): δ
2.46 (s, 3H, CH3-Ts), 2.79 (d, J3,OH = 8.8 Hz, 1H, OH-3), 2.85 (d, J4,OH = 5.2 Hz, 1H,
OH-4), 3.37 (s, 3H, OCH3), 3.91 (t, J5,6a = J5,6b = 6.2 Hz, 1H, H-5), 4.04 (m, 1H, H-4),
4.19-4.26 (m, 2H, H-2, H-6a), 4.32 (m, 1H, H-6b), 4.39 (m, 1H, H-3), 5.06 (d, J1,2 =
8.2 Hz, 1H, H-1), 7.37, 7.71, 7.82 (m, 8H, 2C6H4); 
13C NMR (125 MHz, CD3OD): δ
22.08 (CH3-Ts), 54.54 (C-2), 57.18 (OCH3), 68.11 (C-6), 68.51 (C-4), 68.75 (C-3),
72.44 (C-5), 99.82 (C-1), 123.87, 128.41, 130.44, 132.12, 132.83, 134.55, 145.70
(12C, 2C6H4), 168.99 (2CO).
Methyl 2-deoxy-3,4-O-isopropylidene-2-phthalimido-β-D-galactopyranoside (85),
(CR III 34).
Galactoside 88 (7.20 g, 12.0 mmol) was dissolved in THF (245 mL) and 1 M
tetrabutylammonium fluoride solution in THF (24 mL, 24 mmol) was added. The
mixture was stirred at r.t. for 3 h. The solvent was evaporated under reduced
pressure. Purification by silica gel chromatography (PE/EA 2:3, +0.5% Et3N) gave 85
(3.70 g, 85%) as a colorless oil.   
€ 
[α]
D
21 +33.6 (c = 1.24, CHCl3); 
1H NMR (500 MHz,
CDCl3): δ 1.32, 1.63 (2s, 6H, C(CH3)2), 3.43 (s, 3H, OCH3), 3.91 (m, 1H, H-6a), 4.06
(m, 2H, H-5, H-6b), 4.25 (m, 2H, H-2, H-4), 4.80 (m, 1H, H-3), 5.00 (d, J1,2  = 8.7 Hz,
1H, H-1), 7.71, 7.83 (m, 4H, C6H4); 
13C NMR (125 MHz, CDCl3): δ 26.75, 28.15
(C(CH3)2), 55.25 (C-2), 56.95 (OCH3), 60.64 (C-6), 73.70, 74.14, 74.51 (C-3, C-4, C-
5), 99.37 (C-1), 110.98 (C(CH3)2), 132.13, 134.31 (6C, C6H4); Missing signals are
due to low resolution. MS (ESI): Calcd for C18H21NNaO7 [M+Na]
+: 386.12; Found
m/z: 386.03; Anal. calcd for C18H21NO7 + 0.75 H2O: C 57.37; H 6.02; N 3.72; Found :
C 57.64; H 6.05; N 3.47.
Methyl 2-deoxy-4,6-O-isopropylidene-2-phthalimido-β-D-galactopyranoside (86),
(CRIII 29A).
Compound 83 (40 mg, 0.12 mmol) was dissolved under argon in dry CH3CN (2.6
mL). 2,2-Dimethoxypropane (23 µL, 3.8 mmol) was added with vigorous stirring
followed by a catalytic amount of camphor sulfonic acid in acetonitrile (100 µL, 10.2
mg/mL, 0.0440 mmol). After stirring at r.t. for 55 h the reaction was neutralized by
addition of Et3N (2 mL). The material was concentrated under reduced pressure. The
residue was purified by silica gel chromatography (PE/EA 1:1, +1% Et3N) to afford 86
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(43 mg, 96%) as colorless oil. 1H NMR (500 MHz, CD3OD): δ 1.49, 1.52 (2s, 6H,
C(CH3)2), 2.44 (m, 1H, OH-3), 3.44 (s, 3H, OCH3), 3.52 (m, 1H, H-5), 4.03 (m, 1H, H-
6a), 4.14 (m, 1H, H-6b), 4.23 (d, J3,4 = 1.8 Hz, 1H, H-4), 4.38 (m, 2H, H-2, H-3), 5.12
(m, 1H, H-1), 7.72, 7.83 (m, 4H, C6H4); 
13C NMR (125 MHz, CD3OD): δ 19.27, 29.62
(2C, C(CH3)2), 54.98 (C-2), 57.11 (OCH3), 63.00 (C-6), 67.04 (C-5), 68.15, 68.29 (C-
3, C-4), 99.46 (C-1), 99.76 (C(CH3)2), 123.49, 123.96, 132.39, 134.37, 168.83 (8C,
C6H4, 2CO).
Methyl 2-deoxy-6-O-[(1,1-dimethylethyl)diphenylsilyl]-2-phthalimido-β-D-
galactopyranoside (87), (CR III 31).
83 (4.9 g, 15 mmol) was dissolved in DCM (58 mL) under argon. To this solution
were added tert-butyl-diphenylchlorosilane (4.7 mL, 18.2 mmol), Et3N (2.6 mL, 18
mmol) and DMAP (74 mg, 0.61 mmol). The reaction was stirred for 12 h at r.t. and
then concentrated under reduced pressure. The residue was redissolved in DCM (50
mL) and washed with water (2 x 25 mL). The organic phase was dried with Na2SO4,
filtered and concentrated under reduced pressure. Purification by silica gel
chromatography (PE/EA 2:1 to 4:3) gave 87 (8.1 g, 96%).   
€ 
[α]
D
21 +7.9 (c = 0.74,
CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.08 (s, 9H, C(CH3)3), 2.68 (d, J3,OH = 9.6 Hz,
1H, OH-3), 3.14 (d, J4,OH = 4.9 Hz, 1H, OH-4), 3.42 (s, 3H, OCH3), 3.70 (m, 1H, H-5),
3.99 (m, 2H, H-6), 4.19 (m, 1H, H-4), 4.35 (m, 2H, H-2, H-3), 5.09 (d, J1,2 = 6.9 Hz,
1H, H-1), 7.39-7.48, 7.70-7.75, 7.82-7.84 (m, 14H, 2C6H5, C6H4); 
13C NMR
(125 MHz, CDCl3): δ  19.28 (C(CH3)3), 26.90 (3C, C(CH3)3), 54.80 (C-2), 56.62
(OCH3), 63.83 (C-6), 69.13 (C-3), 69.58 (C-4), 73.94 (C-5), 99.60 (C-1), 127.98,
128.02, 130.11, 132.02, 132.72, 132.94, 134.12, 135.69, 135.81 (18C, 2C6H5, C6H4);
Missing signals are due to overlapping or low resolution. MS (ESI): Calcd for
C31H35NNaO7Si [M+Na]
+: 584.21; Found m/z: 584.23; Anal. calcd for C31H35NO7Si +
H2O: C 64.23; H 6.43; N 2.42; Found : C 64.43; H 6.40; N 2.31.
Methyl 2-deoxy-6-O-[(1,1-dimethylethyl)diphenylsilyl]-3,4-O-isopropylidene-2-
phthalimido-β-D-galactopyranoside (88), (CR III 32).
Compound 87 (87 mg, 0.15 mmol) was dissolved under argon in dry CH3CN (3 mL).
2,2-Dimethoxypropane (28 µL, 0.23 mmol) was added with vigorous stirring followed
by a catalytic amount of p-toluene sulfonic acid monohydrate in acetonitrile (100 µL,
8.80 mg/mL, 4.60 µmol). After stirring for 16 h at r.t. the reaction was neutralized by
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addition of Et3N (1 mL). The solution was concentrated under reduced pressure. The
residue was purified by silica gel chromatography (PE/EA 4:1, +1% Et3N) to afford 88
(90 mg, 96%) as white foam.   
€ 
[α]
D
21 +13.5 (c = 0.71, CHCl3); 
1H NMR (500 MHz,
CDCl3): δ 1.07 (s, 9H, C(CH3)3), 1.33, 1.64 (2s, 6H, C(CH3)2), 3.39 (s, 3H, OCH3),
3.98-4.14 (m, 3H, H-5, H-6), 4.27 (m, 1H, H-2), 4.37 (m, 1H, H-4), 4.80 (m, 1H, H-3),
4.98 (d, J1,2  = 4.3 Hz, 1H, H-1), 7.38-7.45, 7.70-7.74, 7.83 (m, 14H, 2C6H5, C6H4);
13C NMR (125 MHz, CDCl3): δ  19.64 (C(CH3)3), 26.85 (C(CH3)2), 27.14 (3C,
C(CH3)3), 28.40 (C(CH3)2), 55.62 (C-2), 56.88 (OCH3), 63.09 (C-6), 73.54 (C-4),
73.99 (C-3), 74.51 (C-5), 99.49 (C-1), 110.71 (C(CH3)2), 128.07, 128.14, 130.14,
132.38, 133.72, 133.81, 134.40, 135.99, 136.04 (18C, 2C6H5, C6H4), 171.54 (2CO);
MS (ESI): Calcd for C34H39NNaO7Si [M+Na]
+: 624.24; Found m/z: 624.25; Anal.
calcd for C34H39NO7Si: C 67.86; H 6.53; N 2.33; Found : C 67.73; H 6.54; N 2.32.
Methyl 2-deoxy-3,4-O-isopropylidene-6-O-methanesulfonyl-2-phthalimido-β-D-
galactopyranoside (89), (CR III 35).
Compound 85 (3.38 g, 9.29 mmol) was dissolved in pyridine (90 mL). Mesyl chloride
(1.45 mL, 18.6 mmol) was added dropwise at 0°C. After 15 min the reaction was
warmed to r.t. and stirring continued for 2.5 h. The reaction was diluted with EtOAc
(50 mL) and extracted with 1 N HCl (2 x 50 mL), saturated aqueous NaHCO3 solution
(2 x 50 mL) and brine (40 mL). The organic layer was dried with Na2SO4, filtered and
concentrated. Silica gel chromatography (PE/EA 1:1, +1% Et3N) of the residue gave
89 (3.90 g, 95%) as white solid.   
€ 
[α]
D
21 +25.0 (c = 1.24, CHCl3); 
1H NMR (500 MHz,
CDCl3): δ 1.32, 1.63 (2s, 6H, C(CH3)2), 3.09 (s, 3H, SCH3), 3.42 (s, 3H, OCH3), 4.22-
4.30 (m, 3H, H-2, H-4, H-5), 4.82 (m, 1H, H-3), 5.00 (d, J1,2 = 8.7 Hz, 1H, H-1), 7.72,
7.84 (m, 4H, C6H4); 
13C NMR (125 MHz, CDCl3): δ 26.89, 28.25 (C(CH3)2), 37.82
(SCH3), 55.11 (C-2), 57.26 (OCH3), 69.20 (C-6), 71.46 (C-5), 73.29 (C-4), 74.47 (C-
3), 99.44 (C-1), 111.35 (C(CH3)2), 132.23, 134.53 (6C, C6H4); Missing signals are
due to low resolution. MS (ESI): Calcd for C19H23NNaO9S [M+Na]
+: 464.10; Found
m/z: 464.11;
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Methyl 6-azido-2-deoxy-3,4-O-isopropylidene-2-phthalimido-β-D-
galactopyranoside (90), (CR III 36).
89 (1.21 g, 2.74 mmol) was dissolved under argon in dry DMF (130 mL). Sodium
azide (890 mg, 13.7 mmol) was added followed by 15-crown-5 (217 µL, 1.10 mmol).
The reaction was vigorously stirred under argon at 100°C for 5 d. The reaction
mixture was then diluted at 0°C with EtOAc (70 mL) and washed with ice-cold water
(2 x 70 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL). The
combined organic phases were dried with Na2SO4, filtered, concentrated and the
resulting syrup was purified by silica gel chromatography (PE/EA 8:1 to 3:1, +1%
Et3N) to afford 90 (1.02 g, 96%) as white solid.   
€ 
[α]
D
21 +14.9 (c = 0.71, CHCl3); 
1H NMR
(500 MHz, CDCl3): δ 1.32, 1.64 (2s, 6H, C(CH3)2), 3.39-3.44 (m, 4H, H-6a, OCH3),
4.12 (m, 1H, H-5), 4.17 (m, 1H, H-4), 4.27 (t, J1,2 = J2,3 = 8.9 Hz, 1H, H-2), 4.80 (m,
1H, H-3), 5.01 (d, J1,2 = 8.7 Hz, 1H, H-1), 7.72, 7.84 (m, 4H, C6H4); 
13C NMR (125
MHz, CDCl3): δ 26.87, 28.28 (C(CH3)2), 51.58 (C-6), 55.28 (C-2), 57.16 (OCH3),
73.39, 74.08, 74.48 (C-3, C-4, C-5), 99.47 (C-1), 111.23 (C(CH3)2), 132.31, 134.48
(6C, C6H4); Missing signals are due to low resolution. MS (ESI): Calcd for
C18H20N4NaO6 [M+Na]
+: 411.13; Found m/z: 411.11; IR (NaCl) ν 2100 s (-N=N+-N-),
1610 vs (CO) (cm-1); Anal. calcd for C18H20N4O6: C 55.67; H 5.19; N 14.43; Found : C
55.67; H 5.16; N 14.23.
Methyl 6-azido-2-deoxy-2-phthalimido-β-D-galactopyranoside (91), (CR III 37).
Compound 90  (1.24 g, 3.19 mmol) was stirred at 80°C in 80% aqueous AcOH (100
mL) for 2 h. After cooling to r.t., the solvents were coevaporated with toluene.
Purification by silica gel chromatography (DCM/MeOH 9:1) gave 91 (1.10 g,
quantitative) as white foam.   
€ 
[α]
D
21 -37.2 (c = 0.52, MeOH); 1H NMR (500 MHz, CDCl3):
δ 3.33 (dd, J5,6a = 3.5 Hz, J6a,6b = 12.5 Hz, 1H, H-6a), 3.45 (m, 4H, OCH3, OH-3), 3.62
(d, J4,OH = 5.4 Hz, OH-4), 3.75-3.83 (m, 2H, H-5, H-6b), 3.97 (m, 1H, H-4), 4.26 (m,
1H, H-2), 4.40 (m, 1H, H-3), 5.10 (d, J1,2 = 8.4 Hz, 1H, H-1), 7.70, 7.79 (m, 4H, C6H4);
13C NMR (125 MHz, CDCl3): δ 51.64 (C-6), 54.57 (C-2), 57.28 (OCH3), 69.06 (C-3),
69.81 (C-4), 74.85 (C-5), 99.89 (C-1), 123.87, 132.09, 134.55 (6C, C6H4) 169.15
(2CO); MS (ESI): Calcd for C15H16N4NaO6 [M+Na]
+: 371.10; Found m/z: 371.04; IR
(NaCl) ν 2097 s (-N=N+-N-),1705 vs (CO) (cm-1); Anal. calcd for C15H16N4O6: C 51.72;
H 4.63; N 16.09; Found : C 51.84; H 4.86; N 15.62.
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Methyl 3,4-O-[(1RS)-4-(Allyl carboxylate)-benzylidene]-6-azido-2-deoxy-2-
phthalimido-β-D-galactopyranoside (92a/b), (CR III 38a/b), (a:b 7:2).
A soxhlet extractor with activated powdered molecular sieves (3 Å), was conditioned
under argon at 105°C with dry CH3CN (100 mL) for 20 h. After cooling to r.t., dry 91
(417 mg, 1.20 mmol) dissolved in CH3CN (5 mL) and 2 (240 mg, 1.02 mmol)
dissolved in CH3CN (5 mL) were added. Toluene-4-sulfonic acid monohydrate (0.96
mL of a 10 mg/mL solution in CH3CN) was added to the mixture. The mixture was
refluxed at 105°C for 66 h. After cooling to r.t., the reaction was neutralized by
addition of Et3N (30 mL) (pH 7) and the mixture was concentrated under reduced
pressure. Purification by silica gel chromatography (PE/EA 8:1 to 4:1, +1% Et3N)
afforded 92a/b (339 mg, 64%) as isomeric mixture. 1H NMR (500 MHz, CDCl3): δ
3.39-3.49 (m, 4H of 92a, H-6a, OCH3; 4H of 92b, H-6a, OCH3), 3.83-3.88 (m, 1H of
92a, H-6b; 1H of 92b, H-6b), 4.10 (m, 1H of 92b, H-5), 4.17 (m, 1H of 92b, H-4), 4.21
(m, 1H of 92a, H-5), 4.28-4.33 (m, 2H of 92a, H-2, H-4), 4.36 (t, J1,2 = J2,3 = 8.8 Hz,
1H of 92b, H-2), 4.83 (m, 2H of 92a, CH2CHCH2O; 2H of 92b, CH2CHCH2O), 5.01-
5.13 (m, 2H of 92a, H-1, H-3; 2H of 92b, H-1, H-3), 5.29 (m, 1H of 92a, Ha of
CH2CHCH2O; 1H of 92b , Ha of CH 2CHCH2O), 5.41 (m, 1H of 92a , Hb of
CH2CHCH2O; 1H of 92b, Hb of CH2CHCH2O), 5.96 (s, 1H of 92a, CHO2), 6.05 (m,
1H of 92a, CH2CHCH2O; 1H of 92b, CH2CHCH2O), 6.35 (s, 1H of 92b, CHO2), 7.48,
7.68 (m, 2H of 92a, 2H of C6H4; 2H of 92b, 2H of C6H4), 7.74, 7.86 (m, 4H of 92a,
Phth; 4H of 92b, Phth), 8.05, 8.15 (m, 2H of 92a, 2H of C6H4; 2H of 92b, 2H of C6H4);
13C NMR (125 MHz, CDCl3): δ 51.46 (C-6, 92a), 51.80 (C-6, 92b), 52.53 (C-2, 92b),
55.97 (C-2, 92a), 57.18, 57.28 (OCH3, 92a/b), 66.05 (CH2CHCH2O, 92a/b), 73.18 (C-
5, 92a), 73.57 (C-5, 92b), 74.37 (C-4, 92a/b), 76.08, 76.51 (C-3, 92a/b), 99.37, 99.55
(C-1, 92a/b), 103.14 (CHO2, 92b), 105.01 (CHO2, 92a), 118.73 (CH2CHCH2O,
92a/b), 123.93, 126.6, 127.49, 130.20, 130.30, 131.70, 132.21, 132.50, 132.58,
134.58, 134.67, 141.32 (30C, CH2CHCH2O, 92a/b; C6H4, 92a/b; Phth, 92a/b),
166.27 (CO, 92a/b); Missing signals are due to overlapping or low resolution. MS
(ESI): Calcd for C26H24N4NaO8 [ M+Na]
+: 543.15; Found m/z: 543.19; IR (NaCl)
ν 2102 s (-N=N+-N-),1716 vs (CO) (cm-1); Anal. calcd for C26H24N4O8: C 60.00; H
4.65; N 10.76; Found : C 59.57; H 4.72; N 10.37.
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Methyl 6-azido-2-deoxy-2-phthalimido-3,4-O-[(1RS)-4-(triethylammonium
carboxylate)-benzylidene]-β-D-galactopyranoside (93a/b), (CR III 39a/b), (a:b
7:2).
Compound 92a/b (571 mg, 1.10 mmol) was dissolved in degassed THF. N-Methyl
morpholine (1.2 mL, 11 mmol) was added to the solution followed by Pd(PPh3)4 (127
mg, 0.110 mmol). The reaction was excluded from light and then pyrrolidine (0.92
mL, 11 mmol) was added at 0°C. The reaction was stirred for 30 min at 0°C and then
concentrated under reduced pressure. Silica gel chromatography (DCM/MeOH 20:1,
+1% Et3N) of the crude material 93a/b (634 mg, 86%) as white foam.   
€ 
[α]
D
21 +91.0 (c =
0.99, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 1.12 (m, 9H of 93a, CH3 of Et3NH
+; 9H of
93b, CH3 of Et3NH
+),2.79 (m, 6H of 93a, CH2 of Et3NH
+; 6H of 93b, CH2 of Et3NH
+),
3.38-3.44 (m, 4H of 93a, H-6a, OCH3; 4H of 93b, H-6a, OCH3), 3.83 (m, 1H of 93a,
H-6b; 1H of 93b, H-6b), 4.14 (m, 1H of 93b, H-5), 4.17 (m, 1H of 93a, H-5; 1H of
93b, H-4), 4.21 (dd, J3,4 = 5.8 Hz, J4,5 = 2.4 Hz, 1H of 93a, H-4), 4.35 (m, 1H of 93a,
H-2; 1H of 93b, H-2), 4.95-5.04 (m, 2H of 93a, H-1, H-3; 2H of 93b, H-1, H-3), 5.86
(s, 1H of 93a, CHO2), 6.30 (s, 1H of 93b, CHO2), 7.35, 7.55 (m, 2H of 93a, 2H of
C6H4; 2H of 93b, 2H of C6H4), 7.7.67, 7.80 (m, 4H of 93a, Phth; 4H of 93b, Phth),
8.01, 8.10 (m, 2H of 93a, 2H of C6H4; 2H of 93b, 2H of C6H4); 
13C NMR (125 MHz,
CDCl3): δ 10.30 ((CH3CH2)3NH
+, 93a/b), 45.80 ((CH3CH2)3NH
+, 93a/b), 51.45 (C-6,
93a), 51.87 (C-6, 93b), 52.55 (C-2, 93b), 56.05 (C-2, 93a), 57.09, 57.18 (OCH3,
93a/b), 73.35, 73.76 (C-5, 93a/b), 74.09, 74.18 (C-3, 93a/b), 75.89 (C-4, 93b), 76.35
(C-4, 93a), 99.35 (C-1, 93b), 99.35 (C-1- 93a), 103.82 (CHO2, 93b), 105.75 (CHO2,
93a), 123.85, 125.91, 126.97, 129.91, 130.00, 132.19, 134.45, 134.58, 137.94,
138.90, (28C, C6H4, 93a/b; Phth, 93a/b), 172.65 (CO, 93a/b); Missing signals are
due to overlapping or low resolution. MS (ESI): Calcd for C23H20N4NaO8 [M+Na]
+:
503.12; Found m/z: 503.21; IR (NaCl) ν 2103 s (-N=N+-N-), 1716 vs (CO) (cm-1).
Test compounds for solid phase synthesis
Methyl 3,4-O-isopropylidene-β-D-galactopyranoside  (12), (CR II 1).
Methyl β-D-galactopyranoside (400 mg, 2.06 mmol) was dissolved under argon in
DMF (7.5 mL). 2,2-Dimethoxypropane (380 µL, 3.10 mmol) was added with vigorous
stirring followed by a catalytic amount of p-toluene sulfonic acid monohydrate (17 mg,
0.090 mmol). After stirring at 80°C for 4 h the reaction was neutralized by addition of
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Et3N (3 mL). The solution was concentrated under reduced pressure. Purification by
silica gel chromatography (DCM/MeOH 20:1) afforded 12 (481 mg, quantitative).   
€ 
[α]
D
21
-16.0 (c = 0.80, MeOH); 1H NMR (500 MHz, CDCl3): δ 1.35, 1.52 (2s, 6H, C(CH3)2),
3.55 (m, 4H, H-2, OCH3), 3.86 (m, 2H, H-5, H-6a), 4.01 (m, 1H, H-6b), 4.11 (m, 2H,
H-1, H-3), 4.17 (d, J3,4 = 5.3 Hz, 1H, H-4); 
13C NMR (125 MHz, CDCl3): δ 26.73, 28.49
(C(CH3)2), 57.53 (OCH3), 62.89 (C-6), 73.83, 74.14, 74.41 (C-2, C-4, C-5), 79.25 (C-
3), 103.68 (C-1).
Methyl 2,6-di-O-benzyl-3,4-O-isopropylidene-β-D-galactopyranoside (94), (CR II
2).
NaH (509 mg of 55% NaH in oil, 11.6 mmol) was washed with hexane (3 x 10 mL)
under argon and dried in high vacuum. After suspending the NaH in dry DMF (5 mL),
benzyl bromide (1.2 mL, 10 mmol) was added dropwise over 30 min at 0°C. Then a
solution of 12 (929 mg, 3.96 mmol) in DMF (7 mL) was added dropwise at 0°C. The
reaction was warmed to r.t. and stirred for 4 h. The reaction was quenched by
addition of thiocarbamide (303 mg, 3.97 mmol), and stirred for 30 min. After dilution
with EtOAc (10 mL), the organic phase was washed with 1 M KH2PO4  (10 mL) and
brine (10 mL). The organic phase was dried with Na2SO4, filtered and concentrated
under reduced pressure. The residue was purified by silica gel chromatography
(PE/EA 5:1 to 4:1) to obtain 94 (1.03 g, 63%) which was immediately used in the
following step. Analytical data were in accordance with the literature.
Methyl 2,6-di-O-benzyl-β-D-galactopyranoside (95), (CR II 3).
94 (815 mg, 1.97 mmol), was stirred in 80% aqueous AcOH (20 mL) at 80°C for 3 h.
After cooling to r.t., the solvents were coevaporated five times with toluene.
Purification by silica gel chromatography (PE/EA 1:1) gave 95 (695 mg, 94%).
Analytical data were in accordance with the literature.
Methyl 3,4-O-[(1RS)-4-(Allyl carboxylate)-benzylidene]-2,6-di-O-benzyl-β-D-
galactopyranoside (96a/b), (CR II 4a/b), (a:b 1:1).
Compound 95 (323 mg, 0.863 mmol) was dissolved in DCM (3 mL) and a catalytic
amount of p-toluenesulfonic acid (12 mg, 0.063 mmol) was added. Compound 1 was
dissolved in DCM (3 mL) and added to the previous solution. Additional DCM (4mL)
was added. The reaction was stirred at r.t. for 24 h. The solvent was evaporated
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under reduced pressure and the residue purified by silica gel chromatography
(PE/EA 3:1) to obtain 96a/b (197 mg, 63%) as colorless oil. 1H NMR (500 MHz,
CDCl3): δ 3.37 (m, 1H of 96a, H-2; 1H of 96b, H-2), 3.56, 3.60 (2s, 3H of 96a, OCH3;
3H of 96b, OCH3), 3.84 (m, 1H of 96a, H-6a; 1H of 96b, H-6a), 3.90 (m, 1H of 96a,
H-6b; 1H of 96b, H-6b), 4.02 (m, 1H of 96a, H-5; 1H of 96b, H-5), 4.17-4.36 (m, 3H
of 96a, H-1, H-3, H-4; 3H of 96b, H-1, H-3, H-4), 4.57-4.75 (m, 4H of 96a, 2CH2 of
Bn; 4H of 96b , 2CH2 of Bn), 4.84 (m, 2H of 96a, CH2CHCH2O; 2H of 96b,
CH2CHCH2O), 5.31 (m, 1H of 96a , Ha of CH2CHCH2O; 1H of 96b , Ha of
CH2CHCH2O), 5.43 (m, 1H of 96a , Hb of CH2CHCH2O; 1H of 96b , Hb of
CH2CHCH2O), 5.93, 5.96 (2s, 1H of 96a, CHO2; 1H of 96b, CHO2), 6.02-6.09 (m, 1H
of 96a, CH2CHCH2O; 1H of 96b, CH2CHCH2O), 7.24-7.41 (m, 10H of 96a, 2C6H5;
10H of 96b, 2C6H5), 7.45, 8.01, 8.09, 8.10 (m, 4H of 96a, C6H4; 4H of 96b, C6H4);
13C NMR (125 MHz, CDCl3): δ 57.00, 57.04 (OCH3, 96a/b), 65.75 (CH2CHCH2O,
96a/b), 69.35 (C-6, 96a/b), 71.98,72.39 (C-5, 96a/b), 73.55, 73.82 (4CH2 of Bn,
96a/b), 76.37, 78.84 (C-3, 96a/b; C-4, 96a/b), 79.88, 80.14 (C-2, 96a/b), 103.82,
104.00 (4C, C-1, 96a/b; CHO2, 96a/b), 118.39 (CH2CHCH2O, 96a/b), 126.42,
126.77, 126.84, 126.91, 127.75, 127.84, 127.90, 127.94, 128.17, 128.34, 128.38,
128.57, 129.82, 129.88, 130.92, 132.31, 138.15, 142.35 (36C, 2C6H5, 96a/b; C6H4,
96a/b), 166.05 (CO, 96a/b).
Solid phase synthesis of methyl β-D-galactose-derivatives
General procedure for lantern loading
Lantern swelling: The lanterns were immersed for 30 min in DMF.
Lantern activation: The lanterns were treated with 20% Et3N in DMF (3 x 10 min).
Standard washing procedure: The lanterns were washed with DMF (3 x 10 min) and
DCM (3 x 10 min).
Loading: The coupling solution consisted of 93a/b [3.3 eq x 35 µmol x (no. of lanters
+ 0.5)] and HOBt [3.3 eq x 35 µmol x (no. of lanters + 0.5)] in DMF [0.5 mL x (no. of
lanters + 0.5)]. Of the coupling solution, 0.5 mL per well was pipetted in a 96-well
plate followed by DIC (17.7 µL, 3.3 eq x 35 µmol). After 2 min of pre-activation, the
lantern was added and the plate was left at r.t. in the shaker for 15 to 21 h. The
lanterns were then washed according to the above washing procedure.
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General procedure for cleavage of the phthalimide
The loaded lanterns were treated with hydrazine monohydrate (0.15 mL/lantern, 80
eq) in dry MeOH (2 mL/lantern) in a sealed tube (bombenrohr) under argon at 80°C
(3 x 4 h and 2 x overnight). The lanterns were then washed with MeOH (3x 10 min)
followed by the standard washing procedure.
General procedure for amino acid coupling
Two stock solutions were freshly prepared. Solution A consisted of the Fmoc
protected amino acid [4 eq x 35 µmol x (no. of lanterns + 1)] and HOBt [4 eq x 35
µmol x (no. of lanterns + 1)] in DMF [250 µL x (no. of lanterns +1)]. Solution B
consisted of HBTU [3.6 eq x 35 µmol x (no. of lanterns + 1)] in DMF [250 µL x (no. of
lanterns + 1)]. 250 µL of freshly prepared stock solution A, 250 µL of freshly prepared
stock solution B, and 48 µL of DIPEA  (8 eq x 35 µmol) were combined in a 96-well
plate. After 2 min of pre-activation the lantern was added. The coupling procedure
was repeated five times, each time fresh solutions A + B were used. The first
coupling was left on the shaker overnight, followed by three couplings of 4 h each.
Finally, the fifth coupling was run overnight. The lanterns were then washed
according to the standard washing procedure.
General procedure for the synthesis of 1,4-disubstituted 1,2,3-triazoles
Stock solutions of sodium ascorbate (113 mg/mL) and CuSO4⋅5H2O (28.5 mg/mL)
were freshly prepared. Per well (of a 96-well plate) a 2.4 M solution of the
corresponding alkyne (30 eq x 35 µmol) in H2O/t-BuOH (440 µL) was added,
followed by sodium ascorbate stock solution (20 µL) and CuSO4⋅5H2O stock solution
(10 µL). The lantern was added and the plate was left at r.t. on the shaker. Five
additions of freshly prepared stock solutions (equal amounts as the initial one) were
performed during one day every 3 h. The whole process was repeated on four
consecutive days. The last two additions performed at the last two days, included a
catalytic amount of CuCl. The lanterns were then washed with DMF (5 x 10 min) and
DCM (5 x 10 min).
General procedure for the cleavage of Fmoc The lanterns were treated with 20%
piperidine in DMF (3 x 10 min). The standard washing procedure was then applied.
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General procedure for the cleavage from the solid phase
Each lantern was treated with 80% aqueous AcOH containing 2% TFA (2 mL) (2 x 15
h). The solvents were evaporated under reduced pressure.
General procedure for purification
Products were purified by chromatography on RP-18 (5% gradient MeOH in H2O).
After concentration under reduced pressure and filtration, the samples were
lyophilized from H2O/dioxane (1:1).
Methyl 2-(amino-acetamido)-6-azido-2-deoxy-β-D-galactopyranoside (98), (CR III
57).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-glycine and cleaved from the solid phase after Fmoc
cleavage. During the evaporation of the solvents, partial decomposition occurred
(drastic color change of the solution) and after purification 98 (2 mg, 21%) was
obtained as pale green powder. 1H NMR (500 MHz, CD3OD): δ 3.24 (m, 1H, H-6a),
3.47 (s, 3H, OCH3), 3.62 (dd, J2,3 = 10.7 Hz, J3,4 = 3.2 Hz, 1H, H-3), 3.69 (m, 4H, H-5,
H-6b, CH2 of Gly), 3.77 (d, J3,4 = 3.1 Hz, 1H, H-4), 3.97 (m, 1H, H-2), 4.32 (d, J1,2 =
8.4 Hz, 1H, H-1); 13C NMR (125 MHz, CD3OD): δ 41.85 (CH2 of Gly), 53.07 (C-6),
54.17 (C-2), 57.14 (OCH3), 70.14 (C-4), 73.43 (C-3), 76.40 (C-5), 103.96 (C-1), MS
(ESI): Calcd for C9H17N5NaO5 [M+Na]
+: 298.11; Found m/z: 298.03; IR (NaCl) ν 2105
s (-N=N+-N-);1680 vs (CO) (cm-1). Melting point: 115°C (decomposition).
Methyl 2-[(S)-2-amino-3-methyl-butyrylamido]-6-azido-2-deoxy-β-D-
galactopyranoside (100), (CR III 54).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-valine and cleaved from solid phase after Fmoc
cleavage. Compound 100 (14 mg, 100% recovery, ≥98% purity) was obtained as the
acetate. After purification and a final lyophilization from dioxane/H2O (1:1) 100 (7 mg,
67%) was obtained as white powder.   
€ 
[α]
D
21 -4.9 (c = 0.52, MeOH); 1H NMR (500 MHz,
CD3OD): δ 1.09 (m, 6H, 2CH3 of Val), 2.20 (m, 1H, CH(CH3)2), 3.24 (m, 1H, H-6a),
3.48 (s, 3H, OCH3), 3.62-3.70 (m, 4H, H-3, H-5, H-6b, CHNH2), 3.75 (d, J3,4 = 3.2 Hz,
1H, H-4), 3.90 (m, 1H, H-2), 4.42 (d, J1,2 = 8.4 Hz, 1H, H-1); 
13C NMR (125 MHz,
CD3OD): δ 17.84, 19.02 (CH(CH3)2), 31.41 (CH(CH3)2), 52.47 (C-6), 54.08 (C-2),
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56.86 (OCH3), 59.49 (CHNH2), 69.61 (C-4), 72.63 (C-3), 75.80 (C-5), 102.94 (C-1);
MS (ESI): Calcd for C12H24N5O5 [M+H]
+: 318.18; Found m/z: 318.16; Melting point:
121°C-125°C.
Methyl 2-(amino-acetamido)-6-{4-butyl-[1,2,3]-triazol-1-yl}-2-deoxy-β-D-
galactopyranoside (102), (CR III 48).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-glycine, reacted with 1-hexine and cleaved from
solid phase after Fmoc cleavage. Each day one extra aliquot of 1-hexine was added
(30 eq, 135 µL) due to its fast evaporation. The acetate salt of 102 (15.1 mg, 100%
recovery) was obtained as the only product. After purification and a final lyophilization
from dioxane/H2O (1:1) 102 (7 mg, 56%) was obtained as white powder.   
€ 
[α]
D
21 +15.5
(c = 0.49, MeOH); 1H NMR (500 MHz, CD3OD): δ 0.93 (t, J3’,4’ = 7.3 Hz, 3H, CH3 of
CH2CH2CH2CH3), 1.31-1.40 (m, 2H, H-3’), 1.60-1.66 (m, 2H, H-2’), 2.69 (t, J1’,2’ =
7.3 Hz, 2H, H-1’), 3.28 (s, 3H, OCH3), 3.62-3.68 (m, 3H, H-3, CH2-Gly), 3.84 (d, J3,4 =
2.8 Hz, 1H, H-4), 3.92 (m, 1H, H-5), 3.99 (m, 1H, H-2), 4.19 (d, J1,2 = 8.4 Hz, 1H, H-
1), 4.65 (d, J5,6a = J5,6b = 6.4 Hz, 2H, H-6), 7.75 (s, 1H, C2HN3); 
13C NMR (125 MHz,
CD3OD): δ 14.08 (C-4’), 22.82 (C-3’), 25.53 (C-1’), 32.49 (C-2’), 41.07 (CH2 of Gly),
51.71 (C-6), 53.61 (C-2), 56.88 (OCH3), 69.01 (C-4), 72.83 (C-3), 74.87 (C-5), 102.95
(C-1), 124.31 (2C, C2HN3); MS (ESI): Calcd for C15H27N5NaO5 [M+Na]
+: 380.19;
Found m/z: 380.20.
Methyl 2-(amino-acetamido)-2-deoxy-6-{4-(napht-2-yl)-[1,2,3]-triazol-1-yl}-β-D-
galactopyranoside (103), (CR III 50).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-glycine, reacted with 1-ethynyl naphtalene and
cleaved from the solid phase after Fmoc-cleavage. Compound 103 (17 mg, 100%
recovery, ≥98% purity) was obtained as the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 103 (7 mg, 47%) was obtained as white
powder.   
€ 
[α]
D
21 +19.4 (c = 0.50, MeOH); 1H NMR (500 MHz, CD3OD): δ 3.33 (s, 3H,
OCH3), 3.71 (m, 3H, H-3, CH2 of Gly), 3.94 (d, J3,4 = 3.0 Hz, 1H, H-4), 4.03-4.10 (m,
2H, H-2, H-5), 4.28 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.84 (d, J5,6a = J5,6b = 6.5 Hz, 2H, H-6),
7.49-7.57, 7.68, 7.94, 8.22 (m, 8H, C2HN3, C10H7); 
13C NMR (125 MHz, CD3OD): δ
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41.08 (CH2 of Gly), 51.79 (C-6), 53.55 (C-2), 56.71 (OCH3), 69.87 (C-4), 72.85 (C-3),
74.78 (C-5), 103.21 (C-1), 125.99, 126.37, 127.14, 128.29, 129.31 (12C, C2HN3,
C10H7); MS (ESI): Calcd for C21H26N5O5 [M+H]
+: 428.19; Found m/z: 428.24; Melting
point: 142°C-146°C.
Methyl 2-[(S)-2-amino-propionamido]-6-{4-butyl-[1,2,3]-triazol-1-yl}-2-deoxy-β-
D-galactopyranoside (104), (CR III 47).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with 1-hexine and cleaved from the
solid phase after Fmoc-cleavage. Each day one extra aliquot of 1-hexine was added
(30 eq, 135 µL) due to its fast evaporation.  Compound 104 (12.4 mg, 82% recovery)
was obtained as the acetate salt. After purification and a final lyophilization from
dioxane/H2O (1:1) 104 (11.5 mg, 89%) was obtained as white powder.   
€ 
[α]
D
21 +28.3 (c
= 0.72, MeOH); 1H NMR (500 MHz, CD3OD): δ 0.93 (t, J3’,4’ = 7.3 Hz, 3H, H-4’), 1.33-
1.40 (m, 2H, H-3’), 1.53 (d, 3H, CH3 of Ala), 1.61-1.67 (m, 2H, H-2’), 2.70 (t, J1’,2’ =
7.6 Hz, 2H, H-1’), 3.28 (s, 3H, OCH3), 3.67 (m, 1H, H-3), 3.84 (d, J3,4 = 2.4 Hz, 1H, H-
4), 3.89-3.98 (m, 3H, H-2, H-5, CH of Ala), 4.22 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.65 (d,
J5,6a = J5,6b = 6.4 Hz, 2H, H-6), 7.76 (s,1H, C2HN3); 
13C NMR (125 MHz, CD3OD): δ
14.48 (C-4’), 18.17 (CH3 of Ala), 23.55 (C-3’), 26.28 (C-1’), 33.20 (C-2’), 50.91 (CH of
Ala), 52.44 (C-6), 54.42 (C-2), 57.20 (OCH3), 70.33 (C-4), 73.15 (C-3), 75.28 (C-5),
103.89 (C-1), 124.76 (2C, C2HN3), 172.09 (CO); MS (ESI): Calcd for C16H29N5NaO5
[M+Na]+: 394.21; Found m/z: 394.31; Melting point: 123°C-125°C.
Methyl 2-[(S)-2-amino-propionamido]-2-deoxy-6-{4-(napht-2-yl)-[1,2,3]-triazol-1-
yl}-β-D-galactopyranoside (105), (CR III 49).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with 1-ethynyl naphtalene and
cleaved from the solid phase after Fmoc-cleavage. Compound 105 (16.4 mg, 93%
recovery, ≥98% purity) was obtainedas the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 105 (9 mg, 58%) was obtained as white
powder.   
€ 
[α]
D
21 +22.9 (c = 0.44, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.53 (d, 3H,
CH3 of Ala), 3.33 (s, 3H, OCH3), 3.71 (dd, J2,3 = 10.9 Hz, J3,4 = 3.2 Hz, 1H, H-3), 3.91
(m, 2H, H-4, CH of Ala), 4.01 (m, 1H, H-2), 4.09 (t, J5,6a = J5,6b = 6.4 Hz, 1H,  H-5),
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4.30 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.84 (d, J5,6a = J5,6b = 6.5 Hz, 2H, H-6), 7.49-7.57,
7.68, 7.94  (m, 7H, C10H7), 8.33 (s, 1H, C2HN3); 
13C NMR (125 MHz, CD3OD): δ
18.03 (CH3 of Ala), 49.91 (CH of Ala), 52.09 (C-6), 53.72 (C-2), 56.79 (OCH3), 69.47
(C-4), 72.91 (C-3), 75.09 (C-5), 102.97 (C-1), 126.20, 127.33, 128.49, 129.35 (12C,
C2HN3, C10H7); MS (ESI): Calcd for C22H27N5NaO5 [M+Na]
+: 464.19; Found m/z:
464.26; Melting point: 145°C-148°C.
Methyl 2-[(S)-2-amino-propionamido]-6-{4-(3-chloro-phenyl)-[1,2,3]-triazol-1-yl}-
2-deoxy-β-D-galactopyranoside (106), (CR III 46).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with3-chloro-1-ethynyl benzene and
cleaved from the solid phase after Fmoc-cleavage. Compound 106 (13.6 mg, 80%
recovery, ≥98% purity) was obtained as the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 106 (8 mg, 53%) was obtained as white
powder.   
€ 
[α]
D
21 +14.5 (c = 0.40, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.52 (d, 3H,
CH3 of Ala), 3.28 (s, 3H, OCH3), 3.68 (dd, J2,3 = 10.7 Hz, J3,4 = 3.0 Hz, 1H, H-3), 3.89
(m, 2H, H-4, CH of Ala), 3.99 (m, 2H, H-2, H-5), 4.25 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.75
(d, J5,6a = J5,6b = 6.4 Hz, 2H, H-6), 7.35, 7.42, 7.72 (m, 4H, C6H4), 8.41 (s, 1H, C2HN3);
13C NMR (125 MHz, CD3OD): δ 18.16 (CH3 of Ala), 50.90 (CH of Ala), 52.71 (C-6),
54.41 (C-2), 57.19 (OCH3), 70.31 (C-4), 73.19 (C-3), 75.18 (C-5), 103.89 (C-1),
124.47, 125.27, 126.82, 129.62, 132.04, 134.16, 136.40, 147.61 (C2HN3, C6H4); MS
(ESI): Calcd for C18H25ClN5O5 [M+Na]
+: 426.15; Found m/z: 426.18; Melting point:
139°C-141°C.
Methyl 2-[(S)-2-amino-propionamido]-6-{4-(benzotriazol-1-ylmethyl)-[1,2,3]-
triazol-1-yl}-2-deoxy-β-D-galactopyranoside (107), (CR III 42).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with 1-propargyl-1H-benzotriazole
and cleaved from the solid phase after Fmoc-cleavage. Compound 107 (10.6 mg,
60% recovery, ≥98% purity) was obtained as the acetate salt. After purification and a
final lyophilization from dioxane/H2O (1:1) 107 (7 mg, 46%) was obtained as white
powder.   
€ 
[α]
D
21 +32.4 (c = 0.37, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.48 (d, 3H,
CH3 of Ala), 2.90 (s, 3H, OCH3), 3.59 (dd, J2,3 = 10.6 Hz, J3,4 = 2.6 Hz, 1H, H-3), 3.82-
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3.90 (m, 4H, H-2, H-4, H-5, CH of Ala), 4.04 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.67 (m, 2H,
H-6), 6.06 (d, JHa,Hb = 6.4 Hz, 2H, CCH2N), 7.43, 7.55, 7.85, 7.96 (m, 4H, C6H4N3),
8.07 (s, 1H, C2HN3); 
13C NMR (125 MHz, CD3OD): δ 18.00 (CH3 of Ala), 44.20
(CCH2N), 49.83 (CH of Ala), 52.32 (C-6), 53.96 (C-2), 56.65 (OCH3), 69.88 (C-4),
73.73 (C-3), 74.71 (C-5), 103.32 (C-1), 111.63, 119.97, 125.79, 126.49, 128.97,
134.07, 143.06, 146.83 (C2HN3, C6H4N3); MS (ESI): Calcd for C19H26N8NaO5
[M+Na]+: 469.19; Found m/z: 469.21; Melting point: 144°C-147°C.
Methyl 2-[(S)-2-amino-propionamido]-2-deoxy-6-{4-(thiophen-3-yl)-[1,2,3]-
triazol-1-yl}-β-D-galactopyranoside (108), (CR III 51).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with 3-ethynyl-thiophene and
cleaved from the solid phase after Fmoc-cleavage. Compound 108 (16.5 mg, 100%
recovery, ≥98% purity) was obtained as the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 108 (7.5 mg, 54%) was obtained as white
powder.   
€ 
[α]
D
21 +9.1 (c = 0.53, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.52 (d, 3H, CH3
of Ala), 3.28 (s, 3H, OCH3), 3.54 (dd, J2,3 = 10.7 Hz, J3,4 = 3.2 Hz, 1H, H-3), 3.90 (m,
2H, H-4, CH of Ala), 3.98 (m, 2H, H-2, H-5), 4.25 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.73 (d,
J5,6a = J5,6b = 6.5 Hz, 2H, H-6), 7.50, 7.75  (m, 3H, C4H3S), 8.25 (s, 1H, C2HN3);
13C NMR (125 MHz, CD3OD): δ 17.41 (CH3 of Ala), 49.72 (CH of Ala), 51.60 (C-6),
53.34 (C-2), 57.11 (OCH3), 69.09 (C-4), 72.67 (C-3), 74.81 (C-5), 102.89 (C-1),
121.30, 122.59, 126.46, 127.63 (6C, C2HN3, C4H3S); MS (ESI): Calcd for C16H24N5O5
[M+H]+: 398.15; Found m/z: 398.24; Melting point: 169°C (decomposition).
Methyl 2-[(S)-2-amino-propionamido]-2-deoxy-6-{4-(3-trifluoromethyl-phenyl)-
[1,2,3]-triazol-1-yl}-β-D-galactopyranoside (109), (CR III 52).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with 3-ethynyl-trifluorotoluene and
cleaved from the solid phase after Fmoc-cleavage. Compound 109 (16.9 mg, 93%
recovery, ≥98% purity) was obtained as the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 109 (8.5 mg, 53%) was obtained as white
powder.   
€ 
[α]
D
21 +15.2 (c = 0.50, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.52 (d, 3H,
CH3 of Ala), 3.28 (s, 3H, OCH3), 3.68 (dd, J2,3 = 10.8 Hz, J3,4 = 3.2 Hz, 1H, H-3), 3.90
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(m, 2H, H-4, CH of Ala), 3.97-4.03 (m, 2H, H-2, H-5), 4.25 (d, J1,2 = 8.4 Hz, 1H, H-1),
4.77 (d, J5,6a = J5,6b = 6.4 Hz, 2H, H-6), 7.65, 8.08, 8.15 (m, 4H, C6H4), 8.45 (s, 1H,
C2HN3); 
13C NMR (125 MHz, CD3OD): δ 17.71 (CH3 of Ala), 49.82 (CH of Ala), 51.88
(C-6), 53.54 (C-2), 56.84 (OCH3), 69.38 (C-4), 72.82 (C-3), 74.89 (C-5), 102.72 (C-
1), 122.55, 123.90, 125.65, 129.56, 130.23 (8C, C2HN3, C7H4F3); MS (ESI): Calcd for
C19H25F3N5O5 [M+Na]
+: 460.18; Found m/z: 460.21; Melting point: 128°C-131°C.
Methyl 2-[(S)-2-amino-propionamido]-2-deoxy-6-{4-(4-methyl phenyl)-[1,2,3]-
triazol-1-yl}-β-D-galactopyranoside (110), (CR III 55).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-alanine, reacted with 4-etynyl-toluene and cleaved
from the solid phase after Fmoc-cleavage. Compound 110 (14.6 mg, 100% recovery,
≥98% purity) was obtainedas the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 110 (9 mg, 63%) was obtained as white
powder.   
€ 
[α]
D
21 +13.0 (c = 0.42, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.52 (d, 3H,
CH3 of Ala), 2.36 (s, 3H, CH3), 3.28 (s, 3H, OCH3), 3.67 (m, 1H, H-3), 3.89 (m, 2H, H-
4, CH of Ala), 3.99 (m, 2H, H-2, H-5), 4.25 (d, J1,2 = 8.4 Hz, 1H, H-1), 4.74 (d, J5,6a =
J5,6b = 6.5 Hz, 2H, H-6), 7.25, 7.68 (m, 4H, C6H4), 8.28 (s, 1H, C2HN3); 
13C NMR
(125 MHz, CD3OD): δ 17.63 (CH3 of Ala), 21.16 (CH3), 50.20 (CH of Ala), 51.68 (C-
6), 53.69 (C-2), 56.78 (OCH3), 69.02 (C-4), 72.92 (C-3), 74.93 (C-5), 102.76 (C-1),
122.57, 126.59, 130.04 (8C, C2HN3, C6H4); MS (ESI): Calcd for C19H27N5NaO5
[M+Na]+: 428.19; Found m/z: 428.24; Melting point: 143°C-147°C.
Methyl 2-[(S)-2-amino-3-methyl-butyrylamido]-2-deoxy-6-{4-(4-methyl phenyl)-
[1,2,3]-triazol-1-yl}-β-D-galactopyranoside (111), (CR III 56).
According to the general procedures for solid phase synthesis 93a/b was loaded,
deprotected, coupled with Fmoc-valine, reacted with 4-ethynyl-toluene and cleaved
from the solid phase after Fmoc-cleavage. Compound 111 (18 mg, 100% recovery,
≥98% purity) was obtained as the acetate salt. After purification and a final
lyophilization from dioxane/H2O (1:1) 111 was obtained as white powder. 
1H NMR
(500 MHz, CD3OD): δ 1.08 (m, 6H, CH(CH3)2), 2.19 (m, 1H, CH(CH3)2), 2.36 (s, 3H,
CH3), 3.29 (s, 3H, OCH3), 3.61 (d, J = 5.4 Hz, 1H, CHNH2), 3.70 (dd, J2,3 = 10.8 Hz,
J3,4 = 3.1 Hz, 1H, H-3), 3.86 (d, J3,4 = 2.9 Hz, 1H, H-4), 3.97 (m, 2H, H-2, H-5), 4.31
(d, J1,2 = 8.4 Hz, 1H, H-1), 4.74 (d, J5,6a = J5,6b = 6.4 Hz, 2H, H-6), 7.25, 7.69 (m, 4H,
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C6H4), 8.35 (s, 1H, C2HN3); 
13C NMR (125 MHz, CD3OD): δ 18.61 (2C, CH(CH3)2),
21.40 (CH3), 51.81 (C-6), 54.08 (C-2), 56.88 (OCH3), 59.50 (CHNH2), 69.63 (C-4),
72.95 (C-3), 75.05 (C-5), 102.83 (C-1), 122.56, 126.49, 130.24 (8C, C2HN3, C6H4);
MS (ESI): Calcd for C21H31N5NaO5 [ M+Na]
+: 434.24; Found m/z: 434.26; Melting
point: 141°C-145°C.
Methyl 2-[(S)-2-amino-propionamido]-6-azido-2-deoxy-β-D-galactopyranoside
(99), (CR III 40).
93a/b was loaded to the solid support and the phthalimido group cleaved according
to the general procedures for solid phase synthesis. Fmoc-alanine was coupled by 3
alternative parallel methods at r.t. After Fmoc-cleavage 99 was cleaved from the solid
phase and purified according to the general procedures for solid phase synthesis.
Purification and a final lyophilization from dioxane/H2O (1:1) were done with all three
combined batches. Compound 99 (16 mg, 53%) was obtained as white powder.
Method A for amino acid coupling:
According to the general procedure described above for solid phase synthesis, 99
was obtained (9.9 mg, 81% recovery, ≥ 98%) as the acetate salt.
Method B for amino acid coupling:
A stock solution of Ala-Fmoc (4 eq x 35 µmol x 1.5 lantern) and HOBt (4 eq x 35
µmol x 1.5 lantern) in DMF (750 µL) was freshly prepared. In a 96-well plate the
freshly prepared stock solution (500 µL) and DIC (4 eq, 21.7 µL) were combined.
After 2 min of pre-activation the lantern was added. Five rounds of coupling were
performed, each time fresh coupling solutions were used. The first coupling was run
overnight. The next three cycles were run for 4 h each and the last one overnight.
Compound 99 was obtained (11.6 mg, 95% recovery, ≥ 98%) as the acetate salt.
Method C for amino acid coupling:
Two stock solutions were freshly prepared. Solution A consisted of Fmoc-alanine (5
eq x 35 µmol x 1.5 lantern) and HOBt (5 eq x 35 µmol x 1.5 lantern) in DMF (375 µL).
Solution B consisted of PyBOP (4.9 eq x 35 µmol x 1.5 lantern) in DMF (375 µL). In a
96-well plate 250 µL of stock solution A, 250 µL of stock solution B, and DIPEA  (10
eq, 59.9 µL) were combined. After 2 min of pre-activation the lantern was added.
Five rounds of coupling were performed, each time fresh coupling solutions were
used. The first coupling was run overnight. The next three cycles were run for 4 h
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each and the final one overnight. Compound 99 was obtained (9.9 mg, 81%
recovery, ≥ 98%) as the acetate salt   
€ 
[α]
D
21 -13.9 (c = 0.23, MeOH); 1H NMR (500 MHz,
CD3OD): δ 1.53 (d, 3H, CH3 of Ala), 3.24 (m, 1H, H-6a), 3.47 (s, 3H, OCH3), 3.64-
3.72 (m, 3H, H-3, H-5, H-6b), 3.76 (d, J3,4 = 2.9 Hz, 1H, H-4), 3.93 (m, 2H, H-2, CH of
Ala), 4.36 (d, J1,2 = 8.4 Hz, 1H, H-1); 
13C NMR (125 MHz, CD3OD): δ 18.20 (CH3 of
Ala), 50.93 (CH of Ala), 52.96 (C-6), 54.58 (C-2), 57.41 (OCH3), 70.66 (C-4), 73.19
(C-3), 76.42 (C-5), 104.01 (C-1), MS (ESI): Calcd for C10H19N5NaO5 [M+Na]
+:
312.13; Found m/z: 312.23; Melting point: 145°C (decomposition).
Other tests performed
3-(2-Hydroxyethyl-sulfanyl)-cyclohexanone (14), (CRV 7).
2-Cyclohexen-1-one (56 µL, 0.58 mmol) was dissolved under argon in degassed
DCM (3 mL). Freshly distilled and degassed diethylamine (1.6 mL) was added
followed by 2-mercaptoethanol (27 µL, 0.38 mmol). The reaction was stirred at r.t. for
6 h and then concentrated under reduced pressure. The resulting material was
purified by silica gel chromatography (PE/EA 1:1) to obtain 14 (48 mg, 72%) as
colorless oil. 1H NMR (500 MHz, CDCl3): δ 1.70, 2.10, 2.25-2.38 (m, 7H, C6H9), 2.54
(s, 1H, OH), 2.70 (m, 3H, CH2S, 1H of C6H9), 3.09 (m, 1H, CH), 3.70 (m, 2H,
CH2OH); 
13C NMR (125 MHz, CDCl3): δ 24.10, 31.67 (2C, 2 CH2  of C6H9), 33.55
(CH2S), 40.88 (CH2  of C6H9), 42.73 (CH), 48.18 (CH2  of C6H9), 61.06 (CH2OH),
208.96 (CO).
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Annex 1: Data extracted from the literature
In this section, the data extracted from the literature are summarized. Inhibition
values determined for various monovalent monosaccharides, as well as natural
ligands, for different mammalian hepatic lectins are presented. The binding assays
performed were usually based on 125I-marked natural ligands, which were put to
compete with different concentrations of the inhibitors under study. For each case the
assays are shortly described. This data was of high relevance for the basis of the
present work. Each publication is presented separately and in chronological order.
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1. Extracted from: J.U. Baezinger, Y. Maynard, J. Biol. Chem. 1980, 255, 4607-
4613.
Data reported: Preliminary inhibitory studies in human hepatic lectin.
Table I: Inhibition constants for binding by the human hepatic lectin
Gal GalNAc ki
Residues /mol of
protein or
glycopeptide
[M]
Asialo-orosomucoid 20 0 1.7x10-9
Asialofetuin 12 3 1.7x10-8
Asialoceruloplasmin 12 0 8.6x10-8
Asialotransferrin 5 0 3.3x10-6
Lactose 1 2.2x10-4
β-Methylgalactoside 1 2.5x10-4
α-Methylgalactoside 1 2.7x10-4
€ 
ki =
i[ ]
kd
i
kd
−1
 
 
 
 
 
 
€ 
i[ ] molar concentration of inhibitor.
€ 
kd         dissociation constant in absence of the inhibitor
€ 
kd
i        dissociation constant in presence of the inhibitor
€ 
ki       values established by carrying out binding assays with increasing  amounts of 125I-
asialo-orosomucoid in the presence of a known amount of inhibitory ligand
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Assay description:
A modification of the assay A described by Hudgin et al.[13] was used. Aliquots of
crude Triton X-100 extracts, affinity column fractions, or purified protein containing
0.5 – 5.0 µg of the hepatic lectin, were incubated for 30 min at 25 °C with 360 ng of
125I-asialo-orosomucoid in 0.5 mL or 50 mM Tris-HCl, pH 7.8, 40mM CaCl2, 1M NaCl
and 0.2% Triton X-100. The lectin-125I-asialo-orosomucoid complexes were then
precipitated by addition of saturated ammonium sulfate, which had been adjusted to
pH 7.8 with solid Tris, and chilled for 10 min on ice. The precipitates were collected
on glass fiber filters and washed three times with a cold 50% saturated ammonium
sulfate solution containing 10 mM CaCl2. Blanks consisted of the same incubation
mixture, but without binding protein. Under the conditions used, 1 µg of human
carbohydrate binding protein bound approximately 45-50 ng of asialo-orosomucoid.
180
2. Extracted from: D. T. Connolly, R. R. Townsend, K. Kawaguchi, W. R. Bell, Y. C.
Lee, J. Biol. Chem. 1982, 257, 939-945.
Data reported: Inhibitory action of glycosides towards the rabbit receptor.
Table: Inhibition of 125I-asialoorosmucoid binding to isolated hepatic lectin and to rabbit hepatocytes
by various glycosides and monosaccharides
Inhibitors Isolated lectin IC50
(µM)
Hepatocytes IC50 (µM)
Asialo-orosomucoid 0.005 0.003
Aminohexyl β-D-Gal 280 300
Aminohexyl β-D-thio-Gal 380 400
Aminohexyl α-D-thio-Gal 150 250
p-Nitrophenyl β-D-thio-Gal 200 500
Methyl β-D-Gal 1000 1000
Methyl β-D-thio-Gal 1300 1000
Methyl α-D-Gal 1600 1900
GalNAc 90 70
Lactose 300 400
Gal 1700 1900
Glc 60.000 90.00
Man 30.000 >100.000
GlcNAc 300.000 >100.000
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Assay description:
a) Binding assays using the purified hepatic lectin were based on assay A of Hudgin
et al.[13]
The lectin (90ng) was incubated with 125I-asialo-orosomucoid (5 ng, 5 x 105 cpm),
and varying amounts of inhibitors for 30 min at 25 °C in 0.5 mL of buffer (0.05 M Tris,
pH 7.8, 1M NaCl, 0.05 M CaCl2, 0.6% BSA, and 0.5% Triton X-100). Bound 
125I-
asialo-orosomucoid was determined by ammonium sulfate precipitation followed by
filtration. Nonspecific binding to the filter was corrected for by subtracting the amount
of 125I-asialo-orosomucoid retained on the filter in the absence of lectin.
b) Binding assays using hepatocytes in suspension culture.
Were carried out in capped 12 x 75 mm polystyrene tubes, which were rotated
vertically (4 rpm) at 0-1 °C. The reaction mixtures contained the inhibitors to be
tested, 125I-asialo-orosomucoid (5 ng, 5 x 105 cpm), and 2.5 x 106 rabbit hepatocytes
in 1.0 mL of modified Dulbecco’s Eagle medium. After 100 min incubation, 100 µL
sample were removed and added to 400 µL microfuge tubes containing 100 µL of a
4:1 (v/v) mixture of silicon oil and light mineral oil. After centrifuging for 10-12 s in an
Eppendorf centrifuge, the aqueous upper layer was removed by aspiration. The
microfuge tubes were washed twice more before removing most of the oil layer. The
cell pellet remaining was counted for radioactivity. Nonspecific binding was corrected
for by subtracting the amount of 125I-asialo-orosomucoid that became cell associated
under the above conditions but in the presence of 8 mM EGTA.
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3. Extracted from: R.T. Lee, R. W. Myers, Y.C. Lee, Biochemistry 1982, 21, 6292-
6298.
Data reported: Binding characteristics of rabbit liver Gal/GalNAc-specific lectin
Table I: IC50 values of analogues of Methyl α-D-Galactopyranoside having different substituents at
C-5
C-5 substituent IC50 (mM) C-5 substituent IC50 (mM)
CH2OH (Gal)
a 1.6 H (L-Ara) 12
CH2-H(D-Fuc) 1.6 CO2Me 16
CH2N3 1.2 CONH2 19
CH2Br 1.1 CONHNH2 9
CH2NH2 4.3 CO2H ∼200
CH2NH2
b 1.9
CH2OTs
c 1.0
a The IC50
 value is from Connolly et al.[34] b Methyl glycoside of  β configuration. C Due to insufficient
solubility of the methyl glycoside, the reducing sugar (6-O-tosyl-D-galactose) was used.
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Table II: IC50 values of various β-Glycosides of  D-galactopyranose and D-glucopyranose
aglycon Glc (IC50 mM) Gal (IC50 mM)
none 16 1.7b
OCH3
c 26 1.6b
OCH3 17 1.0
b
OCH2CH=CH2 12 0.47
O(CH2)6NH2 0.28
SCH2CO2H 12 2.0
SCH2CN 2.0 0.13
SCH2C(=NH)NH2 0.8 0.3
OPh 4.0
OC6H4NO2 (para) 1.7
SCH2CONHCH2CO2Et 2.5 0.7
SCH2CONHCH2CO2H 2.1
SCH2C(=NH)NHCH2CO2H 0.75 0.6
SCH2CONHCH2CH(OMe)2 2.0 0.75
S(CH2)5CONHCH2CH(OMe)2 4.3 0.23
(1,4)Glc 2.0 (cellobiose) 0.3 (lactose)
(1,4)Glcc 2.6 (maltose)
(1,4)GlcSCH2CN 1.5 (cyanomethyl
thiocellobioside)
a Name of the compound is given in parentheses. b Data from Connolly et al.[34]
c α-glycoside
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Table III: IC50 values of miscellaneous sugars and glycosides
Compound IC50 mM
Galβ(1→3)GlcNAc 0.9
Galβ(1→4)GlcNAc 0.8
Galβ(1→6)GlcNAc 0.3
Galβ(1→3)GlcNAcO(CH2)6NH2 (β) 0.2
Galβ(1→4)GlcNAcO(CH2)6NH2 (β) 0.4
Galβ(1→6)GlcNAcO(CH2)6NH2 (β) 0.5
Galβ(1→6)Glc 0.9
Galα(1→6)Glc 2.8
GlcNAcβ(1→6)Gal 2.8
GlcNAcβ(1→6)Gal-SCH2CONHCH2CH(OMe)2(β) 0.6
N-acetylgalactosaminea 0.09
Me 2-O-Ac-α-Gal 0.04
1-cyano-1-deoxy.Gal (β) 1.0
1-carboxyl-1-deoxy.Gal (β) 2.5
Me 3,6-anhydro-α-Gal >>180b
Me 4,6-O-benzylidene-α-Gal >>20b
a From Connolly et al.[34] b Not inhibitory at the concentration shown
Assay description:
Based on assay A of Hudgin et al.[13]
An inhibitor (usually in the concentration range of 5 x 10-2 to 5 x 10-6 M) and 125I-
asialo-orosomucoid (approx. 6 x 10-10 M) were incubated with the lectin (approx. 4 x
10-10 M) in a total volume of 0.5 mL at pH 7.8 in the presence of 0.05 M CaCl2, 0.6%
BSA, and 0.5% Triton X-100 for 0.5 h at 25 °C.  The lectin was precipitated with 45%
ammonium sulfate and collected by filtration through a glass fiber disk. Radioactivity
on the disk was counted to determine the amount of 125I-asialo-orosomucoid bound
to the lectin.
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4. Extracted from: R.T. Lee, Y.C. Lee, Biochemistry 1986, 25, 6835-6841.
Data reported: Inhibitory studies in isolated hepatic lectin from rabbit or rat
hepatocytes.
Table I: Binding affinity of glycopeptide derivatives.
Stages of Gal modification Ki for purified rabbit
lectin (µM)
Ki for rat hepatocytes
(µM)
none 2 90
6-oxo 120 Not inhibitory at 100µM
6-(benzylamino)-6-deoxy 0.9 280
6-amino-6-deoxy 0.9 270
6-(4-azidobenzoamido)-6-deoxy 1.4 430
Assay description:
The inhibition assay was based on assay A of Hudgin et al[13], and carried out
according to Connolly et al.[34]
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5. Extracted from: T.C. Wong, R.R. Townsend, Y.C. Lee, Carbohydrate Research
1987, 170, 27-46.
Data reported: Binding studies using isolated rat hepatocytes with synthetical D-
Galactosamine derivatives.
Modifications on:
O
R5
R4
R3
R6
R1
R2
Table I: Inhibition results showing effect of changes in N-substitution.
R1 (β) R3 IC50 (mM) Relative
potency
OCH2CH2OH NHAc
(NHCOCH3)
0.2 1
OCH2CH2OH NHCOCH2CH3 0.2 1
OCH2CH2OH NHCOC6H5 0.8 0.25
OCH2CH2OH NPhth 8.0 0.025
O(CH2)6NH2 NHCOCF3 0.2 1
O(CH2)6NH2 NHAc 0.06
a 3.333
a This result was personal communication from R.T. Lee, and has been adjusted according to the
potency of GalNAc of the authors and her experiment.
187
Table II: Inhibition results showing effect of changes of hydroxyl groups.
R1 (β) R2 (α) R3 R4 R5 IC50 (mM) Relative
potency
OCH2CH=CH2 H OH OH OH 0.2 1
OCH2CH=CH2 H OH OH OCH3 0.08 2.5
OCH2CH=CH2 H OCH3 OH OH 70 0.0029
OCH2CH=CH2 H OH OCH3 OCH3 31 0.0065
H OCH2CH=CH2 OH OH OH 0.12 1.7
H OCH2CH=CH2 OH F OH >1.5 Inactive at 1.5
mM
Assay description:
Freshly isolated rat hepatocytes (0.25 mL) were added to 0.75 mL of medium
containing the desired concentrations of inhibitors and 125 pM 125I-asialo-
orosomucoid in 1.5 mL polypropylene tubes. After incubation for 2 h at 0-2°C with
end-over-end rotation, the total cell-associated radioactivity was determined by
centrifuging 200 µL of the cell suspension over 4:1 silicone-mineral oil at 10.000 g for
30 s. The snipped pellets were counted for radioactivity. Total cell-associated
radioactivity in the absence of inhibitor was also determined. Nonspecific binding was
determined by placing 200 µL of the cell suspension from tubes not containing
inhibitor in a tube containing 4 µL of 0.5 M EDTA, pH 7.8 solution and determining
after 10 min the cell-associated radioactivity.
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6. Extracted from: S.T. Iobst, K. Drickamer, J. Biol. Chem. 1996, 271, 6686-6693.
Data reported: Competition assays in isolated RHL1-CRD and CRD of macrophage
galactose receptor of rat.
Table I: Binding constants of galactosamine derivatives binding to RHL1
Inhibition constants for derivatives of galactosamine acylated on the N-2 position were determined
using solid phase binding competition assays. The Ki for each sugar derivative relative to the Ki for
GalNAc is reported.
Sugar derivative Acyl Chain (on N-2) Ki/KiGalNAc
N-formylgalactosamine -COH 13 ±1
N-acetylgalactosamine -COCH3 1
N-propionylgalactosamine -COCH2CH3 0.13 ± 0.04
N-n-butanoylgalactosamine -COCH2CH2CH3 0.29 ± 0.06
N-iso-butanoylgalactosamine -COCH(CH3)2 0.82 ± 0.06
Ki: concentration of monosaccharide giving 50% inhibition of neoglycoprotein binding
according to the equation: Bound radioactivity= MAX/(Ki+ [monosaccharide]). MAX is
the total amount of radioactivity bound in the absence of competing monosaccharide.
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Table II: Dissociation constants and relative inhibition constants were determined using the solid
phase binding assay. Ki values for GalNAc relative to the Ki for Gal are reported along with
dissociation constants for Gal34-BSA.
CRD KiGal/Ki,GalNAc KD
MGR 1.2 ± 0.4 90 ± 40
RHL1 60 ± 8 70 ± 10
KD : concentration of the ligand at which half-maximal specific saturable binding is achieved
Assay description:
a) Competitive binding assay
The protein was immobilized on polystyrene wells. The coating was performed
overnight at 4°C with 50 µL/well CRD at a concentration of approximately 50 ng/mL
in loading buffer. The protein was removed, and the wells were rinsed in salt solution
(1.25 M NaCl, 25 mM Tris-Cl, pH 7.8). After rinsing, the wells were immediately
treated with 5% bovine serum albumin in salt solution for 2 h. This solution was
discarded, and the wells were again rinsed in salt solution. Ligand (18.000 cpm/well
125I-Gal34-BSA) in blocking solution containing the appropriate concentration of Ca
+2
and competing ligands was pippeted into the wells and incubated for 2 h. Wells were
rinsed with loading buffer and shaken until excess moisture was removed. Residual
radioactivity was counted.[101] Each assay was performed in duplicate. A non linear,
least squares fitting program (Sigma Plot, Jandel Scientific) was used to obtain Ki
values, corresponding to the concentration of monosaccharide giving 50% inhibition.
Mean ± standard deviation values for at least three independent assays were used
to calculate Ki values.
b) Direct binding assay
Polystyrene plates were coated with CRD and blocked with BSA as for the
competition assay. 125I-Gal34-BSA was diluted with non radioactive Gal34-BSA to a
final specific activity of 1-2 x 105 cpm/µg. Serial dilutions (2 fold) prepared in BSA-
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loading buffer (1.25 M NaCl, 25mM CaCl2, 25 mM Tris-Cl, pH 7.8, containing 5%
BSA) were incubated in wells for 2h at 4°C. Wells were emptied, rinsed three times
with loading buffer at 4°C, and counted. Assays were performed in duplicate. Values
reported are the mean ± standard deviation for three independent assays.
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7. Extracted from: D. Yi, R.T. Lee, P. Longo, E. T. Boger, Y.C. Lee, W.A. Petri Jr, R.
L. Schnaar, Glycobiology 1998, 8, 1037-1043.
Data reported: Inhibition studies performed in rat hepatic lectin (lectin not isolated).
Table I: Lectin inhibition by GalNAc and related derivatives
Inhibitor Rat hepatic
membranes IC50(µM)
GalNAc 150
Allyl β-GalNAc 160
Allyl α-GalNAc 89
Allyl 3-deoxy-β-GalNAc (2500)a
Allyl 4-deoxy-β-GalNAc (2500)a
Allyl 6-O-methyl-β-GalNAc 90
Allyl 4-fluoro-α-GalNAc (2500)a
N-benzoyl  galactosamine 1300
GalNH2 >25.000
aValues in parentheses indicate no inhibition at the given value (highest concentration tested)
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Assay description:
Binding of 125I-GalNAc39BSA to rat hepatic plasma membranes was performed in a
100 µL reaction containing assay buffer (25 mM Tris-HCl buffer pH7.8, 150 mM
NaCl, 20 mM CaCl2, 10 mg/mL BSA, 0.02% Triton X-100), and the indicated
concentrations of radioligand, rat liver plasma membranes and saccharide inhibitors.
Reactions were incubated with gentle agitation for 90 min at 4°C, then rapidly diluted
with assay buffer without BSA and rinsed onto glass fiber filters (presoaked in 25 mM
Tris buffer (pH 7.8), 1 mg/mL BSA). Specific radioligand binding was determined by
using a radiation counter.
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Annex 2: Competitive target-based assay
All curves obtained from the competitive target-based assay used for IC50
determination for all the synthesized compounds as well as for references are here
presented.
The competitive target-based assay was developed in our institute by Daniela
Stokmaier.[50] Assays were run by herself, who also kindly taught me how to run the
assay and by her diploma student Katrin Schwingruber. A general description of the
procedure can be found here.
Experimental
Nunc MaxiSorb 96 well plates were coated with H1-CRD monomer from the same
production batch (3 µg/mL in HEPES assay buffer containing 1 mM of Ca+2). Plates
were incubated overnight at 4°C. One row contained only buffer to be employed for
background and blank. The assay buffer consisted in 20 mM HEPES, 150 mM NaCl,
1 mM CaCl2 and with the pH adjusted to 7.4 with NaOH 10 M.
The following day, the coating solution was discarded and the plates were dried by
tapping them on several layers of tissue paper. The plates were then incubated with
150 µL/well of blocking buffer for 1 h at 4°C. The blocking buffer consisted in 3%
BSA in assay buffer with added 5 mL NaN3 (10%)/ 500 mL buffer. The plates were
then washed with assay buffer (3 x 150 µL/well) tapping plates dry between wash
steps. First, inhibitors diluted in assay buffer  (2 x concentrated, 50 µL/well) with
DMSO were added (see inhibitors solutions), then biotinylated β-GalNAc-
polyacrylamide-polymer and the streptavidin peroxidase complex (0.5 µg/mL, 2 x
concentrated, 50 µL/well) was added. The plates were left in the shaker for 2 h at r.t.
and were then washed as before. For detection, 100 µL/well of ABTS peroxidase
substrate kit was added. After 10 min the colour development was stop by adding
100 µL/well of oxalic acid 2% in H2O. The optical densitiy (O.D.) was determined at
415 nm on a plate reader.
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Inhibitors solutions:
20 mM stock solutions of inhibitors were prepared in DMSO to overcame the problem
of solubility of some inhibitors. Dilutions were done with HEPES assay buffer to
obtain 20 mM, 6 mM, 2 mM, 0.6 mM, 0.2 mM and lower in the cases required
(concentrations on the plate were therefore half of each mentioned concentration).
The maximum amount of DMSO on plate was of 5% for the most concentrated
inhibitor solution. As in presence of DMSO IC50 values were always higher than
without it, all compounds and references were measured containing DMSO to obtain
comparable results.
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2. Library of galactose mimics based on the lyxo-hexitol core (28 to 39 and
45 and 50)
0.8678
0.4154 0.6230
10-2 10-1 100 101 102
0
25
50
75
100
CR-V-8 07/14IC50(mM)
CR-V-8 07/14
28
mM
O
HO S
HO
O
10-2 10-1 100 101 102
0
25
50
75
100
CR-VI-16
0.5857
CR-V-16 07/20
0.5640
CR-V-16 07/14
IC50(mM)
CR-V-16 07/20
29
mM
O
HO S
HO
O
10-2 10-1 100 101 102
0
25
50
75
100
CR-V-12 07/13
0.4514
CR-V-12 07/20
0.4476
IC50(mM)
CR-V-12 07/13
CR-V-12 07/20
30
mM
O
HO S
HO
O
10-2 10-1 100 101 102
0
25
50
75
100 CR-V-20 07/13
CR-V-20 07/20
31
CR-V-20 07/13 CR-V-20 07/20
mM
O
HO S
HO
O
10-2 10-1 100 101 102
0
25
50
75
100
CR-V-21 07/12
0.3195
CR-V-21 07/20
0.6244
IC50(mM)
CR-V-21 07/12
CR-V-21 07/20
32
mM
O
HO S
HO
O
F
10-2 10-1 100 101 102
0
25
50
75
100
CR-V-22 07/13
0.4293
CR-V-22 07/20
0.6194
IC50(mM)
CR-V-22 07/13
CR-V-22 07/20
33
mM
O
HO S
HO
O
Cl
28 29
30
31
32 33
198
10 -2 10 -1 100 101 102
0
25
50
75
100
CR-V-31 07/14
0.08177
CR-V-31 07/21
0.1069
IC50(mM)
CR-V-31 07/14
CR-V-31 07/21
41
mM
10 -2 10 -1 100 101 102
0
25
50
75
100
CR-V-27 07/14
2.259
CR-V-27 07/20
0.9825
CR-V-27 07/14
IC50(mM)
CR-V-27 07/20
36
mM
10 -2 10 -1 100 101 102
0
25
50
75
100
CR-V-30 07/14
0.3728
CR-V-30 07/21
0.3201
CR-V-30 07/14
IC50(mM)
CR-V-30 07/21
38
mM
O
HO S
HO
O
H3CO
OCH3
O
HO S
HO
O
O
HO S
HO
O
HOS
OH
10 -3 10 -2 10 -1 100 101
0
25
50
75
100
CR-VII-12
0.5712
CR-VII-12
50
n = 2
IC50(mM)
051013 CR-VII-12 from stocksol. 13.10.05 STO
mM
O
HO
HO
N
NN
CF3
45
34 36
39
10 -3 10 -2 10 -1 100 101
0
25
50
75
100
CR-VII-12
0.3912
CR-VII-12
50
IC50(mM)
051019 CR-VII-12 from stocksol. 19.10.05 STO
mM
47
199
10 -2 10 -1 100 101 102
0
25
50
75
100
CR-VII-8
0.4214
IC50(mM)
CR-VII-8
51
n = 2
mM
O
HO
HO
N
NN S
050816
50
200
3. Library of methyl α-D-galacto-derivatives (66 to 75)
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4. Library of methyl β-D-galacto-derivatives
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Annex 3: Biacore experiments
Surface plasmon resonance data obtained for the compounds analyzed can be found
in this section. Biacore experiments were run in our institute, Institute of Molecular
Pharmacy of the University of Basel, by Dr. D. Ricklin.
Experimental
All Biacore experiments were performed at 25°C on a Biacore 3000 instrument
(Biacore AB, Uppsala, Sweden) equipped with research-grade CM5 sensor chips.
Monomeric H1-CRD was covalently immobilized using a standard amine coupling
protocol.[102] For this purpose, a single flow cell of the sensor chip was activated by
injecting a 1:1 mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimidehydrochloride (EDC) for 10 min at a flow rate of 5
µl/min. Purified H1-CRD in 10 mM HEPES, 2 mM EDTA, pH 7.4 was diluted in 10
mM sodium acetate buffer pH 4.5 to a concentration of approximately 10-50 µg/ml
and was injected for 10 min. Finally, the flow cell was deactivated by an injection of 1
M ethanolamine for 10 min. 10 mM HEPES, 50 mM CaCl2, pH 7.4 was used as a
running buffer. The immobilization density was determined as the signal increase
between the baseline after activation and after the final deactivation step. An
untreated flow cell was used as a reference cell in order to eliminate artificial signals
from non-specific binding and instrument noise. Data acquisition was done with
BIAcontrol software (version 3.1; Biacore AB, Uppsala, Sweden) and the raw data
were processed with Scrubber (version 1.1g; BioLogic Pty., Australia).
Compound ranking
5% DMSO were added to the running buffer for the ranking experiment. Sample
solutions were prepared by diluting 200 mM stock solutions in DMSO of each
compound in DMSO-free buffer to a sample concentration of 10 mM in 5% DMSO.
These solutions were further diluted in running buffer, resulting in 1 mM sample
solutions. Each sample was injected for 60 s at a flow rate of 20 µl/min, followed by a
undisturbed dissociation phase of 60 s, except for 72 where the dissociation time was
prolonged to 120 s. A 10 mM galactose solution was injected at the end of each cycle
208
for regeneration of the surface. For compound 72, since the signal did not return to
the baseline, the surface was regenerated with a 1 min injection of HBS-EP buffer
(10 mM HEPES, 150 mM NaCl, 0.005% polysorbate 20, 3 mM EDTA, pH 7.4), and
was reconstituted in running buffer for 10 min. A series of 1 mM galactose, GalNAc,
and Glucose was injected at the beginning, in the middle, and at the end of the
ranking experiment as positive and negative controls. After subtraction of the
reference cell, the binding signals were determined 10 s before injection end and
were corrected for the molecular weight (normalization). All signals for 72 had a
positive sign and were not mirrored before fitting. Despite the rather slow binding
kinetics, the apparent KD value could be estimated by fitting the values at 25 s to a
simple 1:1 binding model. However, the binding curves did not fit to a standard
kinetic model.
High-resolution screening
Running buffer with 3% DMSO was used for all high-resolution screening
experiments. 200 mM stock solutions in DMSO were diluted with DMSO-free buffer
to a compound concentration of 6 mM in 3% DMSO. Threefold dilution series
between 6 mM and 2.7 µM (8 concentrations) were prepared in running buffer. All
samples were injected as randomized triplicates for 30 s at a flow rate of 50 µl/min,
followed by 20 s undisturbed dissociation. No regeneration had to be applied
between the cycles. Eight buffer blanks were injected during each experiment for
conditioning the surface and for double referencing.[103] Since injection of sugar
ligands to immobilized H1-CRD is described to cause negative binding responses,[53]
all signals were mirrored by multiplication of each data point per -1. The processed
steady state responses were plotted against the concentration and were fitted to a
single binding site model.
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